

10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer

New England Journal of Medicine

375, 1415-1424

DOI: [10.1056/nejmoa1606220](https://doi.org/10.1056/nejmoa1606220)

Citation Report

#	ARTICLE	IF	CITATIONS
1	2531 Measuring the quality of personal care in prostate cancer radiotherapy. <i>European Journal of Cancer</i> , 2015, 51, S485.	1.3	0
2	Prostate Cancer Radiation Therapy: What Do Clinicians Have to Know?. <i>BioMed Research International</i> , 2016, 2016, 1-14.	0.9	44
3	Risk Factors for Prostate Cancer: Which Are Truly Predictive of Clinically Significant Disease?. <i>Journal of Clinical Oncology</i> , 2016, 34, 4310-4311.	0.8	1
4	Precision management of localized prostate cancer. <i>Expert Review of Precision Medicine and Drug Development</i> , 2016, 1, 505-515.	0.4	6
7	The Prostate Testing for Cancer and Treatment (ProtecT) study: what have we learnt?. <i>BJU International</i> , 2016, 118, 843-843.	1.3	5
8	Treatment or Monitoring for Early Prostate Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 1482-1483.	13.9	15
9	Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 1425-1437.	13.9	962
10	Who Should Consider Active Surveillance?. <i>Journal of Urology</i> , 2016, 196, 1604-1605.	0.2	0
11	Patients with Differentiated Thyroid Cancers 1 to 2 cm Are Treated Differently from Those With Tumors Smaller than 1 cm. <i>Clinical Thyroidology</i> , 2016, 28, 296-298.	0.0	0
12	Clinical News. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2016, 77, 556-559.	0.2	0
13	Determining optimal therapy of early-stage disease remains complicated. <i>Nature Reviews Urology</i> , 2016, 13, 703-704.	1.9	0
14	Discerning the survival advantage among patients with prostate cancer who undergo radical prostatectomy or radiotherapy: The limitations of cancer registry data. <i>Cancer</i> , 2017, 123, 1617-1624.	2.0	24
15	Trends in Radiation Therapy among Cancer Survivors in the United States, 2000–2030. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 963-970.	1.1	93
16	Diagnostic accuracy of multi-parametric MRI and transrectal ultrasound-guided biopsy in prostate cancer. <i>Lancet, The</i> , 2017, 389, 767-768.	6.3	4
20	Sharp Decline In Prostate Cancer Treatment Among Men In The General Population, But Not Among Diagnosed Men. <i>Health Affairs</i> , 2017, 36, 108-115.	2.5	25
21	Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2017, 35, 1341-1367.	0.8	318
22	In Defense of Randomized Clinical Trials in Surgery: Let Us Not Forget Archie Cochrane's Legacy. <i>European Urology</i> , 2017, 71, 820-821.	0.9	4
23	10-Year Outcomes in Localized Prostate Cancer. <i>New England Journal of Medicine</i> , 2017, 376, 178-181.	13.9	16

#	ARTICLE	IF	CITATIONS
24	Is a negative prostate biopsy a risk factor for a prostate cancer related death?. <i>Lancet Oncology</i> , The, 2017, 18, 162-163.	5.1	7
25	Risk of prostate cancer diagnosis and mortality in men with a benign initial transrectal ultrasound-guided biopsy set: a population-based study. <i>Lancet Oncology</i> , The, 2017, 18, 221-229.	5.1	54
26	Reply to Thomas Zilli, Gilles CrÃ©hange and Olivier Chapet's Letter to the Editor re: Pascal Rischmann, Albert Gelet, Benjamin Riche, et al. Focal High Intensity Focused Ultrasound of Unilateral Localized Prostate Cancer: A Prospective Multicentric Hemiablation Study of 111 Patients. <i>Eur Urol</i> 2017;71:267-73. <i>European Urology</i> , 2017, 72, e15-e16.	0.9	1
27	Impact of Radical Prostatectomy on Long-Term Oncologic Outcomes in a Matched Cohort of Men with Pathological Node Positive Prostate Cancer Managed by Castration. <i>Journal of Urology</i> , 2017, 198, 86-91.	0.2	20
28	Reply to: 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. Hamdy et al. <i>NEJM</i> October 2016. <i>World Journal of Urology</i> , 2017, 35, 1465-1465.	1.2	0
29	Patient characterization and usage trends of proton beam therapy for localized prostate cancer in the United States: A study of the National Cancer Database. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 438-446.	0.8	13
30	Pathological Findings in Multiparametric Magnetic Resonance Imaging/Ultrasound Fusion-guided Biopsy: Relation to Prostate Cancer Focal Therapy. <i>Urology</i> , 2017, 105, 18-23.	0.5	11
31	Active Surveillance Versus Treatment of Prostate Cancer: Should Metastasis Be the Primary End Point?. <i>Journal of Clinical Oncology</i> , 2017, 35, 1638-1640.	0.8	12
32	Helping Patients Decide on Treatment Options for Actinic Keratosisâ€”Living in Cryo Nation. <i>JAMA Dermatology</i> , 2017, 153, 251.	2.0	4
33	Adjuvant and Salvage Radiotherapy after Radical Prostatectomy in Prostate Cancer Patients. <i>European Urology</i> , 2017, 72, 689-709.	0.9	73
34	Reassurance for patients with non-specific conditions â€” a user's guide. <i>Brazilian Journal of Physical Therapy</i> , 2017, 21, 1-6.	1.1	19
36	Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculator for Initial Prostate Biopsy by Incorporating the 2014 International Society of Urological Pathology Gleason Grading and Cribriform growth. <i>European Urology</i> , 2017, 72, 45-51.	0.9	63
37	Does early resection of presumed low-grade glioma improve survival? A clinical perspective. <i>Journal of Neuro-Oncology</i> , 2017, 133, 137-146.	1.4	35
38	Commentary: Prostate cancer screeningâ€”A long run for a short slide. <i>Seminars in Oncology</i> , 2017, 44, 57-59.	0.8	0
39	Pre- and post-prostatectomy variables associated with pelvic post-operative radiotherapy in prostate cancer patients: a national registry-based study. <i>Acta OncolÃ³gica</i> , 2017, 56, 1295-1301.	0.8	8
40	The need for active surveillance for low risk prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 487-489.	1.1	3
41	Patient Knowledge and Qualities of Treatment Decisions for Localized Prostate Cancer. <i>Journal of the American Board of Family Medicine</i> , 2017, 30, 288-297.	0.8	15
42	Comparative effectiveness in urology. <i>Current Opinion in Urology</i> , 2017, 27, 380-394.	0.9	2

#	ARTICLE	IF	CITATIONS
43	â€˜The prostateâ€™™ in patients with metastatic prostate cancer: to treat or not to treat?. Nature Reviews Urology, 2017, 14, 398-399.	1.9	3
44	Variation in Use of Prostate Biopsy Following Changes in Prostate Cancer Screening Guidelines. Journal of Urology, 2017, 198, 1046-1053.	0.2	6
45	Comparative effectiveness of prostate cancer treatments for patient-centered outcomes. Medicine (United States), 2017, 96, e6790.	0.4	18
46	A prospective multicentre phase III validation study of AZGP1 as a biomarker in localized prostate cancer. Annals of Oncology, 2017, 28, 1903-1909.	0.6	17
47	Scanning Magneto-Inductive Sensor for Quantitative Assay of Prostate-Specific Antigen. IEEE Magnetics Letters, 2017, 8, 1-5.	0.6	16
48	Magnetic resonance imaging targeted transperineal prostate biopsy: a local anaesthetic approach. Prostate Cancer and Prostatic Diseases, 2017, 20, 311-317.	2.0	55
49	Weighing the evidence from surgical trials. BJU International, 2017, 119, 659-660.	1.3	10
50	Media reporting of ProtecT: a disconnect in information dissemination?. Prostate Cancer and Prostatic Diseases, 2017, 20, 401-406.	2.0	2
51	Prostate Cancer and the John West Effect. European Urology, 2017, 72, 7-9.	0.9	6
52	Breast and Prostate Cancer: Lessons to Be Shared. International Journal of Radiation Oncology Biology Physics, 2017, 98, 263-268.	0.4	3
53	Overactive bladder syndrome and lower urinary tract symptoms after prostate cancer treatment. Current Opinion in Urology, 2017, 27, 307-313.	0.9	16
54	Does mpMRI improve clinical criteria in selecting men with prostate cancer for active surveillance?. Prostate Cancer and Prostatic Diseases, 2017, 20, 323-327.	2.0	16
55	Insights from the PLCO trial about prostate cancer screening. Cancer, 2017, 123, 546-548.	2.0	2
56	Extended mortality results for prostate cancer screening in the PLCO trial with median followâ€™up of 15 years. Cancer, 2017, 123, 592-599.	2.0	178
57	Clinical and molecular rationale to retain the cancer descriptor for Gleason score 6 disease. Nature Reviews Urology, 2017, 14, 59-64.	1.9	3
59	Toxicity after postâ€™prostatectomy imageâ€™guided intensityâ€™modulated radiotherapy using Australian guidelines. Journal of Medical Imaging and Radiation Oncology, 2017, 61, 804-811.	0.9	2
60	High-dose-rate brachytherapy as salvage modality for locally recurrent prostate cancer after definitive radiotherapy. Strahlentherapie Und Onkologie, 2017, 193, 683-691.	1.0	18
61	Prognostic Significance of a Negative Confirmatory Biopsy on Reclassification Among Men on Active Surveillance. Urology, 2017, 107, 184-189.	0.5	9

#	ARTICLE	IF	CITATIONS
62	Personalised Medicine Approaches to Screening and Prevention. <i>New Bioethics</i> , 2017, 23, 21-29.	0.5	4
63	Prognostic utility of biopsy-derived cell cycle progression score in patients with National Comprehensive Cancer Network low-risk prostate cancer undergoing radical prostatectomy: implications for treatment guidance. <i>BJU International</i> , 2017, 120, 808-814.	1.3	48
64	Brachytherapy in the Management of Prostate Cancer. <i>Surgical Oncology Clinics of North America</i> , 2017, 26, 491-513.	0.6	17
65	Active surveillance in prostate cancer: new efforts, new voices, new hope. <i>BJU International</i> , 2017, 120, 4-5.	1.3	1
66	Prostate-specific membrane antigen radioguided surgery: a promising utility. <i>BJU International</i> , 2017, 120, 5-6.	1.3	9
67	Intermediate Risk Prostate Cancer and Active Surveillance: Maximize Utilization while Minimizing Failure. <i>Journal of Urology</i> , 2017, 198, 493-495.	0.2	0
68	You Pays Your Money, You Takes Your Choice: Functional Outcomes Following Curative Treatment for Clinically Localized Prostate Cancer. <i>Urology</i> , 2017, 107, 3-4.	0.5	0
69	Contemporary management of men with high-risk localized prostate cancer in the United States. <i>Prostate Cancer and Prostatic Diseases</i> , 2017, 20, 283-288.	2.0	32
70	New advances in focal therapy for early stage prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 737-743.	1.1	16
71	The Contemporary Role of Multiparametric Magnetic Resonance Imaging in Active Surveillance for Prostate Cancer. <i>Current Urology Reports</i> , 2017, 18, 52.	1.0	15
72	Radical Prostatectomy for High-risk Localized or Node-Positive Prostate Cancer: Removing the Primary. <i>Current Urology Reports</i> , 2017, 18, 53.	1.0	7
73	Understanding and Improving Recruitment to Randomised Controlled Trials: Qualitative Research Approaches. <i>European Urology</i> , 2017, 72, 789-798.	0.9	105
74	Adjuvant Versus Early Salvage Radiation Therapy Following Radical Prostatectomy for Men with Localized Prostate Cancer. <i>Current Urology Reports</i> , 2017, 18, 55.	1.0	15
75	GP-patient communication about possible cancer in primary care: Re-evaluating GP as gatekeeper. <i>European Journal of Cancer Care</i> , 2017, 26, e12699.	0.7	2
76	In Regard to Shaverdian et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 216-217.	0.4	1
78	When no treatment is the best treatment: Active surveillance strategies for low risk prostate cancers. <i>Cancer Treatment Reviews</i> , 2017, 58, 14-21.	3.4	12
79	Value of Prostate Cancer Care: New Information on New Therapies Suggest Less is More. <i>European Urology</i> , 2017, 72, 736-737.	0.9	3
80	Updates on the diagnosis and treatment of prostate cancer. <i>British Journal of Radiology</i> , 2017, 90, 20170180.	1.0	14

#	ARTICLE	IF	CITATIONS
81	Prevention of Prostate Cancer Morbidity and Mortality. <i>Medical Clinics of North America</i> , 2017, 101, 787-806.	1.1	115
82	Patient-reported outcome measures in urology. <i>Current Opinion in Urology</i> , 2017, 27, 366-374.	0.9	29
83	A Framework for Treatment Decision Making at Prostate Cancer Recurrence. <i>Medical Decision Making</i> , 2017, 37, 905-913.	1.2	6
84	Comparing quality of life outcomes after prostate cancer treatment. <i>Nature Reviews Urology</i> , 2017, 14, 396-397.	1.9	1
85	Long-Term Quality of Life in Prostate Cancer Patients Treated With Cesium-131. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 1053-1058.	0.4	6
86	Re: Long-term Oncological Outcomes of an Active Surveillance Program in Recurrent Low Grade Ta Bladder Cancer. <i>European Urology</i> , 2017, 72, 152.	0.9	2
87	National Trends and Predictors of Androgen Deprivation Therapy Use in Low-Risk Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 338-343.	0.4	9
88	Editorial Comment. <i>Journal of Urology</i> , 2017, 197, 1066-1066.	0.2	0
90	<sc>GATA</sc>3 expression in benign prostate glands with radiation atypia: a diagnostic pitfall. <i>Histopathology</i> , 2017, 71, 150-155.	1.6	13
91	Patient-Reported Outcomes Following Treatment for Localized Prostate Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 1121.	3.8	15
92	Association Between Radiation Therapy, Surgery, or Observation for Localized Prostate Cancer and Patient-Reported Outcomes After 3 Years. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 1126.	3.8	261
93	Redox/pH dual-sensitive hybrid micelles for targeting delivery and overcoming multidrug resistance of cancer. <i>Journal of Materials Chemistry B</i> , 2017, 5, 2964-2978.	2.9	34
94	Extracellular vesicles for liquid biopsy in prostate cancer: where are we and where are we headed?. <i>Prostate Cancer and Prostatic Diseases</i> , 2017, 20, 251-258.	2.0	82
95	Exosomes and Exosomal MicroRNAs in Prostate Cancer Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 982-995.	0.4	56
96	Androgen deprivation therapy for prostate cancer and dementia risk: a systematic review and meta-analysis. <i>Prostate Cancer and Prostatic Diseases</i> , 2017, 20, 259-264.	2.0	60
97	Prostate Cancer Screening "A Perspective on the Current State of the Evidence. <i>New England Journal of Medicine</i> , 2017, 376, 1285-1289.	13.9	106
98	To ProtecT Our Patients With Prostate Cancer. <i>JAMA Oncology</i> , 2017, 3, 1461.	3.4	2
99	Low-risk Prostate Cancer: Identification, Management, and Outcomes. <i>European Urology</i> , 2017, 72, 238-249.	0.9	55

#	ARTICLE	IF	CITATIONS
100	Re: Ten-year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. <i>European Urology</i> , 2017, 71, 491-492.	0.9	2
101	Risk stratification: a tool to predict the course of active surveillance for localized prostate cancer?. <i>BJU International</i> , 2017, 120, 212-218.	1.3	9
102	Clinically localized prostate cancer in 2017: A review of comparative effectiveness. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 40-41.	0.8	20
103	Continued Benefit to Rectal Separation for Prostate Radiation Therapy: Final Results of a Phase III Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 976-985.	0.4	276
104	ProtecTion™ from overtreatment: does a randomized trial finally answer the key question in localized prostate cancer?. <i>BJU International</i> , 2017, 119, 513-514.	1.3	5
105	Improved outcomes and precision medicine come within reach. <i>Nature Reviews Urology</i> , 2017, 14, 71-72.	1.9	4
106	A Comparison Between Low-Dose-Rate Brachytherapy With or Without Androgen Deprivation, External Beam Radiation Therapy With or Without Androgen Deprivation, and Radical Prostatectomy With or Without Adjuvant or Salvage Radiation Therapy for High-Risk Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 962-975.	0.4	45
107	Surgery-based Multimodal Management of High-risk Prostate Cancer Patients: What Is the Functional Price To Pay for Optimal Disease Control?. <i>European Urology</i> , 2017, 71, 337-339.	0.9	3
108	Contemporary Active Surveillance. <i>Urologic Clinics of North America</i> , 2017, 44, 565-574.	0.8	20
111	Protecting Low-Risk Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 515-517.	0.4	3
112	IGF-1R associates with adverse outcomes after radical radiotherapy for prostate cancer. <i>British Journal of Cancer</i> , 2017, 117, 1600-1606.	2.9	35
113	Definitive Radiotherapy for Older Patients with Prostate Cancer: Experience of a Medical Center in Taiwan. <i>Scientific Reports</i> , 2017, 7, 13880.	1.6	5
114	Developments in urologic oncology – OncoForum: The best of 2016. <i>Actas Urológicas Españolas (English Edition)</i> , 2017, 41, 543-551.	0.2	0
115	Thyroid cancer incidence: The discovery of the hidden iceberg. <i>Endocrinología y Nutrición (English Ed)</i> , 2017, 64, 285-287.	0.1	0
116	Clinical Case Discussion: Primary Treatment for Prostate Cancer in an Elderly Man – Treatment of the Primary Tumor is Necessary. <i>European Urology Focus</i> , 2017, 3, 326-327.	1.6	2
118	Prostatectomy versus Observation for Early Prostate Cancer. <i>New England Journal of Medicine</i> , 2017, 377, 1301-1303.	13.9	9
119	Current Role of Magnetic Resonance Imaging in Prostate Cancer. <i>Current Radiology Reports</i> , 2017, 5, 1.	0.4	1
120	What role does stereotactic ablative radiotherapy have in advanced castrate-resistant prostate cancer?. <i>Future Oncology</i> , 2017, 13, 2121-2124.	1.1	2

#	ARTICLE	IF	CITATIONS
121	Active Surveillance Versus Watchful Waiting for Localized Prostate Cancer: A Model to Inform Decisions. <i>European Urology</i> , 2017, 72, 899-907.	0.9	23
122	African-American Prostate Cancer Disparities. <i>Current Urology Reports</i> , 2017, 18, 81.	1.0	77
123	In localised prostate cancer, radical prostatectomy was associated with more sexual dysfunction and urinary incontinence than radiation or active surveillance. <i>Evidence-Based Medicine</i> , 2017, 22, 192-192.	0.6	1
124	Ten-year Mortality in Men With Nonmetastatic Prostate Cancer in Norway. <i>Urology</i> , 2017, 110, 140-147.	0.5	8
125	Making the grade: The newest US Preventive Services Task Force prostate cancer screening recommendation. <i>Cancer</i> , 2017, 123, 3875-3878.	2.0	1
127	Trends in active surveillance for very low-risk prostate cancer: do guidelines influence modern practice?. <i>Cancer Medicine</i> , 2017, 6, 2410-2418.	1.3	26
128	A House Divided: The Irradiation Versus Prostatectomy Debate Continues. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 512-514.	0.4	3
129	Tissue-based biomarkers in prostate cancer. <i>Expert Review of Precision Medicine and Drug Development</i> , 2017, 2, 249-260.	0.4	20
131	Short- and Long-term Functional Outcomes and Quality of Life after Radical Prostatectomy: Patient-reported Outcomes from a Tertiary High-volume Center. <i>European Urology Focus</i> , 2017, 3, 615-620.	1.6	44
132	Laparoscopic and robotic-assisted versus open radical prostatectomy for the treatment of localised prostate cancer. <i>The Cochrane Library</i> , 2017, 2017, CD009625.	1.5	103
133	Circulating steroid hormone variations throughout different stages of prostate cancer. <i>Endocrine-Related Cancer</i> , 2017, 24, R403-R420.	1.6	34
134	Magnetic resonance imaging in the early detection of prostate cancer and review of the literature on magnetic resonance imaging-stratified clinical pathways. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 1159-1168.	1.1	4
135	The Natural History of Erectile Dysfunction After Prostatic Radiotherapy: A Systematic Review and Meta-Analysis. <i>Journal of Sexual Medicine</i> , 2017, 14, 1071-1078.	0.3	50
136	Prevalence and associations of general practitioners' ordering of 'non-symptomatic' prostate-specific antigen tests: A cross-sectional analysis. <i>International Journal of Clinical Practice</i> , 2017, 71, e12998.	0.8	3
137	Active Surveillance for Low-Risk Cancers – A Viable Solution to Overtreatment?. <i>New England Journal of Medicine</i> , 2017, 377, 203-206.	13.9	61
138	Early Stage Cancer in Older Adults. <i>Cancer Journal (Sudbury, Mass)</i> , 2017, 23, 238-241.	1.0	9
139	Current trends in patient enrollment for robotic-assisted laparoscopic prostatectomy in Belgium. <i>Cancer</i> , 2017, 123, 4139-4146.	2.0	8
140	Avances en uroncología «OncoForum»: lo mejor de 2016. <i>Actas Urológicas Españolas</i> , 2017, 41, 543-551.	0.3	0

#	ARTICLE	IF	CITATIONS
141	Potential overtreatment among men aged 80 years and older with localized prostate cancer in Japan. <i>Cancer Science</i> , 2017, 108, 1673-1680.	1.7	5
143	Adaptation of the By-Band randomized clinical trial to By-Band-Sleeve to include a new intervention and maintain relevance of the study to practice. <i>British Journal of Surgery</i> , 2017, 104, 1207-1214.	0.1	34
144	Incidencia de c�ncer de tiroides: el descubrimiento del iceberg oculto. <i>Endocrinologia, Diabetes Y Nutrici�n</i> , 2017, 64, 285-287.	0.1	1
145	Management and outcomes of Gleason six prostate cancer detected on needle biopsy: A single-surgeon experience over 6�years. <i>Prostate International</i> , 2017, 5, 139-142.	1.2	3
146	Surgical Techniques to Optimize Early Urinary Continence Recovery Post Robot Assisted Radical Prostatectomy for Prostate Cancer. <i>Current Urology Reports</i> , 2017, 18, 71.	1.0	54
147	Intratumoural evolutionary landscape of high-risk prostate cancer: the PROGENY study of genomic and immune parameters. <i>Annals of Oncology</i> , 2017, 28, 2472-2480.	0.6	45
148	Diagnostic accuracy of the PROMIS study. <i>Lancet, The</i> , 2017, 390, 362.	6.3	1
149	Quality of Life Outcomes after Primary Treatment for Clinically Localised Prostate Cancer: A Systematic Review. <i>European Urology</i> , 2017, 72, 869-885.	0.9	182
150	Management of Urethral Stricture and Bladder Neck Contracture Following Primary and Salvage Treatment of Prostate Cancer. <i>Current Urology Reports</i> , 2017, 18, 76.	1.0	43
151	Salvage surgery for nodal recurrent prostate cancer. <i>Current Opinion in Urology</i> , 2017, 27, 604-611.	0.9	10
152	Improving postoperative radiotherapy following radical prostatectomy. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 925-937.	1.1	0
154	The phythological future of prostate cancer staging: PSMA-PET and the dandelion theory. <i>Future Oncology</i> , 2017, 13, 1801-1807.	1.1	3
155	Diagnostic characteristics of lethal prostate cancer. <i>European Journal of Cancer</i> , 2017, 84, 18-26.	1.3	31
156	A Roadmap for Improving the Management of Favorable Risk Prostate�Cancer. <i>Journal of Urology</i> , 2017, 198, 1220-1222.	0.2	20
157	Active Surveillance for Intermediate Risk Prostate Cancer. <i>Current Urology Reports</i> , 2017, 18, 80.	1.0	29
158	Clinical Factors Predicting Tumour Upgrading in Patients Under Active Surveillance and Elected to Active Treatment after Disease Reclassification or Progression. <i>Urologia Internationalis</i> , 2017, 99, 186-193.	0.6	2
159	Is Advocacy for Active Surveillance Over Definitive Intervention in Low-Risk Prostate Cancer Applicable to African American Patients?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 1076-1077.	0.4	2
160	The prostate cancer screening clinic in the Bahamas: a model for low- and middle-income countries. <i>Cancer Causes and Control</i> , 2017, 28, 1187-1193.	0.8	4

#	ARTICLE	IF	CITATIONS
161	Comparative study of laparoscopic radical prostatectomy and robot-assisted radical prostatectomy on perioperative, oncological and functional outcomes. <i>Surgical Practice</i> , 2017, 21, 141-148.	0.1	2
162	Prostatectomy versus radiotherapy for early-stage prostate cancer (PREPaRE) study: protocol for a mixed-methods study of treatment decision-making in men with localised prostate cancer. <i>BMJ Open</i> , 2017, 7, e018403.	0.8	3
163	Approach to the Patient with High-Risk Prostate Cancer. <i>Urologic Clinics of North America</i> , 2017, 44, 635-645.	0.8	6
164	Neurovascular bundle size measured on 3.0-T magnetic resonance imaging is associated with the recovery of erectile function after robot-assisted radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 542.e11-542.e17.	0.8	4
165	The Diagnosis and Treatment of Prostate Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 2532.	3.8	959
167	Follow-up of Prostatectomy versus Observation for Early Prostate Cancer. <i>New England Journal of Medicine</i> , 2017, 377, 132-142.	13.9	460
171	Diagnosis, staging, and risk stratification in prostate cancer: Utilizing diagnostic tools to avoid unnecessary therapies and side effects. <i>Cancer Biology and Therapy</i> , 2017, 18, 470-472.	1.5	4
172	Identification of endonuclease domain-containing 1 as a novel tumor suppressor in prostate cancer. <i>BMC Cancer</i> , 2017, 17, 360.	1.1	8
173	The evolution of brachytherapy for prostate cancer. <i>Nature Reviews Urology</i> , 2017, 14, 415-439.	1.9	106
174	Relevance of DNA damage repair in the management of prostate cancer. <i>Current Problems in Cancer</i> , 2017, 41, 287-301.	1.0	16
175	What Early ProtecT Results Have Confirmed About Risk-stratified Prostate Cancer Management. <i>European Urology</i> , 2017, 71, 389-390.	0.9	1
176	Active Surveillance: A Ten-year Journey. <i>European Urology</i> , 2017, 72, 542-543.	0.9	3
177	Diffusion-weighted endorectal MR imaging at 3T for prostate cancer: correlation with tumor cell density and percentage Gleason pattern on whole mount pathology. <i>Abdominal Radiology</i> , 2017, 42, 918-925.	1.0	26
178	Introduction. <i>Seminars in Radiation Oncology</i> , 2017, 27, 1-2.	1.0	0
179	Je le pansai, Dieu le guerit. <i>European Urology</i> , 2017, 72, 343-344.	0.9	5
180	Mortality Among Men with Advanced Prostate Cancer Excluded from the ProtecT Trial. <i>European Urology</i> , 2017, 71, 381-388.	0.9	41
181	Screening and treatment: where do we go from here?. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 7-8.	12.5	1
182	Magnetic Resonance Imaging for Membranous Urethral Length Assessment Prior to Radical Prostatectomy: Can it Really Improve Prostate Cancer Management?. <i>European Urology</i> , 2017, 71, 379-380.	0.9	6

#	ARTICLE	IF	CITATIONS
183	The Surgical Management of Prostate Cancer. <i>Seminars in Oncology</i> , 2017, 44, 347-357.	0.8	60
184	Incongruence in treatment decision making is associated with lower health-related quality of life among prostate cancer survivors: results from the PiCTure study. <i>Supportive Care in Cancer</i> , 2017, 26, 1645-1654.	1.0	7
185	Reducing Mortality in the Ageing Patient: Treatment of the Primary Tumour Is Not Necessary. <i>European Urology Focus</i> , 2017, 3, 328-329.	1.6	0
186	Early Stage Cancer in Older Adults: Prostate "Avoiding Overtreatment and Undertreatment. <i>Cancer Journal (Sudbury, Mass)</i> , 2017, 23, 238-241.	1.0	6
187	In patients with localised prostate cancer, active surveillance is associated with better sexual function, urinary symptoms and bowel symptoms. <i>Evidence-Based Medicine</i> , 2017, 22, 217-218.	0.6	0
188	Taxane-based chemohormonal therapy for metastatic hormone-sensitive prostate cancer. <i>The Cochrane Library</i> , 0, , .	1.5	3
190	Immune Modulation by Androgen Deprivation and Radiation Therapy: Implications for Prostate Cancer Immunotherapy. <i>Cancers</i> , 2017, 9, 13.	1.7	40
191	Canadian Urological Association recommendations on prostate cancer screening and early diagnosis. <i>Canadian Urological Association Journal</i> , 2017, 11, 298-309.	0.3	55
192	PSA screening for prostate cancer. <i>Revista Da Associação Médica Brasileira</i> , 2017, 63, 722-725.	0.3	8
193	Focal application of low-dose-rate brachytherapy for prostate cancer: a pilot study. <i>Journal of Contemporary Brachytherapy</i> , 2017, 3, 197-208.	0.4	18
194	Data-Based Radiation Oncology: Design of Clinical Trials in the Toxicity Biomarkers Era. <i>Frontiers in Oncology</i> , 2017, 7, 83.	1.3	36
195	Utilization of Patient-Reported Outcomes to Guide Symptom Management during Stereotactic Body Radiation Therapy for Clinically Localized Prostate Cancer. <i>Frontiers in Oncology</i> , 2017, 7, 227.	1.3	5
196	The Long-Term Effect of Radical Prostatectomy on Erectile Function, Urinary Continence, and Lower Urinary Tract Symptoms: A Comparison to Age-Matched Healthy Controls. <i>BioMed Research International</i> , 2017, 2017, 1-5.	0.9	12
197	Influence of Men's Personality and Social Support on Treatment Decision-Making for Localized Prostate Cancer. <i>BioMed Research International</i> , 2017, 2017, 1-8.	0.9	19
198	Melatonin potentiates "inside-out" nano-thermotherapy in human breast cancer cells: a potential cancer target multimodality treatment based on melatonin-loaded nanocomposite particles. <i>International Journal of Nanomedicine</i> , 2017, Volume 12, 7351-7363.	3.3	15
199	Hypo-fractionated SBRT for localized prostate cancer: a German bi-center single treatment group feasibility trial. <i>Radiation Oncology</i> , 2017, 12, 138.	1.2	14
200	Intermediate-term outcome after PSMA-PET guided high-dose radiotherapy of recurrent high-risk prostate cancer patients. <i>Radiation Oncology</i> , 2017, 12, 140.	1.2	34
201	Informed consent in randomised controlled trials: development and preliminary evaluation of a measure of Participatory and Informed Consent (PIC). <i>Trials</i> , 2017, 18, 327.	0.7	9

#	ARTICLE	IF	CITATIONS
203	Stereotactic radiotherapy for prostate cancer: A review and future directions. <i>World Journal of Clinical Oncology</i> , 2017, 8, 389-397.	0.9	22
204	A simple reduction-sensitive micelles co-delivery of paclitaxel and dasatinib to overcome tumor multidrug resistance. <i>International Journal of Nanomedicine</i> , 2017, Volume 12, 8043-8056.	3.3	24
205	Eleven-year Management of Prostate Cancer Patients on Active Surveillance: What have We Learned?. <i>Tumori</i> , 2017, 103, 464-474.	0.6	20
206	Multi-parametric MRI imaging of the prostate—implications for focal therapy. <i>Translational Andrology and Urology</i> , 2017, 6, 453-463.	0.6	19
207	Reply to I.E. Haines. <i>Journal of Clinical Oncology</i> , 2017, 35, 1626-1627.	0.8	0
208	The Burden of Healthcare Costs Associated with Prostate Cancer in Ireland. <i>Global & Regional Health Technology Assessment</i> , 2017, 4, grhta.5000249.	0.2	1
209	Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 3097-3104.	0.8	327
210	Treatment Decision Regret Among Long-Term Survivors of Localized Prostate Cancer: Results From the Prostate Cancer Outcomes Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 2306-2314.	0.8	81
211	Is Low-Risk Prostate Cancer More Indolent in Younger Patients?. <i>Journal of Clinical Oncology</i> , 2017, 35, 1870-1871.	0.8	1
212	Screening and Treating Prostate Cancer in the Older Patient: Decision Making Across the Clinical Spectrum. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 370-381.	1.8	3
213	Role of mpMRI of the prostate in screening for prostate cancer. <i>Translational Andrology and Urology</i> , 2017, 6, 464-471.	0.6	22
214	Prostate Problems. , 2018, , 477-490.		1
215	Screening for Prostate Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 868.	3.8	4
216	Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 883.	3.8	296
217	Biomarker potential of <i>ST6GALNAC3</i> and <i>ZNF660</i> promoter hypermethylation in prostate cancer tissue and liquid biopsies. <i>Molecular Oncology</i> , 2018, 12, 545-560.	2.1	49
218	Androgen Deprivation Therapy Potentiates the Efficacy of Vascular Targeted Photodynamic Therapy of Prostate Cancer Xenografts. <i>Clinical Cancer Research</i> , 2018, 24, 2408-2416.	3.2	19
219	Active Surveillance for Prostate Cancer: Are We Failing Latino Patients at a Large Safety Net Hospital?. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e719-e727.	0.9	4
220	Rectal <i>E. coli</i> above ciprofloxacin ECOFF associate with infectious complications following prostate biopsy. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2018, 37, 1055-1060.	1.3	6

#	ARTICLE	IF	CITATIONS
221	Time-driven activity-based cost comparison of prostate cancer brachytherapy and intensity-modulated radiation therapy. <i>Brachytherapy</i> , 2018, 17, 556-563.	0.2	38
222	Racial and Ethnic Differences in Prostate Cancer Survivors' Perceived Engagement in Treatment Decision-Making. <i>Journal of Racial and Ethnic Health Disparities</i> , 2018, 5, 1273-1283.	1.8	9
223	Integration and Diagnostic Accuracy of 3T Nonendorectal coil Prostate Magnetic Resonance Imaging in the Context of Active Surveillance. <i>Urology</i> , 2018, 116, 137-143.	0.5	10
224	Is radiotherapy the work of the devil?. <i>BJU International</i> , 2018, 121, 6-7.	1.3	4
225	Nanoparticle-based targeted cancer strategies for noninvasive prostate cancer intervention. <i>Journal of Cellular Physiology</i> , 2018, 233, 6408-6417.	2.0	8
226	3 + 4 = 6? Implications of the stratification of localized Gleason 7 prostate cancer by number and percentage of positive biopsy cores in selecting patients for active surveillance. <i>Actas Urológicas Españolas (English Edition)</i> , 2018, 42, 103-113.	0.2	2
227	Long-term functional outcome analysis in a large cohort of patients after radical prostatectomy. <i>Neurourology and Urodynamics</i> , 2018, 37, 2263-2270.	0.8	15
228	Health-related quality of life in active surveillance and radical prostatectomy for low-risk prostate cancer: a prospective observational study (HAROW - Hormonal therapy, Active Surveillance, Radiation,) <i>Tj ETQq1 1.0.7843 14 rgBT / Ov</i>	1.0	14
229	Active Surveillance for Localized Renal Masses: Tumor Growth, Delayed Intervention Rates, and >5-yr Clinical Outcomes. <i>European Urology</i> , 2018, 74, 157-164.	0.9	106
230	Pair-matched patient-reported quality of life and early oncological control following focal irreversible electroporation versus robot-assisted radical prostatectomy. <i>World Journal of Urology</i> , 2018, 36, 1383-1389.	1.2	28
231	Patient-reported outcomes after treatment for clinically localized prostate cancer: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2018, 66, 23-44.	3.4	38
232	Men's perceptions of the impact of the physical consequences of a radical prostatectomy on their quality of life: a qualitative systematic review. <i>JB I Database of Systematic Reviews and Implementation Reports</i> , 2018, 16, 892-972.	1.7	20
233	A biodegradable rectal balloon implant to protect the rectum during prostate cancer radiotherapy for a patient with active Crohn's disease. <i>Technical Innovations and Patient Support in Radiation Oncology</i> , 2018, 6, 1-4.	0.6	5
234	Advancing the Quality of Care for Newly Diagnosed Prostate Cancer Patients: Novel Uses of Patient-Reported Outcomes. <i>Annals of Surgical Oncology</i> , 2018, 25, 1475-1477.	0.7	0
236	Developing new age-specific prostate-specific antigen thresholds for testing for prostate cancer. <i>Cancer Causes and Control</i> , 2018, 29, 383-388.	0.8	15
238	Focal Therapy in Primary Localised Prostate Cancer : The European Association of Urology Position in 2018. <i>European Urology</i> , 2018, 74, 84-91.	0.9	136
239	Prostate Cancer Screening. <i>Medical Clinics of North America</i> , 2018, 102, 199-214.	1.1	134
240	Role of Surveillance Biopsy with No Cancer as a Prognostic Marker for Reclassification: Results from the Canary Prostate Active Surveillance Study. <i>European Urology</i> , 2018, 73, 706-712.	0.9	17

#	ARTICLE	IF	CITATIONS
241	Does Prophylactic Radiation Therapy to Avoid Gynecomastia in Patients With Prostate Cancer Increase the Risk of Breast Cancer?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 211-216.	0.4	8
242	Medical operability and inoperability drive survival in retrospective analyses comparing surgery and SBRT for early-stage lung cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2018, 155, 810-811.	0.4	8
243	Progression and treatment rates using an active surveillance protocol incorporating image-guided baseline biopsies and multiparametric magnetic resonance imaging monitoring for men with favourable-risk prostate cancer. <i>BJU International</i> , 2018, 122, 59-65.	1.3	47
244	Predicting prostate cancer progression: protocol for a retrospective cohort study to identify prognostic factors for prostate cancer outcomes using routine primary care data. <i>BMJ Open</i> , 2018, 8, e019409.	0.8	8
245	The Danger of Applying the ProtecT Trial to Minority Populations. <i>JAMA Oncology</i> , 2018, 4, 291.	3.4	8
246	Long-term outcomes following proton therapy for prostate cancer in young men with a focus on sexual health. <i>Acta Oncologica</i> , 2018, 57, 582-588.	0.8	17
247	Cost-effectiveness of magnetic resonance imaging and targeted fusion biopsy for early detection of prostate cancer. <i>BJU International</i> , 2018, 122, 50-58.	1.3	49
248	Quality of life among men with low-risk prostate cancer during the first year following diagnosis: the PREPARE prospective cohort study. <i>Translational Behavioral Medicine</i> , 2018, 8, 156-165.	1.2	9
249	Nuestra experiencia en el manejo del cncer de prstata en pacientes trasplantados renales. <i>Actas Urolgicas Espaolas</i> , 2018, 42, 249-255.	0.3	6
251	Evaluation of Magnetic Resonance Imaging/Ultrasound-Fusion Biopsy in Patients with Low-Risk Prostate Cancer Under Active Surveillance Undergoing Surveillance Biopsy. <i>Urologia Internationalis</i> , 2018, 100, 155-163.	0.6	12
252	Utilization of Active Surveillance and Watchful Waiting for localized prostate cancer in the daily practice. <i>World Journal of Urology</i> , 2018, 36, 383-391.	1.2	12
254	Superior Biochemical Recurrence and Long-term Quality-of-life Outcomes Are Achievable with Robotic Radical Prostatectomy After a Long Learning Curve—Updated Analysis of a Prospective Single-surgeon Cohort of 2206 Consecutive Cases. <i>European Urology</i> , 2018, 73, 664-671.	0.9	59
255	Curative Radiation Therapy at Time of Progression Under Active Surveillance Compared With Up-front Radical Radiation Therapy for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 702-709.	0.4	1
256	Sipuleucel-T for the treatment of prostate cancer: novel insights and future directions. <i>Future Oncology</i> , 2018, 14, 907-917.	1.1	112
257	Pathologic Outcomes of Candidates for Active Surveillance Undergoing Radical Prostatectomy: Results from a Contemporary Turkish Patient Cohort. <i>Urologia Internationalis</i> , 2018, 100, 43-49.	0.6	5
258	Evolving detection and treatment methods change approaches to prostate cancer. <i>Cancer</i> , 2018, 124, 11-12.	2.0	2
259	The CADMUS trial — Multi-parametric ultrasound targeted biopsies compared to multi-parametric MRI targeted biopsies in the diagnosis of clinically significant prostate cancer. <i>Contemporary Clinical Trials</i> , 2018, 66, 86-92.	0.8	9
260	Supporting prostate cancer survivors in primary care: Findings from a pilot trial of a nurse-led psycho-educational intervention (PROSPECTIV). <i>European Journal of Oncology Nursing</i> , 2018, 32, 73-81.	0.9	17

#	ARTICLE	IF	CITATIONS
261	Re: Impact of Radical Prostatectomy on Long-term Oncologic Outcomes in a Matched Cohort of Men with Pathological Node Positive Prostate Cancer Managed by Castration. <i>European Urology</i> , 2018, 73, 140.	0.9	0
262	A prospective cohort and extended comprehensive-cohort design provided insights about the generalizability of a pragmatic trial: the ProtecT prostate cancer trial. <i>Journal of Clinical Epidemiology</i> , 2018, 96, 35-46.	2.4	16
263	Editorial Comment. <i>Journal of Urology</i> , 2018, 199, 681-681.	0.2	0
264	Comparison of Pathological and Oncologic Outcomes of Favorable Risk Gleason Score 3 + 4 and Low Risk Gleason Score 6 Prostate Cancer: Considerations for Active Surveillance. <i>Journal of Urology</i> , 2018, 199, 1188-1195.	0.2	26
265	Prostate Cancer. <i>Medical Clinics of North America</i> , 2018, 102, 215-229.	1.1	12
266	Are concurrent systematic cores needed at the time of targeted biopsy in patients with prior negative prostate biopsies?. <i>Progres En Urologie</i> , 2018, 28, 18-24.	0.3	10
267	Prostate cancer proteomics: clinically useful protein biomarkers and future perspectives. <i>Expert Review of Proteomics</i> , 2018, 15, 65-79.	1.3	41
268	Prostate Cancer Death After Radiotherapy or Radical Prostatectomy: A Nationwide Population-based Observational Study. <i>European Urology</i> , 2018, 73, 502-511.	0.9	37
269	Prostate cancer high dose-rate brachytherapy: review of evidence and current perspectives. <i>Expert Review of Medical Devices</i> , 2018, 15, 71-79.	1.4	21
270	Study finds link between inflammation and colorectal cancer. <i>Cancer</i> , 2018, 124, 13-13.	2.0	1
271	Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part II: Recommended Approaches and Details of Specific Care Options. <i>Journal of Urology</i> , 2018, 199, 990-997.	0.2	279
272	Moderately hypofractionated prostate external-beam radiotherapy: an emerging standard. <i>British Journal of Radiology</i> , 2018, 91, 20170807.	1.0	12
273	The Utility of PET/CT in the Planning of External Radiation Therapy for Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2018, 59, 557-567.	2.8	41
274	Age at diagnosis and prostate cancer treatment and prognosis: a population-based cohort study. <i>Annals of Oncology</i> , 2018, 29, 377-385.	0.6	77
275	¿Es Ãtil el sistema transobturatriz ajustable ATOMS Â® para el tratamiento de la incontinencia urinaria masculina en centros urolÃ³gicos de bajo y medio volumen?. <i>Actas UrolÃ³gicas EspaÃ±olas</i> , 2018, 42, 267-272.	0.3	12
276	Superior metastasis-free survival for patients with high-risk prostate cancer treated with definitive radiation therapy compared to radical prostatectomy: A propensity score-matched analysis. <i>Advances in Radiation Oncology</i> , 2018, 3, 190-196.	0.6	11
277	A comparison of time taken to return to baseline erectile function following focal and whole gland ablative therapies for localized prostate cancer: A systematic review. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 67-76.	0.8	19
278	An RNA-Based Digital Circulating Tumor Cell Signature Is Predictive of Drug Response and Early Dissemination in Prostate Cancer. <i>Cancer Discovery</i> , 2018, 8, 288-303.	7.7	107

#	ARTICLE	IF	CITATIONS
279	Neoadjuvant degarelix with or without apalutamide followed by radical prostatectomy for intermediate and high-risk prostate cancer: ARNEO, a randomized, double blind, placebo-controlled trial. <i>BMC Cancer</i> , 2018, 18, 354.	1.1	16
280	The Cambridge Prognostic Groups for improved prediction of disease mortality at diagnosis in primary non-metastatic prostate cancer: a validation study. <i>BMC Medicine</i> , 2018, 16, 31.	2.3	36
281	Persisting adverse body composition changes 2 years after cessation of androgen deprivation therapy for localised prostate cancer. <i>European Journal of Endocrinology</i> , 2018, 179, 21-29.	1.9	13
282	Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts. <i>BMJ: British Medical Journal</i> , 2018, 360, j5757.	2.4	153
283	Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part I: Risk Stratification, Shared Decision Making, and Care Options. <i>Journal of Urology</i> , 2018, 199, 683-690.	0.2	606
284	Finding Value for Protons: The Case of Prostate Cancer?. <i>Seminars in Radiation Oncology</i> , 2018, 28, 131-137.	1.0	4
285	African-American men and prostate cancer-specific mortality: a competing risk analysis of a large institutional cohort, 1989-2015. <i>Cancer Medicine</i> , 2018, 7, 2160-2171.	1.3	29
286	Functional outcomes of robot-assisted radical prostatectomy in patients eligible for active surveillance. <i>World Journal of Urology</i> , 2018, 36, 1391-1397.	1.2	4
287	Re: Effect of Prior Focal Therapy on Perioperative, Oncologic and Functional Outcomes of Salvage Robotic Assisted Radical Prostatectomy. <i>Journal of Urology</i> , 2018, 199, 1634-1635.	0.2	0
288	Outcomes and Prognostic Factors in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Recurrence after Radical Prostatectomy. <i>Journal of Urology</i> , 2018, 200, 1075-1081.	0.2	5
289	Factors Influencing Men's Choice of and Adherence to Active Surveillance for Low-risk Prostate Cancer: A Mixed-method Systematic Review. <i>European Urology</i> , 2018, 74, 261-280.	0.9	82
290	Periprostatic fat tissue transcriptome reveals a signature diagnostic for high-risk prostate cancer. <i>Endocrine-Related Cancer</i> , 2018, 25, 569-581.	1.6	19
291	Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer. <i>JAMA Oncology</i> , 2018, 4, e180039.	3.4	238
292	National trends in management of localized prostate cancer: A population based analysis 2004-2013. <i>Prostate</i> , 2018, 78, 512-520.	1.2	49
293	Enhanced expression of SRPK2 contributes to aggressive progression and metastasis in prostate cancer. <i>Biomedicine and Pharmacotherapy</i> , 2018, 102, 531-538.	2.5	19
294	A standardized analysis of the current surgical and non-surgical treatment selection process for men with localized prostate cancer. <i>Journal of Robotic Surgery</i> , 2018, 12, 215-221.	1.0	0
295	Defining the optimal method for reporting prostate cancer grade and tumor extent on magnetic resonance/ultrasound fusion-targeted biopsies. <i>Human Pathology</i> , 2018, 76, 68-75.	1.1	22
296	Time between diagnosis and surgical treatment on pathological and clinical outcomes in prostate cancer: does it matter?. <i>World Journal of Urology</i> , 2018, 36, 1225-1231.	1.2	16

#	ARTICLE	IF	CITATIONS
297	Prostate Cancer: Improving the Flow of Research. <i>Radiology</i> , 2018, 287, 5-9.	3.6	2
298	MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. <i>New England Journal of Medicine</i> , 2018, 378, 1767-1777.	13.9	2,036
299	Patient-Reported Sexual Aid Utilization and Efficacy After Radiation Therapy for Localized Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 376-386.	0.4	7
300	Survival and Complications Following Surgery and Radiation for Localized Prostate Cancer: An International Collaborative Review. <i>European Urology</i> , 2018, 73, 11-20.	0.9	76
301	Randomised Controlled Trials Remain the Key to Progress in Localised Prostate Cancer. <i>European Urology</i> , 2018, 73, 21-22.	0.9	2
302	Long-term oncological outcomes and toxicity in 597 men aged ≥60 years at time of low-dose-rate brachytherapy for localised prostate cancer. <i>BJU International</i> , 2018, 121, 38-45.	1.3	27
303	Erectile function after stereotactic body radiotherapy for localized prostate cancer. <i>BJU International</i> , 2018, 121, 61-68.	1.3	24
304	PTEN Loss but Not ERG Expression in Diagnostic Biopsies Is Associated with Increased Risk of Progression and Adverse Surgical Findings in Men with Prostate Cancer on Active Surveillance. <i>European Urology Focus</i> , 2018, 4, 867-873.	1.6	30
305	Adverse Pathologic Findings for Men Electing Immediate Radical Prostatectomy. <i>JAMA Oncology</i> , 2018, 4, 89.	3.4	52
306	Temporal Trends in Clinical and Pathological Characteristics for Men Undergoing Radical Prostatectomy Between 1995 and 2013 at Rigshospitalet, Copenhagen, Denmark, and Stanford University Hospital, United States. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e181-e192.	0.9	4
307	Oncologic Outcomes of Definitive Treatments for Low- and Intermediate-Risk Prostate Cancer After a Period of Active Surveillance. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e425-e435.	0.9	8
308	Dynamics of rectal balloon implant shrinkage in prostate VMAT. <i>Strahlentherapie Und Onkologie</i> , 2018, 194, 31-40.	1.0	17
309	Prostate Cancer Patient Characteristics Associated With a Strong Preference to Preserve Sexual Function and Receipt of Active Surveillance. <i>Journal of the National Cancer Institute</i> , 2018, 110, 420-425.	3.0	17
310	Healthcare utilization in men with poorer sexual and urinary function recovery following robot-assisted radical prostatectomy. <i>World Journal of Urology</i> , 2018, 36, 21-26.	1.2	2
311	Prospective Phase 2 Trial of Permanent Seed Implantation Prostate Brachytherapy for Intermediate-Risk Localized Prostate Cancer: Efficacy, Toxicity, and Quality of Life Outcomes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 374-382.	0.4	42
312	Cost-Effectiveness of Primary Radiation Therapy Versus Radical Prostatectomy for Intermediate- to High-Risk Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 383-390.	0.4	7
313	Laparoscopic and robot-assisted vs open radical prostatectomy for the treatment of localized prostate cancer: a Cochrane systematic review. <i>BJU International</i> , 2018, 121, 845-853.	1.3	88
314	Radical prostatectomy or radiotherapy reduce prostate cancer mortality in elderly patients: a population-based propensity score adjusted analysis. <i>World Journal of Urology</i> , 2018, 36, 7-13.	1.2	23

#	ARTICLE	IF	CITATIONS
315	Optimising the Diagnosis of Prostate Cancer in the Era of Multiparametric Magnetic Resonance Imaging: A Cost-effectiveness Analysis Based on the Prostate MR Imaging Study (PROMIS). <i>European Urology</i> , 2018, 73, 23-30.	0.9	133
316	Genomic Scores are Independent of Disease Volume in Men with Favorable Risk Prostate Cancer: Implications for Choosing Men for Active Surveillance. <i>Journal of Urology</i> , 2018, 199, 438-444.	0.2	11
317	The accuracy of patients'™ perceptions of the risks associated with localised prostate cancer treatments. <i>BJU International</i> , 2018, 121, 405-414.	1.3	15
318	Are prostate biopsies necessary for all patients 75 years and older?. <i>Journal of Geriatric Oncology</i> , 2018, 9, 124-129.	0.5	4
319	Active surveillance for localized prostate cancer: update of a prospective single-center cohort. <i>Scandinavian Journal of Urology</i> , 2018, 52, 14-19.	0.6	12
320	Targeted Prostate Biopsy in the Era of Active Surveillance. <i>Urology</i> , 2018, 112, 12-19.	0.5	17
321	Erectile Function Recovery After Surgery in Young Men with Low-risk Prostate Cancer: Probably Not Just a Matter of Age, Certainly Not the Main Point of Discussion. <i>European Urology</i> , 2018, 73, 38-39.	0.9	1
322	2017 Update on Medical Overuse. <i>JAMA Internal Medicine</i> , 2018, 178, 110.	2.6	61
323	Summary statement on screening for prostate cancer in Europe. <i>International Journal of Cancer</i> , 2018, 142, 741-746.	2.3	29
324	Preventing clinical progression and need for treatment in patients on active surveillance for prostate cancer. <i>Current Opinion in Urology</i> , 2018, 28, 46-54.	0.9	6
325	A Biopsy-based 17-gene Genomic Prostate Score as a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease. <i>European Urology</i> , 2018, 73, 129-138.	0.9	94
326	Quality of life after brachytherapy or bilateral nerve-sparing robot-assisted radical prostatectomy for prostate cancer: a prospective cohort. <i>BJU International</i> , 2018, 121, 540-548.	1.3	22
327	¿3 + 4 = 6? Implicaciones de la estratificación del cáncer de próstata localizado Gleason 7 por número y porcentaje de cilindros positivos de biopsia en la selección de pacientes para vigilancia activa. <i>Actas Urológicas Españolas</i> , 2018, 42, 103-113.	0.3	2
328	Improved Recovery of Erectile Function in Younger Men after Radical Prostatectomy: Does it Justify Immediate Surgery in Low-risk Patients?. <i>European Urology</i> , 2018, 73, 33-37.	0.9	11
329	Long-term Psychological and Quality-of-life Effects of Active Surveillance and Watchful Waiting After Diagnosis of Low-risk Localised Prostate Cancer. <i>European Urology</i> , 2018, 73, 859-867.	0.9	33
330	Survival Outcomes of Radical Prostatectomy Versus Radiotherapy in Intermediate-Risk Prostate Cancer: A NCDB Study. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e39-e46.	0.9	11
331	Decision aid use during post-biopsy consultations for localized prostate cancer. <i>Health Expectations</i> , 2018, 21, 279-287.	1.1	15
332	Clinical utility of emerging liquid biomarkers in advanced prostate cancer. <i>Cancer Genetics</i> , 2018, 228-229, 151-158.	0.2	11

#	ARTICLE	IF	CITATIONS
333	Biopsy Core Features are Poor Predictors of Adverse Pathology in Men with Grade Group 1 Prostate Cancer. <i>Journal of Urology</i> , 2018, 199, 961-968.	0.2	7
334	Tumor Volume on Biopsy of Low Risk Prostate Cancer Managed with Active Surveillance. <i>Journal of Urology</i> , 2018, 199, 954-960.	0.2	11
335	Active Surveillance for Low and Intermediate Risk Prostate Cancer: Opinions of North American Genitourinary Oncology Expert Radiation Oncologists. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e323-e325.	0.9	13
336	Active Surveillance Offers Functional Advantages Without Impacting Survival for Low-risk Prostate Cancer. <i>European Urology</i> , 2018, 73, 868-869.	0.9	3
337	Trajectories of prostate-specific antigen after treatment for prostate cancer. <i>Journal of Investigative Medicine</i> , 2018, 66, 768-772.	0.7	1
338	Re: Follow-up of Prostatectomy Versus Observation for Early Prostate Cancer. <i>European Urology</i> , 2018, 73, 302-303.	0.9	4
339	Prostate cancer screening with prostate-specific antigen: Where are we going?. <i>Cancer</i> , 2018, 124, 453-455.	2.0	8
340	Combining Prostate Health Index density, magnetic resonance imaging and prior negative biopsy status to improve the detection of clinically significant prostate cancer. <i>BJU International</i> , 2018, 121, 619-626.	1.3	70
341	Too Big to Fail? The Current Status of Proton Therapy in the USA. <i>Clinical Oncology</i> , 2018, 30, 271-273.	0.6	22
342	Communicating your research (part 2): to the wider community. <i>Journal of Clinical Urology</i> , 2018, 11, 208-214.	0.1	0
343	Re: Follow-up of Prostatectomy Versus Observation for Early Prostate Cancer. <i>European Urology</i> , 2018, 73, 477-478.	0.9	0
344	GLUT1 regulates cell glycolysis and proliferation in prostate cancer. <i>Prostate</i> , 2018, 78, 86-94.	1.2	130
345	Review of the comparative effectiveness of radical prostatectomy, radiation therapy, or expectant management of localized prostate cancer in registry data. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 183-192.	0.8	19
346	Pathologic Outcomes of Gleason 6 Favorable Intermediate-Risk Prostate Cancer Treated With Radical Prostatectomy: Implications for Active Surveillance. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 226-234.	0.9	14
347	Atypical small acinar proliferation at index prostate biopsy: rethinking the re-biopsy paradigm. <i>International Urology and Nephrology</i> , 2018, 50, 1-6.	0.6	8
348	Patterns of relapse as determined by 68Ga-PSMA ligand PET/CT after radical prostatectomy. <i>Strahlentherapie Und Onkologie</i> , 2018, 194, 303-310.	1.0	23
349	Use of Alternative Medicine for Cancer and Its Impact on Survival. <i>Journal of the National Cancer Institute</i> , 2018, 110, 121-124.	3.0	198
351	Prognostic role of platelet to lymphocyte ratio in prostate cancer. <i>Medicine (United States)</i> , 2018, 97, e12504.	0.4	28

#	ARTICLE	IF	CITATIONS
352	Prostate Cancer Screening and the Goldilocks Principle: How Much Is Just Right?. Journal of Clinical Oncology, 2018, 36, 937-941.	0.8	7
353	A Younger Man With Localized Prostate Cancer Asks, "Which Type of Radiation Is Right for Me?". Journal of Clinical Oncology, 2018, 36, 1780-1784.	0.8	1
354	Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. Journal of Clinical Oncology, 2018, 36, 1020-1044.	0.8	108
355	High-Risk Localized Prostate Cancer: How Important Is the Addition of Brachytherapy to External-Beam Radiotherapy?. Journal of Clinical Oncology, 2018, 36, 3344-3345.	0.8	2
356	Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline. Journal of Clinical Oncology, 2018, 36, 3411-3430.	0.8	118
357	Prostate Cancer Radiotherapy: An Evolving Paradigm. Journal of Clinical Oncology, 2018, 36, 2909-2913.	0.8	9
358	Reply to A.J. Chang et al and A. Gomez-Iturriaga et al. Journal of Clinical Oncology, 2018, 36, 3345-3347.	0.8	1
359	Brachytherapy-Based Radiotherapy and Radical Prostatectomy Are Associated With Similar Survival in High-Risk Localized Prostate Cancer. Journal of Clinical Oncology, 2018, 36, 1192-1198.	0.8	80
360	Optimal Radical Therapy for Localized Prostate Cancer: Recreation of the Self-Fulfilling Prophecy With Combination Brachytherapy?. Journal of Clinical Oncology, 2018, 36, 2914-2917.	0.8	16
362	Being on active surveillance: the patient perspective. Translational Andrology and Urology, 2018, 7, 182-187.	0.6	2
363	Biomarkers in active surveillance. Translational Andrology and Urology, 2018, 7, 155-159.	0.6	14
364	Quality of life in active surveillance and the associations with decision-making—a literature review. Translational Andrology and Urology, 2018, 7, 160-169.	0.6	8
365	Men with a susceptibility to prostate cancer and the role of genetic based screening. Translational Andrology and Urology, 2018, 7, 61-69.	0.6	19
366	The prostate cancer focal therapy. Gland Surgery, 2018, 7, 89-102.	0.5	15
367	Quality of care and economic considerations of active surveillance of men with prostate cancer. Translational Andrology and Urology, 2018, 7, 203-213.	0.6	2
368	Surrogate endpoints in early prostate cancer research. Translational Andrology and Urology, 2018, 7, 472-482.	0.6	14
369	The future of active surveillance. Translational Andrology and Urology, 2018, 7, 256-259.	0.6	8
370	Contemporary role of postoperative radiotherapy for prostate cancer. Translational Andrology and Urology, 2018, 7, 399-413.	0.6	5

#	ARTICLE	IF	CITATIONS
371	Entering an era of radiogenomics in prostate cancer risk stratification. <i>Translational Andrology and Urology</i> , 2018, 7, S443-S452.	0.6	7
372	Rethinking active surveillance for prostate cancer in African American men. <i>Translational Andrology and Urology</i> , 2018, 7, S397-S410.	0.6	10
373	Rate of misclassification in patients undergoing radical prostatectomy but fulfilling active surveillance criteria according to the European Association of Urology guidelines on prostate cancer: a high-volume center experience. <i>Minerva Urologica e Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2018, 70, 588-593.	3.9	5
374	Brachytherapy for localized prostate cancer in the modern era: a comparison of patient-reported quality of life outcomes among different techniques. <i>Journal of Contemporary Brachytherapy</i> , 2018, 10, 495-502.	0.4	15
375	SpaceOAR to improve dosimetric outcomes for monotherapy high-dose-rate prostate implantation in a patient with ulcerative colitis. <i>Journal of Contemporary Brachytherapy</i> , 2018, 10, 577-582.	0.4	4
376	Current evidence for active surveillance for intermediate risk prostate cancer: editorial on comparison of pathological and oncologic outcomes in "favorable risk" GS 3+4 and low risk GS6 prostate cancer by Gearman et al., <i>Journal of Urology. AME Medical Journal</i> , 2018, 3, 55-55.	0.4	0
377	An Overview on Prostate Pathophysiology: New Insights into Prostate Cancer Clinical Diagnosis. , 2018, , .		2
379	Treatment Options in Oncology. <i>JCO Clinical Cancer Informatics</i> , 2018, 2, 1-10.	1.0	18
380	Multiparametric Magnetic Resonance Imaging Cost-effectiveness in Active Surveillance: More a Belief than Evidence. <i>European Urology Oncology</i> , 2018, 1, 484-485.	2.6	0
381	Impact of Biochemical Failure After Salvage Radiation Therapy on Prostate Cancer-specific Mortality: Competition Between Age and Time to Biochemical Failure. <i>European Urology Oncology</i> , 2018, 1, 276-282.	2.6	6
383	Radiotherapy for Elderly Patients Aged ≥75 Years with Clinically Localized Prostate Cancer—Is There a Role of Brachytherapy?. <i>Journal of Clinical Medicine</i> , 2018, 7, 424.	1.0	8
384	Impact of Pelvic Radiation Therapy on Inflatable Penile Prosthesis Reoperation Rates. <i>Journal of Sexual Medicine</i> , 2018, 15, 1653-1658.	0.3	3
385	Diagnosis of prostate cancer in a Chinese population by using machine learning methods. , 2018, 2018, 1-4.		15
387	A Randomized, Double-blind, Phase II Trial of PSA-TRICOM (PROSTVAC) in Patients with Localized Prostate Cancer: The Immunotherapy to Prevent Progression on Active Surveillance Study. <i>European Urology Focus</i> , 2018, 4, 636-638.	1.6	16
388	Active Surveillance for Papillary Thyroid Microcarcinoma: Challenges and Prospects. <i>Frontiers in Endocrinology</i> , 2018, 9, 736.	1.5	17
389	Focal Salvage Treatment of Radiorecurrent Prostate Cancer: A Narrative Review of Current Strategies and Future Perspectives. <i>Cancers</i> , 2018, 10, 480.	1.7	24
390	The cost of treatment and its related complications for men who receive surgery or radiation therapy for prostate cancer. <i>Canadian Urological Association Journal</i> , 2018, 13, E236-E248.	0.3	4
391	Radical Prostatectomy or Watchful Waiting in Prostate Cancer—29-Year Follow-up. <i>New England Journal of Medicine</i> , 2018, 379, 2319-2329.	13.9	338

#	ARTICLE	IF	CITATIONS
392	Number of radiotherapy treatment machines in the population and cancer mortality: an ecological study. <i>Clinical Epidemiology</i> , 2018, Volume 10, 1249-1273.	1.5	6
393	Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer. <i>Frontiers in Oncology</i> , 2018, 8, 397.	1.3	20
394	Prostate-Associated Gene 4 (PAGE4): Leveraging the Conformational Dynamics of a Dancing Protein Cloud as a Therapeutic Target. <i>Journal of Clinical Medicine</i> , 2018, 7, 156.	1.0	10
395	Exposure to radiation and medical oncology training: A survey of Canadian urology residents and fellows. <i>Canadian Urological Association Journal</i> , 2018, 12, 321-325.	0.3	5
396	Feasibility of anatomical feature points for the estimation of prostate locations in the Bayesian delineation frameworks for prostate cancer radiotherapy. <i>Radiological Physics and Technology</i> , 2018, 11, 434-444.	1.0	2
397	Atypical Breast Proliferative Lesions and Benign Breast Disease. , 2018, , .		0
398	Early toxicity and patient reported quality-of-life in patients receiving proton therapy for localized prostate cancer: a single institutional review of prospectively recorded outcomes. <i>Radiation Oncology</i> , 2018, 13, 179.	1.2	4
399	The Role of Immunohistochemical Analysis as a Tool for the Diagnosis, Prognostic Evaluation and Treatment of Prostate Cancer: A Systematic Review of the Literature. <i>Frontiers in Oncology</i> , 2018, 8, 377.	1.3	18
400	How do we manage overdiagnosis/overtreatment in breast screening?. <i>Clinical Radiology</i> , 2018, 73, 372-380.	0.5	12
401	Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO, and AUA Evidence-Based Guideline. <i>Practical Radiation Oncology</i> , 2018, 8, 354-360.	1.1	151
402	Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline. <i>Journal of Urology</i> , 2018, , .	0.2	16
403	Radiotherapy for Localized and Locally Advanced Prostate Cancer. , 2018, , 1-16.		0
405	Active surveillance for prostate cancer: a systematic review of contemporary worldwide practices. <i>Translational Andrology and Urology</i> , 2018, 7, 83-97.	0.6	99
406	Adjuvant vs. salvage radiation therapy in men with high-risk features after radical prostatectomy: Survey of North American genitourinary expert radiation oncologists. <i>Canadian Urological Association Journal</i> , 2018, 13, E132-E134.	0.3	1
407	Psychometric Evaluation of PROMIS Sexual Function and Satisfaction Measures in a Longitudinal Population-Based Cohort of Men With Localized Prostate Cancer. <i>Journal of Sexual Medicine</i> , 2018, 15, 1792-1810.	0.3	12
408	Taxane-based chemohormonal therapy for metastatic hormone-sensitive prostate cancer. <i>The Cochrane Library</i> , 2018, 2018, CD012816.	1.5	21
409	Extracts of Clove (<i>Syzygium aromaticum</i>) Potentiate FMSP-Nanoparticles Induced Cell Death in MCF-7 Cells. <i>International Journal of Biomaterials</i> , 2018, 2018, 1-10.	1.1	27
410	Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. <i>BMJ: British Medical Journal</i> , 2018, 362, k3519.	2.4	319

#	ARTICLE	IF	CITATIONS
411	Low-risk Prostate Cancer Prior to or After Kidney Transplantation. <i>European Urology Focus</i> , 2018, 4, 148-152.	1.6	13
412	Diagnostic expansion in clinical trials: myocardial infarction, stroke, cancer recurrence, and metastases may not be the hard endpoints you thought they were. <i>BMJ: British Medical Journal</i> , 2018, 362, k3783.	2.4	7
413	Attitude towards active surveillance: a cross-sectional survey among patients with uroandrological disorders. <i>BMJ Open</i> , 2018, 8, e022495.	0.8	1
414	Top 20 POEMs of the Past 20 Years: A Survey of Practice-Changing Research for Family Physicians. <i>Annals of Family Medicine</i> , 2018, 16, 436-439.	0.9	3
415	Emerging role of MRI in radiation therapy. <i>Journal of Magnetic Resonance Imaging</i> , 2018, 48, 1468-1478.	1.9	89
416	Comparing Prognostic Utility of a Single-marker Immunohistochemistry Approach with Commercial Gene Expression Profiling Following Radical Prostatectomy. <i>European Urology</i> , 2018, 74, 668-675.	0.9	34
417	ONE SHOT - single shot radiotherapy for localized prostate cancer: study protocol of a single arm, multicenter phase I/II trial. <i>Radiation Oncology</i> , 2018, 13, 166.	1.2	27
418	Risk of Becoming Lost to Follow-up During Active Surveillance for Prostate Cancer. <i>European Urology</i> , 2018, 74, 704-707.	0.9	18
419	Reduction of MRI-targeted biopsies in men with low-risk prostate cancer on active surveillance by stratifying to PI-RADS and PSA-density, with different thresholds for significant disease. <i>Translational Andrology and Urology</i> , 2018, 7, 132-144.	0.6	43
420	An EM-based semi-supervised deep learning approach for semantic segmentation of histopathological images from radical prostatectomies. <i>Computerized Medical Imaging and Graphics</i> , 2018, 69, 125-133.	3.5	46
421	Predictive value of the UICC and AJCC 8th edition tumor-nodes-metastasis (TNM) classification for patients treated with radical prostatectomy. <i>Cancer Epidemiology</i> , 2018, 56, 126-132.	0.8	7
422	Focal therapy for prostate cancer. <i>Current Opinion in Urology</i> , 2018, 28, 536-543.	0.9	9
423	Genetics and biology of prostate cancer. <i>Genes and Development</i> , 2018, 32, 1105-1140.	2.7	434
424	Patterns of care and outcomes for men diagnosed with prostate cancer in Victoria: an update. <i>ANZ Journal of Surgery</i> , 2018, 88, 1037-1042.	0.3	13
425	Practice-changing radiation therapy trials for the treatment of cancer: where are we 150 years after the birth of Marie Curie?. <i>British Journal of Cancer</i> , 2018, 119, 389-407.	2.9	92
427	Time for a "Radical" Change to Active Surveillance for Prostate Cancer?. <i>European Urology</i> , 2018, 74, 281-282.	0.9	4
428	When Clinical Trials Disagree. <i>Journal of Urology</i> , 2018, 200, 506-507.	0.2	0
429	ACR Appropriateness Criteria® Post-treatment Follow-up Prostate Cancer. <i>Journal of the American College of Radiology</i> , 2018, 15, S132-S149.	0.9	20

#	ARTICLE	IF	CITATIONS
431	The personal and clinical utility of polygenic risk scores. <i>Nature Reviews Genetics</i> , 2018, 19, 581-590.	7.7	1,102
432	Our experience in the management of prostate cancer in renal transplant recipients. <i>Actas Urológicas Españolas (English Edition)</i> , 2018, 42, 249-255.	0.2	1
433	Long-Term Outcomes after Deferred Radical Prostatectomy in Men Initially Treated with Active Surveillance. <i>Journal of Urology</i> , 2018, 200, 779-785.	0.2	11
434	The Diverse Genomic Landscape of Clinically Low-risk Prostate Cancer. <i>European Urology</i> , 2018, 74, 444-452.	0.9	55
435	Primary cryotherapy for localised or locally advanced prostate cancer. <i>The Cochrane Library</i> , 2018, 5, CD005010.	1.5	11
436	miR-106a and prostate cancer radioresistance: a novel role for LITAF in ATM regulation. <i>Molecular Oncology</i> , 2018, 12, 1324-1341.	2.1	39
437	Exercise training as a novel primary treatment for localised prostate cancer: a multi-site randomised controlled phase II study. <i>Scientific Reports</i> , 2018, 8, 8374.	1.6	24
440	Optimizing radiotherapy for intermediate-risk localized disease. <i>Nature Reviews Urology</i> , 2018, 15, 470-471.	1.9	2
441	Heterogeneity in Definitions of High-risk Prostate Cancer and Varying Impact on Mortality Rates after Radical Prostatectomy. <i>European Urology Oncology</i> , 2018, 1, 143-148.	2.6	19
442	Quality of Life after Radical Prostatectomy or Watchful Waiting With or Without Androgen Deprivation Therapy: The SPCG-4 Randomized Trial. <i>European Urology Oncology</i> , 2018, 1, 134-142.	2.6	11
443	Cumulative Cancer Locations is a Novel Metric for Predicting Active Surveillance Outcomes: A Multicenter Study. <i>European Urology Oncology</i> , 2018, 1, 268-275.	2.6	5
444	Functional and Oncologic Outcomes Between Open and Robotic Radical Prostatectomy at 24-month Follow-up in the Swedish LAPPRO Trial. <i>European Urology Oncology</i> , 2018, 1, 353-360.	2.6	61
445	Editorial Comment. <i>Urology</i> , 2018, 116, 142.	0.5	0
446	Long-term outcomes of partial prostate treatment with magnetic resonance imaging-guided brachytherapy for patients with favorable-risk prostate cancer. <i>Cancer</i> , 2018, 124, 3528-3535.	2.0	15
447	A Multicentre Study of 5-year Outcomes Following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer. <i>European Urology</i> , 2018, 74, 422-429.	0.9	220
448	Comprehensive molecular classification of localized prostate adenocarcinoma reveals a tumour subtype predictive of non-aggressive disease. <i>Annals of Oncology</i> , 2018, 29, 1814-1821.	0.6	35
449	Metastatic Involvement of the Prostatic Anterior Fat Pad. <i>American Journal of Clinical Pathology</i> , 2018, 150, 130-136.	0.4	2
451	Landmarks in prostate cancer. <i>Nature Reviews Urology</i> , 2018, 15, 627-642.	1.9	78

#	ARTICLE	IF	CITATIONS
452	Moderate hypofractionation for prostate cancer. <i>Translational Andrology and Urology</i> , 2018, 7, 321-329.	0.6	5
453	Association between rectal bleeding and the absolute dose volume of the rectum following image-guided radiotherapy for patients with prostate cancer. <i>Oncology Letters</i> , 2018, 16, 2741-2749.	0.8	6
454	Distributions of manganese in diverse human cancers provide insights into tumour radioresistance. <i>Metallomics</i> , 2018, 10, 1191-1210.	1.0	19
455	Mind the gap: Physicians' assessment of patients' importance weights in localized prostate cancer. <i>PLoS ONE</i> , 2018, 13, e0200780.	1.1	3
456	Survival outcomes of radical prostatectomy and external beam radiotherapy in clinically localized high-risk prostate cancer: a population-based, propensity score matched study. <i>Cancer Management and Research</i> , 2018, Volume 10, 1061-1067.	0.9	21
458	Low dose rate prostate brachytherapy. <i>Translational Andrology and Urology</i> , 2018, 7, 341-356.	0.6	30
459	Radiation Oncology in the 21st Century: Prospective Randomized Trials That Changed Practice or Didn't!. <i>Frontiers in Oncology</i> , 2018, 8, 130.	1.3	4
460	Proton Beam Therapy Alone for Intermediate- or High-Risk Prostate Cancer: An Institutional Prospective Cohort Study. <i>Cancers</i> , 2018, 10, 116.	1.7	10
461	Author Reply. <i>Urology</i> , 2018, 116, 142-143.	0.5	1
462	Long-term Outcomes of Radiotherapy Regimen of 72 Gy in 30 Fractions for Prostate Cancer. <i>Anticancer Research</i> , 2018, 38, 4207-4212.	0.5	2
464	A Novel Flavonoid Composition Targets Androgen Receptor Signaling and Inhibits Prostate Cancer Growth in Preclinical Models. <i>Neoplasia</i> , 2018, 20, 789-799.	2.3	23
465	Genome-wide Scan Identifies Role for AOX1 in Prostate Cancer Survival. <i>European Urology</i> , 2018, 74, 710-719.	0.9	47
466	Leveraging Engineering of Indocyanine Green-Encapsulated Polymeric Nanocomposites for Biomedical Applications. <i>Nanomaterials</i> , 2018, 8, 360.	1.9	55
467	Magnetic Resonance Imaging-Based Prostate Cancer Screening. <i>JAMA Network Open</i> , 2018, 1, e180220.	2.8	0
468	National Trends in Active Surveillance for Prostate Cancer: Validation of Medicare Claims-based Algorithms. <i>Urology</i> , 2018, 120, 96-102.	0.5	24
469	Randomized Trial of Partial Gland Ablation with Vascular Targeted Phototherapy versus Active Surveillance for Low Risk Prostate Cancer: Extended Followup and Analyses of Effectiveness. <i>Journal of Urology</i> , 2018, 200, 786-793.	0.2	65
470	A panel of DNA methylation markers for the detection of prostate cancer from FV and DRE urine DNA. <i>Clinical Epigenetics</i> , 2018, 10, 91.	1.8	35
471	Reducing overtreatment of prostate cancer by radical prostatectomy in Eastern Ontario: a population-based cohort study. <i>CMAJ Open</i> , 2018, 6, E197-E201.	1.1	5

#	ARTICLE	IF	CITATIONS
472	Screening for Prostate Cancer. JAMA - Journal of the American Medical Association, 2018, 319, 1901.	3.8	876
473	Prostate-Specific Antigen-Based Screening for Prostate Cancer. JAMA - Journal of the American Medical Association, 2018, 319, 1914.	3.8	367
474	Implications of the New USPSTF Prostate Cancer Screening Recommendation Attaining Equipoise. JAMA Internal Medicine, 2018, 178, 889.	2.6	4
475	USPTF Prostate Cancer Screening Recommendations A Step in the Right Direction. JAMA Surgery, 2018, 153, 701.	2.2	3
476	Cost-effectiveness of prostate cancer screening: a systematic review of decision-analytical models. BMC Cancer, 2018, 18, 84.	1.1	30
477	Quality of life after low-dose rate-brachytherapy for prostate carcinoma long-term results and literature review on QLQ-C30 and QLQ-PR25 results in published brachytherapy series. Health and Quality of Life Outcomes, 2018, 16, 21.	1.0	10
478	Health-related quality of life among long-term (5 years) prostate cancer survivors by primary intervention: a systematic review. Health and Quality of Life Outcomes, 2018, 16, 22.	1.0	24
479	A mini-review of quality of life as an outcome in prostate cancer trials: patient-centered approaches are needed to propose appropriate treatments on behalf of patients. Health and Quality of Life Outcomes, 2018, 16, 40.	1.0	8
480	Evaluation and Treatment for Older Men with Elevated PSA. , 2018, , 21-41.		0
481	Focal Therapy for Prostate Cancer: A More Vehement View of the Approach Could Translate into Real Benefits for Our Patients. European Urology, 2018, 74, 537-539.	0.9	7
482	Accuracy of tumor segmentation from multi-parametric prostate MRI and 18F-choline PET/CT for focal prostate cancer therapy applications. EJNMMI Research, 2018, 8, 23.	1.1	22
483	Renaming low risk conditions labelled as cancer. BMJ: British Medical Journal, 2018, 362, k3322.	2.4	31
484	Is the adjustable transobturator system ATOMS® useful for the treatment of male urinary incontinence in low to medium volume urological centers?. Actas Urológicas Españolas (English) Tj ETQq0 0 0 rg82/Overlock 10 Tf 50		
485	Association of Preferences for Papillary Thyroid Cancer Treatment With Disease Terminology. JAMA Otolaryngology - Head and Neck Surgery, 2018, 144, 887.	1.2	25
486	A biological modelling based comparison of radiotherapy plan robustness using photons vs protons for focal prostate boosting. Physics and Imaging in Radiation Oncology, 2018, 6, 101-105.	1.2	4
487	The Prognostic PDE4D7 Score in a Diagnostic Biopsy Prostate Cancer Patient Cohort with Longitudinal Biological Outcomes. Prostate Cancer, 2018, 2018, 1-11.	0.4	10
488	Regional variation in the intensity of prostate cancer care: A study of a large Medicare sample. International Journal of Urology, 2018, 25, 974-975.	0.5	1
491	Genomic diversity in low-risk disease: present and future. Nature Reviews Urology, 2018, 15, 594-596.	1.9	0

#	ARTICLE	IF	CITATIONS
492	Lower urinary tract infections from external beam radiation therapy in prostate cancer: A single institution experience. Reports of Practical Oncology and Radiotherapy, 2018, 23, 298-299.	0.3	0
493	Management of Nonmetastatic Failure Following Local Prostate Cancer Therapy. , 2018, , 1-14.		0
495	Factors influencing prostate cancer patterns of care: An analysis of treatment variation using the SEER database. Advances in Radiation Oncology, 2018, 3, 170-180.	0.6	47
496	Late toxicity in the randomized multicenter HYPRO trial for prostate cancer analyzed with automated treatment planning. Radiotherapy and Oncology, 2018, 128, 349-356.	0.3	16
497	Assessment of the Diagnostic Accuracy of Biparametric Magnetic Resonance Imaging for Prostate Cancer in Biopsy-Naive Men. JAMA Network Open, 2018, 1, e180219.	2.8	135
499	Understanding Medical Decision-making in Prostate Cancer Care. American Journal of Men's Health, 2018, 12, 1635-1647.	0.7	13
500	Active Surveillance for Low-risk Prostate Cancer: The European Association of Urology Position in 2018. European Urology, 2018, 74, 357-368.	0.9	105
501	Overcoming difficulties with equipoise to enable recruitment to a randomised controlled trial of partial ablation vs radical prostatectomy for unilateral localised prostate cancer. BJU International, 2018, 122, 970-977.	1.3	17
502	Variation in prostate cancer treatment and spending among Medicare shared savings program accountable care organizations. Cancer, 2018, 124, 3364-3371.	2.0	8
503	Association Between Prostate Imaging Reporting and Data System (PI-RADS) Score for the Index Lesion and Multifocal, Clinically Significant Prostate Cancer. European Urology Oncology, 2018, 1, 29-36.	2.6	43
504	Prostate Imaging-Reporting and Data System Steering Committee: PI-RADS v2 Status Update and Future Directions. European Urology, 2019, 75, 385-396.	0.9	200
505	The diagnostic accuracy of multiparametric magnetic resonance imaging before biopsy in the detection of prostate cancer. BJU International, 2019, 123, 82-90.	1.3	25
506	Implementation of multiparametric magnetic resonance imaging technology for evaluation of patients with suspicion for prostate cancer in the clinical practice setting. BJU International, 2019, 123, 239-245.	1.3	5
507	Cost-effectiveness of SelectMDx for prostate cancer in four European countries: a comparative modeling study. Prostate Cancer and Prostatic Diseases, 2019, 22, 101-109.	2.0	51
508	Association Between Prostate Magnetic Resonance Imaging and Observation for Low-risk Prostate Cancer. Urology, 2019, 124, 98-106.	0.5	9
509	Role of the 4Kscore test as a predictor of reclassification in prostate cancer active surveillance. Prostate Cancer and Prostatic Diseases, 2019, 22, 84-90.	2.0	17
510	Four-year outcomes from a multiparametric magnetic resonance imaging (MRI)-based active surveillance programme: PSA dynamics and serial MRI scans allow omission of protocol biopsies. BJU International, 2019, 123, 429-438.	1.3	36
511	Active Surveillance Magnetic Resonance Imaging Study (ASIST): Results of a Randomized Multicenter Prospective Trial. European Urology, 2019, 75, 300-309.	0.9	99

#	ARTICLE	IF	CITATIONS
513	Sexual Health Recovery For Prostate Cancer Survivors: The Proposed Role Of Acceptance And Mindfulness-Based Interventions. <i>Sexual Medicine Reviews</i> , 2019, 7, 627-635.	1.5	11
514	The Evolving Paradigm of Prostate Cancer Screening. <i>JAMA Network Open</i> , 2019, 2, e198392.	2.8	1
515	Bioactive and Inflammatory Markers in Emerging Psychotic Disorders. , 2019, , 191-203.		0
516	The Use of MRI and PET Imaging Studies for Prostate Cancer Management: Brief Update, Clinical Recommendations, and Technological Limitations. <i>Medical Sciences (Basel, Switzerland)</i> , 2019, 7, 85.	1.3	6
517	Reply to Francesco Montorsi, Giorgio Gandaglia, Alberto Briganti's Letter to the Editor, re: Veeru Kasivisvanathan, Armando Stabile, Joana B. Neves, et al. Magnetic Resonance Imaging-targeted Biopsy Versus Systematic Biopsy in the Detection of Prostate Cancer: A Systematic Review, Meta-analysis. <i>Eur Urol</i> 2019;76:284-303. <i>European Urology</i> , 2019, 76, e133-e134.	0.9	0
522	Planning feasibility of extremely hypofractionated prostate radiotherapy on a 1.5T magnetic resonance imaging guided linear accelerator. <i>Physics and Imaging in Radiation Oncology</i> , 2019, 11, 16-20.	1.2	10
524	Ductal Carcinoma In Situ Management: All or Nothing, or Something in between?. <i>Current Breast Cancer Reports</i> , 2019, 11, 190-202.	0.5	0
525	Hypofractionated Radiotherapy for Localized Prostate Cancer: When and for Whom?. <i>Current Urology Reports</i> , 2019, 20, 53.	1.0	11
526	Clinical outcomes associated with pathogenic genomic instability mutations in prostate cancer: a retrospective analysis of US pharmacy and medical claims data. <i>Journal of Medical Economics</i> , 2019, 22, 1080-1087.	1.0	4
527	Moderate hypofractionated helical tomotherapy for localized prostate cancer: preliminary report of an observational prospective study. <i>Tumori</i> , 2019, 105, 516-523.	0.6	8
528	Development and validation of a patient decision aid for prostate Cancer therapy: from paternalistic towards participative shared decision making. <i>BMC Medical Informatics and Decision Making</i> , 2019, 19, 130.	1.5	26
529	Moderate versus extreme hypofractionated radiotherapy: a toxicity comparative analysis in low- and favorable intermediate-risk prostate cancer patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 2547-2554.	1.2	26
530	Diagnostic accuracy of ⁶⁸ Ga-prostate-specific membrane antigen (⁶⁸ Ga-PSMA) positron emission tomography (PET) and multiparametric (mp)MRI to detect intermediate-grade intra-prostatic prostate cancer using whole-mount pathology: impact of the addition of ⁶⁸ Ga-PSMA PET to mpMRI. <i>BJU International</i> , 2019, 124, 42-49.	1.3	80
531	Factors associated with trial recruitment, preferences, and treatments received were elucidated in a comprehensive cohort study. <i>Journal of Clinical Epidemiology</i> , 2019, 113, 200-213.	2.4	6
532	Long-term efficacy and urological toxicity of low-dose-rate brachytherapy (LDR-BT) as monotherapy in localized prostate cancer. <i>Brachytherapy</i> , 2019, 18, 583-588.	0.2	14
533	Cost utility analysis of focal high-intensity focussed ultrasound vs active surveillance for low-to intermediate-risk prostate cancer using a Markov multi-state model. <i>BJU International</i> , 2019, 124, 962-971.	1.3	4
534	Decision Support Systems in Prostate Cancer Treatment: An Overview. <i>BioMed Research International</i> , 2019, 2019, 1-10.	0.9	19
535	Exercise during Active Surveillance for prostate cancer: the ERASE trial: a study protocol of a phase II randomised controlled trial. <i>BMJ Open</i> , 2019, 9, e026438.	0.8	10

#	ARTICLE	IF	CITATIONS
537	MRI-Guided Ultrafocal HDR Brachytherapy for Localized Prostate Cancer: Median 4-Year Results of a feasibility study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 1045-1053.	0.4	26
538	Particle therapy for prostate cancer: The past, present and future. <i>International Journal of Urology</i> , 2019, 26, 971-979.	0.5	28
539	Healthcare spending in the State of Louisiana. <i>BMC Health Services Research</i> , 2019, 19, 471.	0.9	0
540	Can automated treatment plans gain traction in the clinic?. <i>Journal of Applied Clinical Medical Physics</i> , 2019, 20, 29-35.	0.8	8
541	Clinical outcomes of external beam radiotherapy in patients with localized prostate cancer: Does dose escalation matter?. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2019, 15, 323-330.	0.7	2
542	Pea Protein/Gold Nanocluster/Indocyanine Green Ternary Hybrid for Near-Infrared Fluorescence/Computed Tomography Dual-Modal Imaging and Synergistic Photodynamic/Photothermal Therapy. <i>ACS Biomaterials Science and Engineering</i> , 2019, 5, 4799-4807.	2.6	21
543	<p>Shared decision making for men facing prostate cancer treatment: a systematic review of randomized controlled trials</p>. <i>Patient Preference and Adherence</i> , 2019, Volume 13, 1153-1174.	0.8	16
544	Randomised Trial of Adjuvant Radiotherapy Following Radical Prostatectomy Versus Radical Prostatectomy Alone in Prostate Cancer Patients with Positive Margins or Extracapsular Extension. <i>European Urology</i> , 2019, 76, 586-595.	0.9	68
545	¹⁸F-Choline PET/mpMRI for Detection of Clinically Significant Prostate Cancer: Part 2. Cost-Effectiveness Analysis. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1705-1712.	2.8	12
546	Identifying quality of life indicators to improve outpatient pharmacy services for prostate cancer patients: a comparison between brazilian and british experiences. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2019, 45, 435-448.	0.7	3
547	Conservative management of lowÊrisk prostate cancer among young versus older men in the United States: Trends and outcomes from a novel national database. <i>Cancer</i> , 2019, 125, 3338-3346.	2.0	15
548	Increasing the use of active surveillance for prostate cancer in younger men. <i>Cancer</i> , 2019, 125, 3292-3295.	2.0	6
549	PatientÊreported sexual quality of life after different types of radical prostatectomy and radiotherapy: Analysis of a populationÊbased prospective cohort. <i>Cancer</i> , 2019, 125, 3657-3665.	2.0	9
550	The pathological upgrading after radical prostatectomy in lowÊrisk prostate cancer patients who are eligible for active surveillance: How safe is it to depend on bioptic pathology?. <i>Prostate</i> , 2019, 79, 1523-1529.	1.2	21
551	The Association of the Long Prostate Cancer Expressed PDE4D Transcripts to Poor Patient Outcome Depends on the TumourÊs TMPRSS2-ERG Fusion Status. <i>Prostate Cancer</i> , 2019, 2019, 1-14.	0.4	8
552	Clinical applications of proton and carbon ion therapy. <i>Seminars in Oncology</i> , 2019, 46, 226-232.	0.8	62
554	SBRT for Localized Prostate Cancer: Is it Ready for Take-Off?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 618-620.	0.4	7
555	Oncological Outcome and Value of Postoperative Magnetic Resonance Imaging after Focal High-Intensity Focused Ultrasound Therapy for Prostate Cancer. <i>Urologia Internationalis</i> , 2019, 103, 270-278.	0.6	16

#	ARTICLE	IF	CITATIONS
556	EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study). <i>European Urology</i> , 2019, 76, 790-813.	0.9	151
557	Dosimetric Impact of Interfractional Variations in Prostate Cancer Radiotherapy—Implications for Imaging Frequency and Treatment Adaptation. <i>Frontiers in Oncology</i> , 2019, 9, 940.	1.3	20
558	A contemporary, nationwide analysis of surgery and radiotherapy treatment for prostate cancer. <i>BJU International</i> , 2019, 124, 31-36.	1.3	27
560	Treatment paths for localised prostate cancer in Italy: The results of a multidisciplinary, observational, prospective study (Pros-IT CNR). <i>PLoS ONE</i> , 2019, 14, e0224151.	1.1	8
561	Adjuvant versus early salvage radiotherapy: outcome of patients with prostate cancer treated with postoperative radiotherapy after radical prostatectomy. <i>Radiation Oncology</i> , 2019, 14, 198.	1.2	6
562	Factors Associated With Treatment Satisfaction After Robot-assisted Radical Prostatectomy. <i>Anticancer Research</i> , 2019, 39, 6339-6346.	0.5	9
563	A systematic review of the unmet supportive care needs of men on active surveillance for prostate cancer. <i>Psycho-Oncology</i> , 2019, 28, 2307-2322.	1.0	20
564	<p><p>Imaging-Based Individualized Response Prediction Of Carbon Ion Radiotherapy For Prostate Cancer Patients<p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 9121-9131.	0.9	18
565	Addition of Iodinated Contrast to Rectal Hydrogel Spacer to Facilitate MRI-Independent Target Delineation and Treatment Planning for Prostate Cancer. <i>Practical Radiation Oncology</i> , 2019, 9, e528-e533.	1.1	7
566	An electronic registry to improve adherence to active surveillance monitoring among men with prostate cancer at a safety-net hospital: protocol for a pilot study. <i>Pilot and Feasibility Studies</i> , 2019, 5, 101.	0.5	2
567	Patient-reported outcomes after open radical prostatectomy, laparoscopic radical prostatectomy and permanent prostate brachytherapy. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 1037-1042.	0.6	6
568	Predictive factors for survival outcomes of oligometastatic prostate cancer patients treated with metastases-directed therapy: a recursive partitioning-based analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 2469-2479.	1.2	14
569	Correlation between 18F-1-amino-3-fluorocyclobutane-1-carboxylic acid (18F-fluciclovine) uptake and expression of alanine-serine-cysteine-transporter 2 (ASCT2) and L-type amino acid transporter 1 (LAT1) in primary prostate cancer. <i>EJNMMI Research</i> , 2019, 9, 50.	1.1	14
570	Long non-coding RNAs in prostate cancer: Functional roles and clinical implications. <i>Cancer Letters</i> , 2019, 464, 37-55.	3.2	56
571	Histopathological evaluation of prostate specimens after thermal ablation may be confounded by the presence of thermally-fixed cells. <i>International Journal of Hyperthermia</i> , 2019, 36, 914-924.	1.1	6
572	Advancing Age and the Odds of Upgrading and Upstaging at Radical Prostatectomy in Men with Gleason Score 6 Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e1116-e1121.	0.9	13
573	Comparison of Outcomes and Toxicity Between Extreme and Moderate Radiation Therapy Hypofractionation in Localized Prostate Cancer: A Propensity Score Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 735-744.	0.4	6
574	Author Reply. <i>Urology</i> , 2019, 131, 174-175.	0.5	0

#	ARTICLE	IF	CITATIONS
575	Understanding of prognosis in non-metastatic prostate cancer: a randomised comparative study of clinician estimates measured against the PREDICT prostate prognostic model. <i>British Journal of Cancer</i> , 2019, 121, 715-718.	2.9	12
576	Low Abundance of Circulating Tumor DNA in Localized Prostate Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-13.	1.5	36
577	Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. <i>Lancet Oncology</i> , The, 2019, 20, 1531-1543.	5.1	362
578	Comparison of Rating Scale, Time Tradeoff, and Conjoint Analysis Methods for Assessment of Preferences in Prostate Cancer. <i>Medical Decision Making</i> , 2019, 39, 816-826.	1.2	3
579	Aberrant KIF20A Expression Is Associated with Adverse Clinical Outcome and Promotes Tumor Progression in Prostate Cancer. <i>Disease Markers</i> , 2019, 2019, 1-10.	0.6	31
581	Feasibility of MRI-guided transurethral ultrasound for lesion-targeted ablation of prostate cancer. <i>Scandinavian Journal of Urology</i> , 2019, 53, 295-302.	0.6	23
582	<p>Changes in risk-group stratification of patients undergoing radical prostatectomy at the Southern Alberta Institute of Urology over time</p>. <i>Research and Reports in Urology</i> , 2019, Volume 11, 69-75.	0.6	1
583	Population-Based Observational Studies in Oncology: Proceed With Caution. <i>Seminars in Radiation Oncology</i> , 2019, 29, 302-305.	1.0	5
584	Consensus statements on the management of clinically localized prostate cancer from the Hong Kong Urological Association and the Hong Kong Society of Uroâ€Oncology. <i>BJU International</i> , 2019, 124, 221-241.	1.3	4
585	Re: Sebastian Berg, Alexander P. Cole, Marieke J. Krimphove, et al. Comparative Effectiveness of Radical Prostatectomy Versus External Beam Radiation Therapy Plus Brachytherapy in Patients with High-risk Localized Prostate Cancer. <i>Eur Urol</i> 2019;75:552â€5. <i>European Urology</i> , 2019, 75, e133-e134.	0.9	0
586	Diet quality and Gleason grade progression among localised prostate cancer patients on active surveillance. <i>British Journal of Cancer</i> , 2019, 120, 466-471.	2.9	8
587	Evaluating the Cost-Effectiveness of Hydrogel Rectal Spacer in Prostate Cancer Radiation Therapy. <i>Practical Radiation Oncology</i> , 2019, 9, e172-e179.	1.1	20
588	Patient Decision-making: Where Are We Going?. <i>European Urology</i> , 2019, 75, 908-909.	0.9	1
589	Cribado del cÃ¡ncer de prÃ³stata con antÃ©geno especÃ­fico prostÃ¡tico en varones mayores de 75 aÃ±os. <i>Medicina ClÃ¡nica</i> , 2019, 152, 237-240.	0.3	3
590	Prognostic Significance for Long-Term Outcomes Following Radical Prostatectomy in Men with Prostate Cancer: Evaluation with Prostate Imaging Reporting and Data System Version 2. <i>Korean Journal of Radiology</i> , 2019, 20, 256.	1.5	12
592	A national survey of radiation oncologists and urologists on prediction tools and nomograms for localized prostate cancer. <i>World Journal of Urology</i> , 2019, 37, 2099-2108.	1.2	4
593	Oligometastatic prostate cancer: The game is afoot. <i>Cancer Treatment Reviews</i> , 2019, 73, 84-90.	3.4	41
594	Should we rename low risk cancers?. <i>BMJ: British Medical Journal</i> , 2019, 364, k4699.	2.4	23

#	ARTICLE	IF	CITATIONS
595	The collaborative management of late urological complications after radiation therapy. <i>BJU International</i> , 2019, 123, 8-9.	1.3	0
596	Individual and Population Comparisons of Surgery and Radiotherapy Outcomes in Prostate Cancer Using Bayesian Multistate Models. <i>JAMA Network Open</i> , 2019, 2, e187765.	2.8	17
597	<p>A new predictor is comparable to the updated nomogram in predicting the intermediate- and high-risk prostate cancer but outperforms nomogram in reducing the overtreatment for the low-risk Pca</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 3753-3763.	0.9	2
598	Association of Black Race With Prostate Cancerâ€™Specific and Other-Cause Mortality. <i>JAMA Oncology</i> , 2019, 5, 975.	3.4	288
599	Magnetic Resonance Imaging-targeted Biopsy Versus Systematic Biopsy in the Detection of Prostate Cancer: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2019, 76, 284-303.	0.9	153
600	â€ˆm not a chance takerâ€™: A mixed methods exploration of factors affecting prostate cancer treatment decision-making. <i>Ethnicity and Health</i> , 2021, 26, 1143-1162.	1.5	12
601	Automatic gas detection in prostate cancer patients during image-guided radiation therapy using a deep convolutional neural network. <i>Physica Medica</i> , 2019, 64, 24-28.	0.4	6
602	Models predicting survival to guide treatment decision-making in newly diagnosed primary non-metastatic prostate cancer: a systematic review. <i>BMJ Open</i> , 2019, 9, e029149.	0.8	15
603	Robot-assisted radical prostatectomy versus volumetric modulated arc therapy: Comparison of front-line therapies for localized prostate cancer. <i>Radiotherapy and Oncology</i> , 2019, 140, 62-67.	0.3	3
604	The psychological impact of being on a monitoring pathway for localised prostate cancer: A UKâ€™wide mixed methods study. <i>Psycho-Oncology</i> , 2019, 28, 1567-1575.	1.0	6
605	Prostate-specific Antigen Bounce After Stereotactic Body Radiotherapy for Prostate Cancer: A Pooled Analysis of Four Prospective Trials. <i>Clinical Oncology</i> , 2019, 31, 621-629.	0.6	5
606	Prostate cancer: On the road of progress. <i>Asian Journal of Urology</i> , 2019, 6, 123-124.	0.5	3
607	Active Surveillance Versus Radical Prostatectomy in Favorable-risk Localized Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e814-e821.	0.9	12
608	Risk-adapted moderate hypofractionation of prostate cancer. <i>Strahlentherapie Und Onkologie</i> , 2019, 195, 894-901.	1.0	5
609	Quality of life after external beam radiotherapy for localized prostate cancer: Comparison with other modalities. <i>International Journal of Urology</i> , 2019, 26, 950-954.	0.5	17
610	Current Treatment for Low-Risk Prostate Cancer in China: A National Network Survey. <i>Journal of Cancer</i> , 2019, 10, 1496-1502.	1.2	8
611	Prostate brachytherapy with iodine-125 seeds: analysis of a single institutional cohort. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2019, 45, 288-298.	0.7	2
612	Image-guided Irreversible Electroporation of Localized Prostate Cancer: Functional and Oncologic Outcomes. <i>Radiology</i> , 2019, 292, 250-257.	3.6	40

#	ARTICLE	IF	CITATIONS
613	Targeting Angiogenesis in Prostate Cancer. International Journal of Molecular Sciences, 2019, 20, 2676.	1.8	94
614	Genetic polymorphism and carbonic anhydrase 9 expression can predict nodal metastatic prostate cancer risk in patients with prostate-specific antigen levels ≥ 10 ng/ml at initial biopsy. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 814.e9-814.e16.	0.8	9
615	Use and early mortality outcomes of active surveillance in patients with intermediate-risk prostate cancer. Cancer, 2019, 125, 3164-3171.	2.0	35
616	Machine learning classifiers can predict Gleason pattern 4 prostate cancer with greater accuracy than experienced radiologists. European Radiology, 2019, 29, 4754-4764.	2.3	55
617	Updated recommendations of the International Society of Geriatric Oncology on prostate cancer management in older patients. European Journal of Cancer, 2019, 116, 116-136.	1.3	134
618	The Patient Journey in Prostate Cancer: Key Points for Nurses. Principles of Specialty Nursing, 2019, , 195-213.	0.2	0
619	Current status of intensity-modulated radiation therapy for prostate cancer: History, clinical results and future directions. International Journal of Urology, 2019, 26, 775-784.	0.5	18
620	Contemporary approach to active surveillance for favorable risk prostate cancer. Asian Journal of Urology, 2019, 6, 146-152.	0.5	32
621	Overactive Surveillance: Is "Conservative" Management for Low-risk Prostate Cancer Too Aggressive?. European Urology, 2019, 76, 467-468.	0.9	1
622	The current state of randomized clinical trial evidence for prostate brachytherapy. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 599-610.	0.8	8
623	Using prognosis to guide inclusion criteria, define standardised endpoints and stratify follow-up in active surveillance for prostate cancer. BJU International, 2019, 124, 758-767.	1.3	20
624	How to choose proper local treatment in men aged ≥ 75 years with cT2 localized prostate cancer?. Cancer Medicine, 2019, 8, 3370-3378.	1.3	4
625	Increased EZH2 expression in prostate cancer is associated with metastatic recurrence following external beam radiotherapy. Prostate, 2019, 79, 1079-1089.	1.2	28
626	Communicative aspects of decision aids for localized prostate cancer treatment "A systematic review. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 409-429.	0.8	23
627	Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer: The European Association of Urology Position in 2019. European Urology, 2019, 76, 142-150.	0.9	80
628	Weakly supervised natural language processing for assessing patient-centered outcome following prostate cancer treatment. JAMIA Open, 2019, 2, 150-159.	1.0	35
630	Survival after radiotherapy vs. radical prostatectomy for unfavorable intermediate-risk prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 813.e11-813.e19.	0.8	5
631	Prostatectomy versus watchful waiting in patients with localized prostate cancer: the survival benefit can be spotted in the long run. AME Medical Journal, 2019, 4, 22-22.	0.4	1

#	ARTICLE	IF	CITATIONS
633	Improved lower urinary tract symptoms after robot-assisted radical prostatectomy: implications for survivorship, treatment selection and patient counselling. <i>BJU International</i> , 2019, 123, 47-53.	1.3	12
634	Radical prostatectomy or radiotherapy for high- and very high-risk prostate cancer: a multidisciplinary prostate cancer clinic experience of patients eligible for either treatment. <i>BJU International</i> , 2019, 124, 811-819.	1.3	28
635	A Tool for Shared Decision Making on Referral for Prostate Biopsy in the Primary Care Setting: Integrating Risks of Cancer with Life Expectancy. <i>Journal of Personalized Medicine</i> , 2019, 9, 19.	1.1	2
636	Radiation oncology crossword: Genitourinary cancer. <i>Reports of Practical Oncology and Radiotherapy</i> , 2019, 24, 281-283.	0.3	3
637	Assessing the relationship between statin use and oncologic outcomes among men electing active surveillance for localized prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 617-623.	2.0	2
638	Triple treatment of high-risk prostate cancer. A matched cohort study with up to 19 years follow-up comparing survival outcomes after triple treatment and treatment with hormones and radiotherapy. <i>Scandinavian Journal of Urology</i> , 2019, 53, 102-108.	0.6	6
639	Health-related quality of life in long-term survivors with localised prostate cancer by therapy—Results from a population-based study. <i>European Journal of Cancer Care</i> , 2019, 28, e13076.	0.7	19
640	Regional Differences in the Treatment of Localized Prostate Cancer: An Analysis of Surgery and Radiation Utilization in the United States. <i>Advances in Radiation Oncology</i> , 2019, 4, 331-336.	0.6	6
641	Economic evaluation of the introduction of the Prostate Health Index as a rule-out test to avoid unnecessary biopsies in men with prostate specific antigen levels of 4-10 in Hong Kong. <i>PLoS ONE</i> , 2019, 14, e0215279.	1.1	8
642	Clinical Significance of Multiparametric Magnetic Resonance Imaging as a Preoperative Predictor of Oncologic Outcome in Very Low-Risk Prostate Cancer. <i>Journal of Clinical Medicine</i> , 2019, 8, 542.	1.0	3
643	Porphyrin-Based Nanomedicines for Cancer Treatment. <i>Bioconjugate Chemistry</i> , 2019, 30, 1585-1603.	1.8	115
644	Literature review of the burden of prostate cancer in Germany, France, the United Kingdom and Canada. <i>BMC Urology</i> , 2019, 19, 19.	0.6	50
646	To see or not to see – what renders prostate cancer visible?. <i>Nature Reviews Urology</i> , 2019, 16, 274-275.	1.9	0
647	Re: Evaluation of Cancer Specific Mortality with Surgery versus Radiation as Primary Therapy for Localized High Grade Prostate Cancer in Men Younger than 60 Years. <i>European Urology</i> , 2019, 76, 129-130.	0.9	0
648	Focal Laser Ablation of Prostate Cancer: Results in 120 Patients with Low- to Intermediate-Risk Disease. <i>Journal of Vascular and Interventional Radiology</i> , 2019, 30, 401-409.e2.	0.2	52
649	<p>The effect of time from biopsy to radical prostatectomy on adverse pathologic outcomes</p>. <i>Research and Reports in Urology</i> , 2019, Volume 11, 53-60.	0.6	11
650	A National Survey of Radiation Oncologists and Urologists on Perceived Attitudes and Recommendations of Active Surveillance for Low-Risk Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e472-e481.	0.9	5
651	Percutaneous MR-guided whole-gland prostate cancer cryoablation: safety considerations and oncologic results in 30 consecutive patients. <i>British Journal of Radiology</i> , 2019, 92, 20180965.	1.0	10

#	ARTICLE	IF	CITATIONS
652	Inhibition of LOXL2 Enhances the Radiosensitivity of Castration-Resistant Prostate Cancer Cells Associated with the Reversal of the EMT Process. <i>BioMed Research International</i> , 2019, 2019, 1-10.	0.9	19
653	Large-scale Circulating microRNA Profiling for the Liquid Biopsy of Prostate Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 3016-3025.	3.2	87
655	Radionuclide Therapy of Metastatic Prostate Cancer. <i>Seminars in Nuclear Medicine</i> , 2019, 49, 313-325.	2.5	54
656	Prostate-specific antigen screening for prostate cancer in males older than 75 years. <i>Medicina Clínica (English Edition)</i> , 2019, 152, 237-240.	0.1	0
657	<p>A chemoenzymatically synthesized cholesterol-g-poly(amine-co-ester)-mediated p53 gene delivery for achieving antitumor efficacy in prostate cancer</p>. <i>International Journal of Nanomedicine</i> , 2019, Volume 14, 1149-1161.	3.3	4
658	Does Interfraction Cone Beam Computed Tomography Improve Target Localization in Prostate Bed Radiotherapy?. <i>Technology in Cancer Research and Treatment</i> , 2019, 18, 153303381983196.	0.8	3
659	Sildenafil in postprostatectomy erectile dysfunction (perspective). <i>International Journal of Impotence Research</i> , 2019, 31, 61-64.	1.0	8
660	Individual prognosis at diagnosis in nonmetastatic prostate cancer: Development and external validation of the PREDICT Prostate multivariable model. <i>PLoS Medicine</i> , 2019, 16, e1002758.	3.9	56
661	Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies. <i>Journal of Visualized Experiments</i> , 2019, , .	0.2	5
662	Effect of Androgen Deprivation Therapy on Other-Cause of Mortality in Elderly Patients with Clinically Localized Prostate Cancer Treated with Modern Radiotherapy: Is There a Negative Impact?. <i>Journal of Clinical Medicine</i> , 2019, 8, 338.	1.0	6
663	Trends in Prostate Cancer Prevalence and Radical Prostatectomy Rate according to Age Structural Changes in South Korea between 2005 and 2015. <i>Yonsei Medical Journal</i> , 2019, 60, 257.	0.9	5
666	End-to-side Somatic-to-autonomic Nerve Grafting to Restore Erectile Function and Improve Quality of Life After Radical Prostatectomy. <i>European Urology</i> , 2019, 76, 189-196.	0.9	13
667	Selection Bias in Population Registry-Based Comparative Effectiveness Research. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 1058-1060.	0.4	6
668	Reirradiation of Locally Recurrent Prostate Cancer With Volumetric Modulated Arc Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 614-621.	0.4	22
669	Patient-Reported Sexual Survivorship Following High-Dose Image-Guided Proton Therapy for Prostate Cancer. <i>Radiotherapy and Oncology</i> , 2019, 134, 204-210.	0.3	5
670	Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline Summary. <i>Journal of Oncology Practice</i> , 2019, 15, 50-54.	2.5	2
671	Ki-67 is an independent predictor of prostate cancer death in routine needle biopsy samples: proving utility for routine assessments. <i>Modern Pathology</i> , 2019, 32, 1303-1309.	2.9	25
672	Outcomes of clinically localized prostate cancer patients managed with initial monitoring approach versus upfront local treatment: a North American population-based study. <i>Clinical and Translational Oncology</i> , 2019, 21, 1673-1679.	1.2	0

#	ARTICLE	IF	CITATIONS
673	MRI Assessment of Prostate-Specific Membrane Antigen (PSMA) Targeting by a PSMA-Targeted Magnetic Nanoparticle: Potential for Image-Guided Therapy. <i>Molecular Pharmaceutics</i> , 2019, 16, 2060-2068.	2.3	15
674	The COMET (Comparison of Operative versus Monitoring and Endocrine Therapy) trial: a phase III randomised controlled clinical trial for low-risk ductal carcinoma in situ (DCIS). <i>BMJ Open</i> , 2019, 9, e026797.	0.8	182
675	Dose Escalation for Prostate Adenocarcinoma: A Long-Term Update on the Outcomes of a Phase 3, Single Institution Randomized Clinical Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 790-797.	0.4	56
676	Intensive Triangulation of Qualitative Research and Quantitative Data to Improve Recruitment to Randomized Trials: The QuinteT Approach. <i>Qualitative Health Research</i> , 2019, 29, 672-679.	1.0	38
677	The European Prostate Cancer Centres of Excellence: A Novel Proposal from the European Association of Urology Prostate Cancer Centre Consensus Meeting. <i>European Urology</i> , 2019, 76, 179-186.	0.9	15
678	Centers of Excellence: What are Realistic Goals?. <i>European Urology</i> , 2019, 76, 187-188.	0.9	1
679	Artificial intelligence in cancer imaging: Clinical challenges and applications. <i>Ca-A Cancer Journal for Clinicians</i> , 2019, 69, 127-157.	157.7	965
680	The role of radiotherapy in localised and locally advanced prostate cancer. <i>Asian Journal of Urology</i> , 2019, 6, 153-161.	0.5	14
681	Dose to the penile bulb and individual patient anatomy are predictive of erectile dysfunction in men treated with ¹²⁵ I low dose rate brachytherapy for localized prostate cancer. <i>Acta Oncologica</i> , 2019, 58, 1029-1035.	0.8	7
682	Re: Marco Moschini, Emanuele Zaffuto, Pierre I. Karakiewicz, et al. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis. <i>Eur Urol</i> 2019;75:319-28. <i>European Urology</i> , 2019, 75, e93-e94.	0.9	1
683	Use of multiparametric magnetic resonance imaging in prostate cancer active surveillance. <i>BJU International</i> , 2019, 124, 730-737.	1.3	14
684	Best practice in active surveillance for men with prostate cancer: a Prostate Cancer UK consensus statement. <i>BJU International</i> , 2019, 124, 47-54.	1.3	23
685	Total anatomical reconstruction during robot-assisted radical prostatectomy: focus on urinary continence recovery and related complications after 1000 procedures. <i>BJU International</i> , 2019, 124, 477-486.	1.3	40
686	Evolution, controversies and the future of prostate cancer grading. <i>Pathology International</i> , 2019, 69, 55-66.	0.6	6
687	Novel Genomic-Based Strategies to Personalize Lymph Node Radiation Therapy. <i>Seminars in Radiation Oncology</i> , 2019, 29, 111-125.	1.0	4
688	Robot or radiation? A qualitative study of the decision support needs of men with localised prostate cancer choosing between robotic prostatectomy and radiotherapy treatment. <i>Patient Education and Counseling</i> , 2019, 102, 1364-1372.	1.0	14
689	Medium-term oncological outcomes in a large cohort of men treated with either focal or hemiablation using high-intensity focused ultrasonography for primary localized prostate cancer. <i>BJU International</i> , 2019, 124, 431-440.	1.3	93
690	In early prostate cancer, radical prostatectomy reduced mortality more than watchful waiting at 23 years. <i>Annals of Internal Medicine</i> , 2019, 170, JC44.	2.0	1

#	ARTICLE	IF	CITATIONS
692	PCASTt/SPCG-17â€”a randomised trial of active surveillance in prostate cancer: rationale and design. <i>BMJ Open</i> , 2019, 9, e027860.	0.8	19
693	Longitudinal study of use and cost of subacromial decompression surgery: the need for effective evaluation of surgical procedures to prevent overtreatment and wasted resources. <i>BMJ Open</i> , 2019, 9, e030229.	0.8	16
695	Resisting recommended treatment for prostate cancer: a qualitative analysis of the lived experience of possible overdiagnosis. <i>BMJ Open</i> , 2019, 9, e026960.	0.8	12
697	Patient-Centered Oncology or Population-Centered Oncologyâ€”Which Do We Want, and Which Tradeoffs Are We Willing To Accept?. <i>Oncologist</i> , 2019, 24, 288-290.	1.9	0
698	Prostate cancer treatment choices: the GPâ€™s role in shared decision making. <i>British Journal of General Practice</i> , 2019, 69, 588-589.	0.7	0
699	Adjuvant radiotherapy in prostate cancer patients with positive margins or extracapsular extension. <i>Annals of Translational Medicine</i> , 2019, 7, S291-S291.	0.7	1
700	Management of erectile dysfunction after prostate cancer treatment: cross-sectional surveys of the perceptions and experiences of patients and healthcare professionals in the UK. <i>BMJ Open</i> , 2019, 9, e030856.	0.8	16
701	Study protocol for Video assisted thoracoscopic lobectomy versus conventional Open LobEcTomy for lung cancer, a UK multicentre randomised controlled trial with an internal pilot (the VIOLET study). <i>BMJ Open</i> , 2019, 9, e029507.	0.8	55
702	Financial Toxicity and Cancer Therapy. <i>Hematology/Oncology Clinics of North America</i> , 2019, 33, 1117-1128.	0.9	16
703	EDITORIAL COMMENT. <i>Urology</i> , 2019, 129, 85.	0.5	0
704	Using Multiparametric Magnetic Resonance Imaging to Shift Prostate Cancer Diagnosis Toward Clinically Significant Disease and Minimize Overdiagnosis (and Overtreatment). <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 915-917.	0.4	0
705	Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer. <i>The Cochrane Library</i> , 2019, , .	1.5	1
706	Translating costâ€”utility modelling into the real world â€” the case of focal highâ€”intensity focussed ultrasound and active surveillance. <i>BJU International</i> , 2019, 124, 900-901.	1.3	1
708	Recommendations of Active Surveillance for Intermediate-risk Prostate Cancer: Results from a National Survey of Radiation Oncologists and Urologists. <i>European Urology Oncology</i> , 2019, 2, 189-195.	2.6	10
709	A Single Educational Seminar Increases Confidence and Decreases Dropout from Active Surveillance by 5 Years After Diagnosis of Prostate Cancer. <i>European Urology Oncology</i> , 2019, 2, 464-470.	2.6	8
710	Magnetic resonance imaging-guided targeted biopsy in risk classification among patients on active surveillance. <i>Medicine (United States)</i> , 2019, 98, e16122.	0.4	1
711	TGF-Î² and microRNA Interplay in Genitourinary Cancers. <i>Cells</i> , 2019, 8, 1619.	1.8	19
712	Combined Modality Therapies for High-Risk Prostate Cancer: Narrative Review of Current Understanding and New Directions. <i>Frontiers in Oncology</i> , 2019, 9, 1273.	1.3	3

#	ARTICLE	IF	CITATIONS
713	Active Treatment in Low-Risk Prostate Cancer: A Population-Based Study. <i>Current Oncology</i> , 2019, 26, 535-540.	0.9	6
714	High-dose-rate prostate brachytherapy appears safe in patients with high baseline International Prostate Symptom Scores. <i>Brachytherapy</i> , 2019, 18, 793-799.	0.2	8
715	Quality of Life and Decision Regret After Postoperative Radiation Therapy to the Prostatic Bed Region With or Without Elective Pelvic Nodal Radiation Therapy. <i>Practical Radiation Oncology</i> , 2019, 9, e516-e527.	1.1	1
716	Tissue-based genomics. <i>Current Opinion in Urology</i> , 2019, 29, 598-604.	0.9	3
717	Risk stratification and avoiding overtreatment in localized prostate cancer. <i>Current Opinion in Urology</i> , 2019, 29, 612-619.	0.9	9
718	Ejaculatory and Orgasmic Dysfunction Following Prostate Cancer Therapy: Clinical Management. <i>Medical Sciences (Basel, Switzerland)</i> , 2019, 7, 109.	1.3	4
719	Polygenic risk-tailored screening for prostate cancer: A benefit-harm and cost-effectiveness modelling study. <i>PLoS Medicine</i> , 2019, 16, e1002998.	3.9	56
720	Cases Having a Gleason Score 3+4=7 With <5% of Gleason Pattern 4 in Prostate Needle Biopsy Show Similar Failure-free Survival and Adverse Pathology Prevalence to Gleason Score 6 Cases in a Radical Prostatectomy Cohort. <i>American Journal of Surgical Pathology</i> , 2019, 43, 1560-1565.	2.1	19
721	Predictors for lower urinary tract symptoms and the urinary specific quality of life in prostate cancer patients. <i>Journal of the Chinese Medical Association</i> , 2019, 82, 482-487.	0.6	4
722	Upregulation of microRNA-191 can serve as an independent prognostic marker for poor survival in prostate cancer. <i>Medicine (United States)</i> , 2019, 98, e16193.	0.4	9
723	Active surveillance for intermediate-risk prostate cancer. <i>Current Opinion in Urology</i> , 2019, 29, 605-611.	0.9	12
724	Men's perceptions of the impact of the physical consequences of a radical prostatectomy on their quality of life. <i>International Journal of Evidence-Based Healthcare</i> , 2019, 17, S41-S42.	0.1	6
725	PSA testing: a personal view. <i>British Journal of General Practice</i> , 2019, 69, 562-562.	0.7	3
726	Claims-Based Approach to Predict Cause-Specific Survival in Men With Prostate Cancer. <i>JCO Clinical Cancer Informatics</i> , 2019, 3, 1-7.	1.0	8
727	Prostate cancer navigation: initial experience and association with time to care. <i>World Journal of Urology</i> , 2019, 37, 1095-1101.	1.2	5
728	MRI-guided localization of the dominant intraprostatic lesion and dose analysis of volumetric modulated arc therapy planning for prostate cancer. <i>Strahlentherapie Und Onkologie</i> , 2019, 195, 145-152.	1.0	10
729	Early and late toxicity profiles of patients receiving immediate postoperative radiotherapy versus salvage radiotherapy for prostate cancer after prostatectomy. <i>Strahlentherapie Und Onkologie</i> , 2019, 195, 131-144.	1.0	4
730	Long-term outcomes in 1121 Australian prostate cancer patients treated with definitive radiotherapy. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2019, 63, 116-123.	0.9	2

#	ARTICLE	IF	CITATIONS
731	A decision analysis comparing 3 active surveillance protocols for the treatment of patients with low-risk prostate cancer. <i>Cancer</i> , 2019, 125, 952-962.	2.0	7
732	Two-stage residual inclusion for survival data and competing risks—An instrumental variable approach with application to SEER-Medicare linked data. <i>Statistics in Medicine</i> , 2019, 38, 1775-1801.	0.8	29
733	Case series on multiple prostate re-irradiation for locally recurrent prostate cancer: something ventured, something gained. <i>Neoplasma</i> , 2019, 66, 308-314.	0.7	6
734	Proton therapy for prostate cancer: A review of the rationale, evidence, and current state. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 628-636.	0.8	20
735	Genomic Classifier for Guiding Treatment of Intermediate-Risk Prostate Cancers to Dose-Escalated Image Guided Radiation Therapy Without Hormone Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 84-91.	0.4	36
736	The QuinteT Recruitment Intervention supported five randomized trials to recruit to target: a mixed-methods evaluation. <i>Journal of Clinical Epidemiology</i> , 2019, 106, 108-120.	2.4	49
737	Correlation of mRNA-PCA3 urine levels with the new grading system in prostate cancer. <i>Revista Espanola De Patologia</i> , 2019, 52, 20-26.	0.6	3
738	Cost Effectiveness of the Oncotype DX Genomic Prostate Score for Guiding Treatment Decisions in Patients With Early Stage Prostate Cancer. <i>Urology</i> , 2019, 126, 89-95.	0.5	12
739	Validation of the Decipher Test for predicting adverse pathology in candidates for prostate cancer active surveillance. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 399-405.	2.0	53
740	Oncological long-term outcome of whole gland HIFU and open radical prostatectomy: a comparative analysis. <i>World Journal of Urology</i> , 2019, 37, 2073-2080.	1.2	9
741	In-bore Multiparametric Magnetic Resonance Imaging Targeted Biopsy: As Good as it Gets?. <i>European Urology</i> , 2019, 75, 579-581.	0.9	4
742	An overview of translational prostate cancer cohorts for prognostic and predictive studies. <i>Histopathology</i> , 2019, 74, 161-170.	1.6	1
743	Reirradiation for isolated local recurrence of prostate cancer: Mono-institutional series of 64 patients treated with salvage stereotactic body radiotherapy (SBRT). <i>British Journal of Radiology</i> , 2019, 92, 20180494.	1.0	50
744	Is time from diagnosis to radical prostatectomy associated with oncological outcomes?. <i>World Journal of Urology</i> , 2019, 37, 1571-1580.	1.2	13
746	Quality assurance guidance for scoring and reporting for pathologists and laboratories undertaking clinical trial work. <i>Journal of Pathology: Clinical Research</i> , 2019, 5, 91-99.	1.3	21
747	Active surveillance for prostate and thyroid cancers: evolution in clinical paradigms and lessons learned. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 168-184.	12.5	41
748	Variation in surgical treatment patterns for patients with prostate cancer in the United States: Do patients in academic hospitals fare better?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 63-70.	0.8	3
749	Optimizing Time to Treatment to Achieve Durable Biochemical Disease Control after Surgery in Prostate Cancer: A Multi-Institutional Cohort Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 570-577.	1.1	9

#	ARTICLE	IF	CITATIONS
750	Cost-effectiveness Analysis of Active Surveillance Strategies for Men with Low-risk Prostate Cancer. <i>European Urology</i> , 2019, 75, 910-917.	0.9	34
751	Low Tristetraprolin Expression Is Associated with Lethal Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 584-590.	1.1	8
752	Surgery vs Radiotherapy in the Management of Biopsy Gleason Score 9-10 Prostate Cancer and the Risk of Mortality. <i>JAMA Oncology</i> , 2019, 5, 213.	3.4	62
753	Referral rates to multidisciplinary team meetings: Is there disparity between tumour streams?. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2019, 63, 378-382.	0.9	16
754	A multicentric study on accurate grading of prostate cancer with systematic and MRI/US fusion targeted biopsies: comparison with final histopathology after radical prostatectomy. <i>World Journal of Urology</i> , 2019, 37, 2109-2117.	1.2	56
755	Characterization of the "Autophagic Flux" in Prostate Cancer Tissue Biopsies by LC3A/LAMP2a Immunofluorescence and Confocal Microscopy. <i>Methods in Molecular Biology</i> , 2019, 1880, 555-560.	0.4	3
756	Comparison of PIRADS 3 lesions with histopathological findings after MRI-fusion targeted biopsy of the prostate in a real world-setting. <i>Clinical Hemorheology and Microcirculation</i> , 2019, 71, 165-170.	0.9	14
757	Outcomes of Prostatectomy versus Radiation Therapy in the Management of Clinically Localized Prostate Cancer Patients Within the PLCO Trial. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e329-e338.	0.9	2
758	A 17-gene Panel for Prediction of Adverse Prostate Cancer Pathologic Features: Prospective Clinical Validation and Utility. <i>Urology</i> , 2019, 126, 76-82.	0.5	36
759	Clinical utility of MRI in the decision-making process before radical prostatectomy: Systematic review and meta-analysis. <i>PLoS ONE</i> , 2019, 14, e0210194.	1.1	31
760	Health-related quality of life in men with prostate cancer undergoing active surveillance versus radical prostatectomy, external-beam radiotherapy, prostate brachytherapy and reference population: a cross-sectional study. <i>Health and Quality of Life Outcomes</i> , 2019, 17, 11.	1.0	17
761	Molecular Mechanisms Related to Hormone Inhibition Resistance in Prostate Cancer. <i>Cells</i> , 2019, 8, 43.	1.8	38
762	Functional results in the treatment of localized prostate cancer. An updated literature review. <i>Revista Internacional De Andrología</i> , 2019, 17, 143-154.	0.1	1
763	Early-Medium-Term Outcomes of Primary Focal Cryotherapy to Treat Nonmetastatic Clinically Significant Prostate Cancer from a Prospective Multicentre Registry. <i>European Urology</i> , 2019, 76, 98-105.	0.9	96
764	50-Gy Stereotactic Body Radiation Therapy to the Dominant Intraprostatic Nodule: Results From a Phase 1a/b Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 320-334.	0.4	28
765	Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degradator of Androgen Receptor (AR) for the Treatment of Prostate Cancer. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 941-964.	2.9	269
766	Technologies for image-guided surgery for managing lymphatic metastases in prostate cancer. <i>Nature Reviews Urology</i> , 2019, 16, 159-171.	1.9	62
767	Randomized prospective phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]. <i>BMC Cancer</i> , 2019, 19, 18.	1.1	86

#	ARTICLE	IF	CITATIONS
768	Meta-analysis of predictive models to assess the clinical validity and utility for patient-centered medical decision making: application to the CAncer of the Prostate Risk Assessment (CAPRA). BMC Medical Informatics and Decision Making, 2019, 19, 2.	1.5	20
769	Perceptions of Barriers Towards Active Surveillance for Low-Risk Prostate Cancer: Results From a National Survey of Radiation Oncologists and Urologists. Annals of Surgical Oncology, 2019, 26, 660-668.	0.7	10
770	Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review. European Urology, 2019, 75, 967-987.	0.9	278
771	Big Data Readiness in Radiation Oncology: An Efficient Approach for Relabeling Radiation Therapy Structures With Their TG-263 Standard Name in Real-World Data Sets. Advances in Radiation Oncology, 2019, 4, 191-200.	0.6	22
772	MRI-TRUS fusion biopsy of the prostate: Quality of image fusion in a clinical setting. Clinical Hemorheology and Microcirculation, 2019, 70, 433-440.	0.9	13
773	Circulating Metabolic Biomarkers of Screen-Detected Prostate Cancer in the ProtecT Study. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 208-216.	1.1	21
774	Germline Mutations in ATM and BRCA1/2 Are Associated with Grade Reclassification in Men on Active Surveillance for Prostate Cancer. European Urology, 2019, 75, 743-749.	0.9	138
775	Stereotactic Radiosurgery for Prostate Cancer. , 2019, , .		1
776	Comparative Effectiveness of Prostate Cancer Treatment Options: Limitations of Retrospective Analysis of Cancer Registry Data. International Journal of Radiation Oncology Biology Physics, 2019, 103, 1053-1057.	0.4	15
777	Outcomes and prognostic factors in intermediate-risk prostate cancer: multi-institutional analysis of the Spanish RECAP database. Clinical and Translational Oncology, 2019, 21, 900-909.	1.2	3
778	Parallels Between Low-Risk Prostate Cancer and Thyroid Cancer. JAMA Oncology, 2019, 5, 556.	3.4	24
779	Conservative management and radical treatment in localised prostate cancer: A systematic review with meta-analysis and trial sequential analysis. Journal of Clinical Urology, 2019, 12, 228-238.	0.1	0
780	Impact of ⁶⁸ Ga-PSMA PET/CT on the Radiotherapeutic Approach to Prostate Cancer in Comparison to CT: A Retrospective Analysis. Journal of Nuclear Medicine, 2019, 60, 963-970.	2.8	44
781	Re: Marco Moschini, Emanuele Zaffuto, Pierre I. Karakiewicz, et al. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis. Eur Urol 2019;75:319-28. European Urology, 2019, 75, e96-e97.	0.9	1
782	Using prognosis to guide early detection and treatment selection in non-metastatic prostate cancer. BJU International, 2019, 123, 562-563.	1.3	3
783	Radiotherapy for Localized and Locally Advanced Prostate Cancer. , 2019, , 1-16.		0
784	Reply to Alba Fiorentino, Angelo Errico, and Marcello Scarcia's Letter to the Editor re: Marco Moschini, Emanuele Zaffuto, Pierre I. Karakiewicz, et al. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis. Eur Urol 2019;75:319-28. European Urology, 2019, 75, e95.	0.9	0
785	Exnovation of Low Value Care: A Decade of Prostate-specific Antigen Screening Practices. Journal of the American Geriatrics Society, 2019, 67, 29-36.	1.3	9

#	ARTICLE	IF	CITATIONS
786	Re: Henk G. van der Poel, Roderick C.N. van den Bergh, Erik Briers, et al. Focal Therapy in Primary Localised Prostate Cancer: The European Association of Urology Position in 2018. Eur Urol 2018;74:84â€“91. European Urology, 2019, 75, e21-e22.	0.9	2
787	External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis. European Urology, 2019, 75, 319-328.	0.9	57
789	Trends in Radical Prostatectomy Risk Group Distribution in a European Multicenter Analysis of 28 572 Patients: Towards Tailored Treatment. European Urology Focus, 2019, 5, 171-178.	1.6	50
790	Risk of Upgrading and Upstaging Among 10 000 Patients with Gleason 3 + 4 Favorable Intermediate-risk Prostate Cancer. European Urology Focus, 2019, 5, 69-76.	1.6	40
791	Erythropoietin to Enhance Recovery of Erectile Function in Men Following Radical Prostatectomy: The ERECT Trial. European Urology Focus, 2019, 5, 698-699.	1.6	1
792	Are the Results of the Prostate Testing for Cancer and Treatment Trial Applicable to Contemporary Prostate Cancer Patients Treated with Radical Prostatectomy? Results from Two High-volume European Institutions. European Urology Focus, 2019, 5, 545-549.	1.6	5
793	Evidence-based approach to active surveillance of prostate cancer. World Journal of Urology, 2020, 38, 555-562.	1.2	9
794	Radiogenomics Consortium Genome-Wide Association Study Meta-Analysis of Late Toxicity After Prostate Cancer Radiotherapy. Journal of the National Cancer Institute, 2020, 112, 179-190.	3.0	71
795	Contemporary national trends in prostate cancer risk profile at diagnosis. Prostate Cancer and Prostatic Diseases, 2020, 23, 81-87.	2.0	39
796	Cardiovascular toxicities of therapy for genitourinary malignancies. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 121-128.	0.8	1
797	Antibiotic resistance, hospitalizations, and mortality related to prostate biopsy: first report from the Norwegian Patient Registry. World Journal of Urology, 2020, 38, 17-26.	1.2	43
798	Evolution of definitive external beam radiation therapy in the treatment of prostate cancer. World Journal of Urology, 2020, 38, 565-591.	1.2	12
799	Causal inference in continuous time: an example on prostate cancer therapy. Biostatistics, 2020, 21, 172-185.	0.9	6
800	Patient-Reported Outcomes: Understanding Surgical Efficacy and Quality from the Patientâ€™s Perspective. Annals of Surgical Oncology, 2020, 27, 56-64.	0.7	26
801	Type of patients in whom biochemical recurrence after radical prostatectomy can be observed without salvage therapy. World Journal of Urology, 2020, 38, 1749-1756.	1.2	6
802	MRI for clinically suspected prostate cancerâ€”the disparity between private and public sectors. Irish Journal of Medical Science, 2020, 189, 461-465.	0.8	0
803	Patient-reported Outcomes Following Treatment of Localised Prostate Cancer and Their Association with Regret About Treatment Choices. European Urology Oncology, 2020, 3, 21-31.	2.6	63
804	Oncological and Quality-of-life Outcomes Following Focal Irreversible Electroporation as Primary Treatment for Localised Prostate Cancer: A Biopsy-monitored Prospective Cohort. European Urology Oncology, 2020, 3, 283-290.	2.6	52

#	ARTICLE	IF	CITATIONS
805	United States trends in active surveillance or watchful waiting across patient socioeconomic status from 2010 to 2015. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 179-183.	2.0	12
806	Single institution followed by national implementation of systematic surgical quality control and feedback for radical prostatectomy: a 20-year journey. <i>World Journal of Urology</i> , 2020, 38, 1397-1411.	1.2	11
808	Rates of Adverse IBD-Related Outcomes for Patients With IBD and Concomitant Prostate Cancer Treated With Radiation Therapy. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 728-733.	0.9	18
809	Moderate hypofractionated helical tomotherapy for prostate cancer in a cohort of older patients: a mono-institutional report of toxicity and clinical outcomes. <i>Aging Clinical and Experimental Research</i> , 2020, 32, 747-753.	1.4	8
810	Development and Initial Evaluation of a Multifaceted Intervention to Improve Mental Health and Quality of Life Among Prostate Cancer Survivors. <i>International Journal of Mental Health and Addiction</i> , 2020, 18, 1067-1080.	4.4	13
811	Magnetic resonance imaging-guided transurethral ultrasound ablation of prostate tissue in patients with localized prostate cancer: single-center evaluation of 6-month treatment safety and functional outcomes of intensified treatment parameters. <i>World Journal of Urology</i> , 2020, 38, 343-350.	1.2	12
812	Multiparametric MRI for prostate cancer diagnosis: current status and future directions. <i>Nature Reviews Urology</i> , 2020, 17, 41-61.	1.9	207
813	The development and comparative effectiveness of a patient-centered prostate biopsy report: a prospective, randomized study. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 144-150.	2.0	9
814	Disparities in prostate cancer incidence and mortality rates: Solvable or not?. <i>Prostate</i> , 2020, 80, 3-16.	1.2	30
815	Development and pilot evaluation of a personalized decision support intervention for low risk prostate cancer patients. <i>Cancer Medicine</i> , 2020, 9, 125-132.	1.3	7
816	Circulating miR-17a-5p expression in prostate cancer. <i>Journal of Clinical Laboratory Analysis</i> , 2020, 34, e23086.	0.9	23
817	Active surveillance in intermediate-risk prostate cancer. <i>BJU International</i> , 2020, 125, 346-354.	1.3	59
818	Impact of time from diagnosis to treatment on erectile function outcomes after radical prostatectomy. <i>Andrology</i> , 2020, 8, 337-341.	1.9	2
819	Informing informed decision-making in primary prostate cancer treatment selection. <i>BJU International</i> , 2020, 125, 194-196.	1.3	1
820	Active Surveillance in Papillary Thyroid Microcarcinomas is Feasible and Safe: Experience at a Single Italian Center. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e172-e180.	1.8	94
821	Survival outcomes of radical prostatectomy vs. external beam radiation therapy in prostate cancer patients with Gleason Score 9-10 at biopsy: A population-based analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 79.e9-79.e14.	0.8	18
822	Active Surveillance of Grade Group 1 Prostate Cancer: Long-term Outcomes from a Large Prospective Cohort. <i>European Urology</i> , 2020, 77, 675-682.	0.9	137
823	The ProtecT trial: analysis of the patient cohort, baseline risk stratification and disease progression. <i>BJU International</i> , 2020, 125, 506-514.	1.3	32

#	ARTICLE	IF	CITATIONS
824	Determining Clinically Based Factors Associated With Reclassification in the Pre-MRI Era using a Large Prospective Active Surveillance Cohort. <i>Urology</i> , 2020, 138, 91-97.	0.5	6
825	Image-guided dose-escalated radiation therapy for localized prostate cancer with helical tomotherapy. <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 229-242.	1.0	6
826	MRI targeted single fraction HDR Brachytherapy for localized Prostate Carcinoma: a feasibility study of focal radiation therapy (ProFocAL). <i>European Radiology</i> , 2020, 30, 2072-2081.	2.3	11
827	Outcomes of treatment for localized prostate cancer in a single institution: comparison of radical prostatectomy and radiation therapy by propensity score matching analysis. <i>World Journal of Urology</i> , 2020, 38, 2477-2484.	1.2	16
828	â€œTo Serve and ProtecTâ€: Has the Pendulum Swung Too Far Towards Surveillance?. <i>European Urology</i> , 2020, 77, 331-332.	0.9	0
829	Reading MRI of the Prostate. , 2020, , .		3
830	Tumor burden and location as prognostic factors in patients treated by iodine seed implant brachytherapy for localized prostate cancers. <i>Radiation Oncology</i> , 2020, 15, 1.	1.2	31
831	Irreversible electroporation (IRE): a narrative review of the development of IRE from the laboratory to a prostate cancer treatment. <i>BJU International</i> , 2020, 125, 369-378.	1.3	25
832	Primary Radical Prostatectomy or Ablative Radiotherapy as Protective Factors for Patients With mCRPC Treated With Radium-223 Dichloride: An Italian Multicenter Study. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 185-191.	0.9	8
833	The decision of targeted, systematic or combined biopsy in a biopsy naÃ“ve patient for the diagnosis of prostate cancer, can be made on the basis of multiparametric magnetic resonance imaging. <i>Journal of Clinical Urology</i> , 2020, 13, 198-204.	0.1	0
834	Developments in MRI-targeted prostate biopsy. <i>Current Opinion in Urology</i> , 2020, 30, 1-8.	0.9	10
835	Recent advances on smallâ€molecule nanomedicines for cancer treatment. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2020, 12, e1607.	3.3	14
836	Seven or less Fractions is Not the Standard of Care for Intermediate-Risk Prostate Cancer. <i>Clinical Oncology</i> , 2020, 32, 175-180.	0.6	5
837	Sexual function outcomes following interventions for prostate cancer: are contemporary reports on functional outcomes misleading?. <i>International Journal of Impotence Research</i> , 2020, 32, 495-502.	1.0	8
838	Survey on the practice of active surveillance for prostate cancer from the Middle East. <i>Prostate International</i> , 2020, 8, 41-48.	1.2	3
839	Sequencing of Androgen-Deprivation Therapy With External-Beam Radiotherapy in Localized Prostate Cancer: A Phase III Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 593-601.	0.8	45
840	Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2020, 38, 1474-1494.	0.8	141
841	Prognostic Value of Pretreatment MRI in Patients With Prostate Cancer Treated With Radiation Therapy: A Systematic Review and Meta-Analysis. <i>American Journal of Roentgenology</i> , 2020, 214, 597-604.	1.0	21

#	ARTICLE	IF	CITATIONS
842	Prostate MRI with PI-RADS v2.1: initial detection and active surveillance. <i>Abdominal Radiology</i> , 2020, 45, 2133-2142.	1.0	6
843	Screening and Early Detection. , 2020, , 375-398.e7.		1
844	A polymeric paste-drug formulation for intratumoral treatment of prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 324-332.	2.0	3
845	Comparison of Radical Prostatectomy Versus Radiation and Androgen Deprivation Therapy Strategies as Primary Treatment for High-risk Localized Prostate Cancer: A Systematic Review and Meta-analysis. <i>European Urology Focus</i> , 2020, 6, 404-418.	1.6	19
846	On High Grade Kidney Cancer and Machine Learning. <i>Academic Radiology</i> , 2020, 27, 169-170.	1.3	1
847	Patient-reported outcome measures after treatment for prostate cancer: Results from the Danish Prostate Cancer Registry (DAPROCAdata). <i>Cancer Epidemiology</i> , 2020, 64, 101623.	0.8	14
848	Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received. <i>European Urology</i> , 2020, 77, 320-330.	0.9	107
849	Health Care Disparities in Urologic Oncology: A Systematic Review. <i>Urology</i> , 2020, 136, 9-18.	0.5	23
850	Age dependence of modern clinical risk groups for localized prostate cancerâ€”A populationâ€based study. <i>Cancer</i> , 2020, 126, 1691-1699.	2.0	25
851	Combination of total length of Gleason pattern 4 and number of Gleason score 3 + 4 = 7 cores detects similar outcome group to Gleason score 6 cancers among cases with â‰¥5% of Gleason pattern 4. <i>Pathology International</i> , 2020, 70, 992-998.	0.6	2
852	Fifteen year quality of life outcomes in men with localised prostate cancer: population based Australian prospective study. <i>BMJ, The</i> , 2020, 371, m3503.	3.0	43
854	Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2020, 21, 1341-1352.	5.1	185
855	The Impact of the COVID-19 Pandemic on Genitourinary Cancer Care: Re-envisioning the Future. <i>European Urology</i> , 2020, 78, 731-742.	0.9	39
857	Assessment of non-inferiority with meta-analysis: example of hypofractionated radiation therapy in breast and prostate cancer. <i>Scientific Reports</i> , 2020, 10, 15415.	1.6	5
858	Relationship between radiation doses and erectile function deterioration in patients with localized prostate cancer treated with permanent prostate brachytherapy. <i>International Journal of Urology</i> , 2020, 27, 1087-1093.	0.5	3
859	Margin verification for hypofractionated prostate radiotherapy using a novel dose accumulation workflow and iterative CBCT. <i>Physica Medica</i> , 2020, 77, 154-159.	0.4	11
860	Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results From the International Staging Collaboration for Cancer of the Prostate. <i>JAMA Oncology</i> , 2020, 6, 1912.	3.4	49
861	Prostate Cancer Characteristics in the US Preventive Services Task Force Grade D Era: A Single-Center Study and Meta-Analysis. <i>Urologia Internationalis</i> , 2020, 104, 692-698.	0.6	2

#	ARTICLE	IF	CITATIONS
862	Differences in treatment choices for localised prostate cancer diagnosed in private and public health services. <i>Medical Journal of Australia</i> , 2020, 213, 411-417.	0.8	14
863	The Correlation between PSCA Expression and Neuroendocrine Differentiation in Prostate Cancer. <i>BioMed Research International</i> , 2020, 2020, 1-9.	0.9	7
864	Combined multiple clinical characteristics for prediction of discordance in grade and stage in prostate cancer patients undergoing systematic biopsy and radical prostatectomy. <i>Pathology Research and Practice</i> , 2020, 216, 153235.	1.0	2
865	Identification of a distinct luminal subgroup diagnosing and stratifying early stage prostate cancer by tissue-based single-cell RNA sequencing. <i>Molecular Cancer</i> , 2020, 19, 147.	7.9	50
866	A Narrative Overview of Active Surveillance for Clinically Localised Prostate Cancer. <i>Seminars in Oncology Nursing</i> , 2020, 36, 151045.	0.7	3
867	The Impact of COVID-19 on Radiation Oncology and Cancer Care: A Perspective from the Cancer Belt Region of India. <i>Asian Journal of Oncology</i> , 0, 06, 47-52.	0.2	1
868	Living with Advanced Hormone-Sensitive Prostate Cancer and Treatment with Abiraterone and Androgen Deprivation Therapy: The Patient, Nursing and Physician Perspective. <i>Oncology and Therapy</i> , 2020, 8, 197-207.	1.0	2
869	Secondary malignancies after radiation therapy in prostate cancer survivors: a propensity-score matched competing-risk analysis. <i>Translational Cancer Research</i> , 2020, 9, 2847-2854.	0.4	0
870	Long-term outcomes of active surveillance for clinically localized prostate cancer in a community-based setting: results from a prospective non-interventional study. <i>World Journal of Urology</i> , 2021, 39, 2515-2523.	1.2	9
871	Simple low-cost approaches to semantic segmentation in radiation therapy planning for prostate cancer using deep learning with non-contrast planning CT images. <i>Physica Medica</i> , 2020, 78, 93-100.	0.4	17
872	Urinary incontinence and erectile dysfunction in patients with localized or locally advanced prostate cancer: A nationwide observational study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 735.e17-735.e25.	0.8	19
873	Radiation oncology in times of COVID-2019: A review article for those in the eye of the storm – An Indian perspective. <i>Seminars in Oncology</i> , 2020, 47, 315-327.	0.8	4
874	Re: Timothy J. Wilt, Tien N. Vo, Lisa Langsetmo, et al. Radical Prostatectomy or Observation for Clinically Localized Prostate Cancer: Extended Follow-up of the Prostate Cancer Intervention Versus Observation Trial (PIVOT). <i>Eur Urol</i> . In press. https://doi.org/10.1016/j.eururo.2020.02.009 . <i>European Urology</i> , 2020, 78, e67-e68.	0.9	0
875	In Vivo Quantification of Water Diffusion, Stiffness, and Tissue Fluidity in Benign Prostatic Hyperplasia and Prostate Cancer. <i>Investigative Radiology</i> , 2020, 55, 524-530.	3.5	26
876	Who Benefits From a Prostate Rectal Spacer? Secondary Analysis of a Phase III Trial. <i>Practical Radiation Oncology</i> , 2020, 10, 186-194.	1.1	13
877	PREDICT Prostate, a useful tool in men with low- and intermediate-risk prostate cancer who are hesitant between conservative management and active treatment. <i>BMC Medicine</i> , 2020, 18, 213.	2.3	1
878	Targeting the cancer lesion, not the whole prostate. <i>Translational Andrology and Urology</i> , 2020, 9, 1518-1525.	0.6	6
879	Prediction of prostate cancer aggressiveness using 18F-Fluciclovine (FACBC) PET and multisequence multiparametric MRI. <i>Scientific Reports</i> , 2020, 10, 9407.	1.6	3

#	ARTICLE	IF	CITATIONS
880	Optimal Androgen Deprivation Therapy Combined with Proton Beam Therapy for Prostate Cancer: Results from a Multi-Institutional Study of the Japanese Radiation Oncology Study Group. <i>Cancers</i> , 2020, 12, 1690.	1.7	5
881	Salvage Radiotherapy Following Partial Gland Ablation for Prostate Cancer: Functional and Oncological Outcomes. <i>European Urology Open Science</i> , 2020, 21, 1-4.	0.2	1
882	Cardiovascular Complications of Prostate Cancer Therapy. Current Treatment Options in <i>Cardiovascular Medicine</i> , 2020, 22, 1.	0.4	6
883	Diagnostic performance of 18F-DCFPyL positron emission tomography/computed tomography for biochemically recurrent prostate cancer and change-of-management analysis. <i>Canadian Urological Association Journal</i> , 2020, 15, 173-178.	0.3	4
884	Trends in prostatectomy utilization: Increasing upfront prostatectomy and postprostatectomy radiotherapy for high-risk prostate cancer. <i>Cancer Medicine</i> , 2020, 9, 8754-8764.	1.3	12
885	Radiotherapy for elder patients aged ≥80 with clinically localized prostate cancer – Brachytherapy enhanced late GU toxicity especially in elderly. <i>Clinical and Translational Radiation Oncology</i> , 2020, 25, 67-74.	0.9	4
886	Surgical management of high-risk, localized prostate cancer. <i>Nature Reviews Urology</i> , 2020, 17, 679-690.	1.9	20
887	Analysis of conventional versus advanced pelvic floor muscle training in the management of urinary incontinence after radical prostatectomy: a systematic review and meta-analysis of randomized controlled trials. <i>Translational Andrology and Urology</i> , 2020, 9, 2031-2045.	0.6	19
888	Impact of Health-related Quality of Life and Prediagnosis Risk of Major Depressive Disorder on Treatment Choice in Low- and Intermediate-Risk Prostate Cancer. <i>European Urology Open Science</i> , 2020, 21, 69-76.	0.2	1
889	In Vitro Study of Calcium Microsecond Electroporation of Prostate Adenocarcinoma Cells. <i>Molecules</i> , 2020, 25, 5406.	1.7	11
890	Contemporary Management of Vesico-Urethral Anastomotic Stenosis After Radical Prostatectomy. <i>Frontiers in Surgery</i> , 2020, 7, 587271.	0.6	15
891	Views of healthcare professionals about the role of active monitoring in the management of ductal carcinoma in situ (DCIS): Qualitative interview study. <i>Breast</i> , 2020, 54, 99-105.	0.9	9
893	Developing a Machine Learning Tool for Dynamic Cancer Treatment Strategies. <i>Proceedings of the AAAI Conference on Artificial Intelligence</i> , 2020, 34, 13742-13743.	3.6	1
894	The role of multiparametric MRI in active surveillance for low-risk prostate cancer: The ROMAS randomized controlled trial. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 433.e1-433.e7.	0.8	10
895	The role of multiparametric magnetic resonance imaging and magnetic resonance-guided biopsy in active surveillance for low-risk prostate cancer: A systematic review. <i>Annals of Medicine and Surgery</i> , 2020, 57, 171-178.	0.5	0
896	Overtreatment and Underutilization of Watchful Waiting in Men With Limited Life Expectancy: An Analysis of the Michigan Urological Surgery Improvement Collaborative Registry. <i>Urology</i> , 2020, 145, 190-196.	0.5	4
897	Examining initial treatment and survival among men with metastatic prostate cancer: An analysis from the CaPSURE registry. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 793.e1-793.e11.	0.8	7
898	Whole and hemi-gland cryoablation for primary localized prostate cancer: Short and medium-term oncological and functional outcomes. <i>Actas Urológicas Españolas (English Edition)</i> , 2020, 44, 172-178.	0.2	3

#	ARTICLE	IF	CITATIONS
899	Epidemiology, Staging and Management of Prostate Cancer. Medical Sciences (Basel, Switzerland), 2020, 8, 28.	1.3	55
900	Focal therapy, time to join the multi-disciplinary team discussion?. Translational Andrology and Urology, 2020, 9, 1526-1534.	0.6	4
901	Rethinking prostate cancer screening: could MRI be an alternative screening test?. Nature Reviews Urology, 2020, 17, 526-539.	1.9	19
902	Prostate cancer screening and treatment: where have we come from and where are we going?. BJU International, 2020, 126, 218-224.	1.3	39
903	The ProtecT randomised trial cost-effectiveness analysis comparing active monitoring, surgery, or radiotherapy for prostate cancer. British Journal of Cancer, 2020, 123, 1063-1070.	2.9	15
904	Phase II prospective trial "Give Me Five" short-term high precision radiotherapy for early prostate cancer with simultaneous boost to the dominant intraprostatic lesion: the impact of toxicity on quality of life (AIRC IG-13218). Medical Oncology, 2020, 37, 74.	1.2	7
905	Magnetic Resonance Imaging Improves Selection for Active Surveillance and Can Extend the Interval Between Biopsies. European Urology, 2020, 78, 518-519.	0.9	2
906	The Advanced Alternative Payment Model: Catalyst for Prostate Brachytherapy Adoption?. International Journal of Radiation Oncology Biology Physics, 2020, 106, 1104-1105.	0.4	1
907	Predictors of ISUP score upgrade in patients with low-risk prostate cancer. Tumori, 2021, 107, 030089162094395.	0.6	2
908	Texture analysis on bi-parametric MRI for evaluation of aggressiveness in patients with prostate cancer. Abdominal Radiology, 2020, 45, 4214-4222.	1.0	5
909	Depression and prostate cancer: implications for urologists and oncologists. Nature Reviews Urology, 2020, 17, 571-585.	1.9	13
910	Proposed Hydrogel-Implant Quality Score and a Matched-Pair Study for Prostate Radiation Therapy. Practical Radiation Oncology, 2020, 10, 202-208.	1.1	7
911	Impact on quality of life 3 years after diagnosis of prostate cancer patients below 75 at diagnosis: an observational case-control study. BMC Cancer, 2020, 20, 757.	1.1	15
912	Systematic Review and Meta-Analysis of Correlation of Progression-Free Survival-2 and Overall Survival in Solid Tumors. Frontiers in Oncology, 2020, 10, 1349.	1.3	22
913	Electroporation-Based Treatments in Urology. Cancers, 2020, 12, 2208.	1.7	19
914	Cryotherapy shows no inferiority compared with radical Prostatectomy for low-risk and intermediate-risk localized Prostate Cancer: a real-world study from the SEER database. Journal of Cancer, 2020, 11, 5738-5745.	1.2	7
916	The Impact of Prostate Cancer Treatment on Quality of Life: A Narrative Review with a Focus on Randomized Data. Research and Reports in Urology, 2020, Volume 12, 533-546.	0.6	9
917	Health-related quality of life in Japanese low-risk prostate cancer patients choosing active surveillance: 3-year follow-up from PRIAS-JAPAN. World Journal of Urology, 2021, 39, 2491-2497.	1.2	9

#	ARTICLE	IF	CITATIONS
918	Modelling the lifetime cost-effectiveness of radical prostatectomy, radiotherapy and active monitoring for men with clinically localised prostate cancer from median 10-year outcomes in the ProtecT randomised trial. <i>BMC Cancer</i> , 2020, 20, 971.	1.1	7
919	Hypofractionated Prostate Radiation Therapy: Adoption and Dosimetric Adherence Through Clinical Pathways in an Integrated Oncology Network. <i>JCO Oncology Practice</i> , 2021, 17, e537-e547.	1.4	3
920	Current management strategy of treating patients with erectile dysfunction after radical prostatectomy: a systematic review and meta-analysis. <i>International Journal of Impotence Research</i> , 2020, , .	1.0	15
921	No detrimental effect of a positive family history on postoperative upgrading and upstaging in men with low risk and favourable intermediate-risk prostate cancer: implications for active surveillance. <i>World Journal of Urology</i> , 2020, 39, 2499-2506.	1.2	7
922	Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19. <i>Advances in Radiation Oncology</i> , 2020, 5, 26-32.	0.6	19
923	The PTEN Conundrum: How to Target PTEN-Deficient Prostate Cancer. <i>Cells</i> , 2020, 9, 2342.	1.8	34
925	Strategies adopted by men to deal with uncertainty and anxiety when following an active surveillance/monitoring protocol for localised prostate cancer and implications for care: a longitudinal qualitative study embedded within the ProtecT trial. <i>BMJ Open</i> , 2020, 10, e036024.	0.8	7
926	Cancer Prevention and Screening for Older Adults: Part 2. Interventions to Prevent and Screen for Breast, Prostate, Cervical, Ovarian, and Endometrial Cancer. <i>Journal of the American Geriatrics Society</i> , 2020, 68, 2684-2691.	1.3	8
927	Sudden PSA rise to ≥ 20 ng/ml and prostate cancer diagnosis in the United States: A population-based study. <i>Prostate</i> , 2020, 80, 1438-1443.	1.2	0
928	<p>Circ-ZNF609 Accelerates the Radioresistance of Prostate Cancer Cells by Promoting the Glycolytic Metabolism Through miR-501-3p/HK2 Axis</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 7487-7499.	0.9	39
929	Heart transplantation in patients with localized prostate cancer—Are we denying a life-saving therapy due to an indolent tumor?. <i>Clinical Transplantation</i> , 2020, 34, e14080.	0.8	2
930	Focal bipolar radiofrequency ablation for localized prostate cancer: Safety and feasibility. <i>International Journal of Urology</i> , 2020, 27, 882-889.	0.5	12
931	Trends in Diagnosis and Disparities in Initial Management of High-Risk Prostate Cancer in the US. <i>JAMA Network Open</i> , 2020, 3, e2014674.	2.8	18
932	Multiparametric prostate MRI-based intensity-modulated radiation therapy guided by prostatic calcifications. <i>British Journal of Radiology</i> , 2020, 93, 20200571.	1.0	1
933	Comparing effectiveness of radical prostatectomy versus external beam radiotherapy in patients with locally advanced prostate cancer. <i>Medicine (United States)</i> , 2020, 99, e21642.	0.4	2
934	Tailoring Intensity of Active Surveillance for Low-Risk Prostate Cancer Based on Individualized Prediction of Risk Stability. <i>JAMA Oncology</i> , 2020, 6, e203187.	3.4	30
935	Rates of primary and secondary treatments for patients on active surveillance for localized prostate cancer—A population-based cohort study. <i>Cancer Medicine</i> , 2020, 9, 6946-6953.	1.3	4
936	MR Imaging-Guided Transurethral Ultrasound Ablation of Localized Prostate Cancer: Preliminary Experience from a Single Center in a Prospective, Multi-Center, Single-Arm Clinical Trial. <i>Journal of Vascular and Interventional Radiology</i> , 2020, 31, 740-746.e4.	0.2	7

#	ARTICLE	IF	CITATIONS
937	Efficacy of 3T Multiparametric MR Imaging followed by 3T in-Bore MR-Guided Biopsy for Detection of Clinically Significant Prostate Cancer Based on PIRADSV2.1 Score. <i>Journal of Vascular and Interventional Radiology</i> , 2020, 31, 1619-1626.	0.2	1
938	The comparison of the survival outcome between robotic-assisted radical prostatectomy and radiation therapy for localized prostate cancer in men over 70 years: Korean Nationwide Observational Study. <i>Journal of Robotic Surgery</i> , 2021, 15, 585-592.	1.0	3
939	Stereotactic Body Radiation Therapy for Intermediate-risk Prostate Cancer With VMAT and Real-time Electromagnetic Tracking. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 628-635.	0.6	6
942	Expanding Active Surveillance Inclusion Criteria: A Novel Nomogram Including Preoperative Clinical Parameters and Magnetic Resonance Imaging Findings. <i>European Urology Oncology</i> , 2022, 5, 187-194.	2.6	20
943	Changes in lifestyle among prostate cancer survivors: A nationwide population-based study. <i>Psycho-Oncology</i> , 2020, 29, 1713-1719.	1.0	6
944	Use of Imaging to Optimise Prostate Cancer Tumour Volume Assessment for Focal Therapy Planning. <i>Current Urology Reports</i> , 2020, 21, 38.	1.0	10
945	Detection of ctDNA in plasma of patients with clinically localised prostate cancer is associated with rapid disease progression. <i>Genome Medicine</i> , 2020, 12, 72.	3.6	35
946	Treatment decision-making in men with localized prostate cancer living in remote area: A cross-sectional observational study. <i>Canadian Urological Association Journal</i> , 2020, 15, E160-E168.	0.3	1
947	Choosing Wisely Africa: Ten Low-Value or Harmful Practices That Should Be Avoided in Cancer Care. <i>JCO Global Oncology</i> , 2020, 6, 1192-1199.	0.8	20
948	Impact of organ confined prostate cancer treatment on quality of life. <i>Actas Urológicas Españolas (English Edition)</i> , 2020, 44, 630-636.	0.2	2
949	The targeted inhibition of prostate cancer by iron-based nanoparticles based on bioinformatics. <i>Journal of Biomaterials Applications</i> , 2020, 36, 088532822097524.	1.2	3
950	Predicting Prostate Cancer Upgrading of Biopsy Gleason Grade Group at Radical Prostatectomy Using Machine Learning-Assisted Decision-Support Models. <i>Cancer Management and Research</i> , 2020, Volume 12, 13099-13110.	0.9	10
951	Shared decision making, physicians' explanations, and treatment satisfaction: a cross-sectional survey of prostate cancer patients. <i>BMC Medical Informatics and Decision Making</i> , 2020, 20, 334.	1.5	20
952	Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer. <i>The Cochrane Library</i> , 2020, 12, CD013245.	1.5	3
953	Radiation Dose to the Rectum With Definitive Radiation Therapy and Hydrogel Spacer Versus Postprostatectomy Radiation Therapy. <i>Advances in Radiation Oncology</i> , 2020, 5, 1225-1231.	0.6	0
954	Effects of leuprolide acetate on the quality of life of patients with prostate cancer: A prospective longitudinal cohort study. <i>Prostate International</i> , 2021, 9, 132-139.	1.2	3
956	Robotic radical prostatectomy: analysis of midterm pathologic and oncologic outcomes: A historical series from a high-volume center. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2021, 35, 6731-6745.	1.3	6
957	Trends in the use of active surveillance and treatments in Medicare beneficiaries diagnosed with localized prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 432.e1-432.e10.	0.8	23

#	ARTICLE	IF	CITATIONS
958	Oligometastatic Prostate Adenocarcinoma. Clinical-Pathologic Study of a Histologically Under-Recognized Prostate Cancer. <i>Journal of Personalized Medicine</i> , 2020, 10, 265.	1.1	3
959	In-Bore MRI-guided Prostate Biopsies in Patients with Prior Positive Transrectal USâ€‘guided Biopsy Results: Pathologic Outcomes and Predictors of Missed Cancers. <i>Radiology Imaging Cancer</i> , 2020, 2, e190078.	0.7	6
960	Impacto en la calidad de vida del tratamiento del cÃ¡ncer de prÃ³stata organoconfinado. <i>Actas UrolÃ³gicas EspaÃ±olas</i> , 2020, 44, 630-636.	0.3	1
961	Active surveillance in prostate cancer is possible for Afro-Caribbean population: Comparison of oncological outcomes with a Caucasian cohort. <i>Progres En Urologie</i> , 2020, 30, 532-540.	0.3	1
962	Dosimetric Impact of the Positional Imaging Frequency for Hypofractionated Prostate Radiotherapy â€‘ A Voxel-by-Voxel Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 564068.	1.3	4
963	Comparison by Race of Conservative Management for Low-Risk and Intermediate-Risk Prostate Cancers in Veterans From 2004 to 2018. <i>JAMA Network Open</i> , 2020, 3, e2018318.	2.8	18
964	Association Between African American Race and Clinical Outcomes in Men Treated for Low-Risk Prostate Cancer With Active Surveillance. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 1747.	3.8	43
965	EDITORIAL COMMENT. <i>Urology</i> , 2020, 145, 195-196.	0.5	0
966	Delivering Clinical impacts of the MRI diagnostic pathway in prostate cancer diagnosis. <i>Abdominal Radiology</i> , 2020, 45, 4012-4022.	1.0	18
967	Comparison of Real-Time Virtual Sonography Navigation Versus BioJet Navigation on Magnetic Resonance Imagingâ€‘Guided Prostate Needle Biopsy: A Single Institutional Analysis. <i>Journal of Endourology</i> , 2020, 34, 739-745.	1.1	3
968	Role of radiation oncology in modern multidisciplinary cancer treatment. <i>Molecular Oncology</i> , 2020, 14, 1431-1441.	2.1	18
969	Re: Radical Prostatectomy or Watchful Waiting in Prostate Cancerâ€‘29-Year Follow-up. <i>European Urology</i> , 2020, 78, 471.	0.9	2
970	Functionalized nano-targeted moieties in management of prostate cancer. <i>Future Oncology</i> , 2020, 16, 869-883.	1.1	8
971	Reply to Roderick C.N. van den Bergh, Massimo Valerio, Derya Tilki, and Giorgio Gandagliaâ€™s Letter to the Editor re: Timothy J. Wilt, Tien N. Vo, Lisa Langsetmo, et al. Radical Prostatectomy or Observation for Clinically Localized Prostate Cancer: Extended Follow-up of the Prostate Cancer Intervention Versus Observation Trial (PIVOT). <i>Eur Urol</i> . In press. http://dx.doi.org/10.1016/j.eururo.2020.02.009 . <i>European Urology</i> , 2020, 78, e69-e70.	0.9	0
972	Radical prostatectomy versus brachytherapy for clinically localized prostate cancer on oncological and functional outcomes: a meta-analysis. <i>Translational Andrology and Urology</i> , 2020, 9, 332-343.	0.6	13
973	A population perspective on the use of external beam radiotherapy in Catalonia, Spain. <i>Clinical and Translational Oncology</i> , 2020, 22, 2222-2229.	1.2	2
974	In reply to Simcock et al.. <i>Clinical and Translational Radiation Oncology</i> , 2020, 23, 65.	0.9	1
975	Estimating the threat posed by prostate cancer. <i>BJU International</i> , 2020, 125, 480-481.	1.3	1

#	ARTICLE	IF	CITATIONS
976	Prostate cancer risk group is associated with other-cause mortality in men with localized prostate cancer. <i>Canadian Urological Association Journal</i> , 2020, 14, E507-E513.	0.3	3
977	TEP/TDM 18F-choline dans les r�cidives biologiques des cancers de la prostate traites par radioth�rapie externe ou curieth�rapie: impact du PSA et de sa cin�tique. <i>Medecine Nucleaire</i> , 2020, 44, 53-64.	0.2	0
978	A Canadian framework for managing prostate cancer during the COVID-19 pandemic: Recommendations from the Canadian Urologic Oncology Group and the Canadian Urological Association. <i>Canadian Urological Association Journal</i> , 2020, 14, 163-168.	0.3	20
979	Re: MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis. <i>European Urology</i> , 2020, 78, 469-470.	0.9	2
980	Unmet expectations in prostate cancer patients and their association with decision regret. <i>Journal of Cancer Survivorship</i> , 2020, 14, 731-738.	1.5	19
981	Simulating the impact of centralization of prostate cancer surgery services on travel burden and equity in the English National Health Service: A national population based model for health service re�design. <i>Cancer Medicine</i> , 2020, 9, 4175-4184.	1.3	8
982	Risks from Deferring Treatment for Genitourinary Cancers: A Collaborative Review to Aid Triage and Management During the COVID-19 Pandemic. <i>European Urology</i> , 2020, 78, 29-42.	0.9	110
983	Health�related quality of life in long�term prostate cancer survivors after nerve�sparing and non�nerve�sparing radical prostatectomy�Results from the multiregional PROCAS study. <i>Cancer Medicine</i> , 2020, 9, 5416-5424.	1.3	6
984	Radical prostatectomy versus deferred treatment for localised prostate cancer. <i>The Cochrane Library</i> , 2020, 6, CD006590.	1.5	23
985	A QSP model of prostate cancer immunotherapy to identify effective combination therapies. <i>Scientific Reports</i> , 2020, 10, 9063.	1.6	26
986	Reconsidering the Trade-offs of Prostate Cancer Screening. <i>New England Journal of Medicine</i> , 2020, 382, 2465-2468.	13.9	53
987	Event-Free Survival, a Prostate-Specific Antigen�Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation. <i>Journal of Clinical Oncology</i> , 2020, 38, 3032-3041.	0.8	37
988	Evidencing the impact of cancer trials: insights from the 2014 UK Research Excellence Framework. <i>Trials</i> , 2020, 21, 486.	0.7	8
989	Standardized Nomenclature and Surveillance Methodologies After Focal Therapy and Partial Gland Ablation for Localized Prostate Cancer: An International Multidisciplinary Consensus. <i>European Urology</i> , 2020, 78, 371-378.	0.9	66
990	The effect of radiation therapy on post-prostatectomy urinary function. <i>Reports of Practical Oncology and Radiotherapy</i> , 2020, 25, 442-446.	0.3	4
991	Re: Randomized Trial of Partial Gland Ablation with Vascular Targeted Phototherapy Versus Active Surveillance for Low Risk Prostate Cancer: Extended Followup and Analyses of Effectiveness. <i>European Urology</i> , 2020, 77, 657-658.	0.9	0
992	Investigating association of perineural invasion on prostate biopsy with Gleason score upgrading at prostatectomy: A multi�institutional analysis. <i>Cancer Medicine</i> , 2020, 9, 3383-3389.	1.3	8
993	Building a High-Dose-Rate Prostate Brachytherapy Program With Real-Time Ultrasound-Based Planning: Initial Safety, Quality, and Outcome Results. <i>Advances in Radiation Oncology</i> , 2020, 5, 388-395.	0.6	2

#	ARTICLE	IF	CITATIONS
994	Metastasis, Mortality, and Quality of Life for Men With NCCN High and Very High Risk Localized Prostate Cancer After Surgical and/or Combined Modality Radiotherapy. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 274-283.e5.	0.9	11
995	Quality of life in active surveillance for early prostate cancer. <i>International Journal of Urology</i> , 2020, 27, 296-306.	0.5	9
996	Preoperative Risk-Stratification of High-Risk Prostate Cancer: A Multicenter Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 246.	1.3	11
997	Associations between self-reported physical activity, quality of life, and emotional well-being in men with prostate cancer on active surveillance. <i>Psycho-Oncology</i> , 2020, 29, 1044-1050.	1.0	8
998	Costing Urologic Complications Following Pelvic Radiation Therapy. <i>Urology</i> , 2020, 140, 64-69.	0.5	6
999	Alterations in the methylome of the stromal tumour microenvironment signal the presence and severity of prostate cancer. <i>Clinical Epigenetics</i> , 2020, 12, 48.	1.8	17
1000	1.5%T MR-guided and daily adapted SBRT for prostate cancer: feasibility, preliminary clinical tolerability, quality of life and patient-reported outcomes during treatment. <i>Radiation Oncology</i> , 2020, 15, 69.	1.2	94
1001	COVID-19: Global radiation oncology's targeted response for pandemic preparedness. <i>Clinical and Translational Radiation Oncology</i> , 2020, 22, 55-68.	0.9	183
1003	William Halsted and Prostate Cancer Progression. <i>European Urology</i> , 2020, 77, 725-726.	0.9	0
1004	Comparison of rectal dose reduction by a hydrogel spacer among 3D conformal radiotherapy, volumetric-modulated arc therapy, helical tomotherapy, CyberKnife and proton therapy. <i>Journal of Radiation Research</i> , 2020, 61, 487-493.	0.8	12
1005	<p>Clinical Documentation to Predict Factors Associated with Urinary Incontinence Following Prostatectomy for Prostate Cancer</p>. <i>Research and Reports in Urology</i> , 2020, Volume 12, 7-14.	0.6	5
1006	A Cost-Effectiveness and Quality of Life Analysis of Different Approaches to the Management and Treatment of Localized Prostate Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 103.	1.3	5
1007	Predictors of the regional variation of prostatectomy or radiotherapy: evidence from German cancer registries. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 1197-1204.	1.2	0
1008	Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review. <i>European Urology</i> , 2020, 77, 614-627.	0.9	101
1009	MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis. <i>New England Journal of Medicine</i> , 2020, 382, 917-928.	13.9	515
1010	Health-related quality of life in Japanese patients with prostate cancer following proton beam therapy: an institutional cohort study. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 519-527.	0.6	2
1011	17-Gene Genomic Prostate Score Test Results in the Canary Prostate Active Surveillance Study (PASS) Cohort. <i>Journal of Clinical Oncology</i> , 2020, 38, 1549-1557.	0.8	48
1012	Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Advances and Treatment Strategies in the First-Line Setting. <i>Oncology and Therapy</i> , 2020, 8, 209-230.	1.0	37

#	ARTICLE	IF	CITATIONS
1013	Real-Time Image Guided Ablative Prostate Cancer Radiation Therapy: Results From the TROG 15.01 SPARK Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 530-538.	0.4	33
1014	Updated evidence on oncological outcomes of surgery versus external beam radiotherapy for localized prostate cancer. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 963-969.	0.6	5
1015	A Genetic Risk Score to Personalize Prostate Cancer Screening, Applied to Population Data. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 1731-1738.	1.1	27
1016	Multiparametric magnetic resonance imaging can exclude prostate cancer progression in patients on active surveillance: a retrospective cohort study. <i>European Radiology</i> , 2020, 30, 6042-6051.	2.3	20
1017	Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2020, 31, 1119-1134.	0.6	485
1018	PTEN and ERG expression in MRI-ultrasound guided fusion biopsy correlated with radical prostatectomy findings in men with prostate cancer. <i>Prostate</i> , 2020, 80, 1118-1127.	1.2	2
1019	Active Surveillance for Intermediate-Risk Prostate Cancer: Systematic Review and Meta-analysis of Current Protocols and Outcomes. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e739-e753.	0.9	26
1020	Patient preferences for reducing bowel adverse events following prostate radiotherapy. <i>PLoS ONE</i> , 2020, 15, e0235616.	1.1	2
1021	The design, synthesis and anti-tumor mechanism study of new androgen receptor degrader. <i>European Journal of Medicinal Chemistry</i> , 2020, 204, 112512.	2.6	16
1022	PTPN14 acts as a candidate tumor suppressor in prostate cancer and inhibits cell proliferation and invasion through modulating LATS1/YAP signaling. <i>Molecular and Cellular Probes</i> , 2020, 53, 101642.	0.9	9
1026	Engineering Prostate Cancer from Induced Pluripotent Stem Cells—New Opportunities to Develop Preclinical Tools in Prostate and Prostate Cancer Studies. <i>International Journal of Molecular Sciences</i> , 2020, 21, 905.	1.8	15
1027	Downgrading of grade group 2 intermediate-risk prostate cancer from biopsy to radical prostatectomy: Comparison of outcomes and predictors to identify potential candidates for active surveillance. <i>Cancer</i> , 2020, 126, 1632-1639.	2.0	8
1028	Outcomes for Young Men With Localized Intermediate-Risk Prostate Cancer: An Analysis of the NCDB. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e531-e542.	0.9	1
1029	Association between PSA density and prostate cancer in men without significant MRI lesions. <i>BJU International</i> , 2020, 125, 763-764.	1.3	8
1030	Decision regret in men living with and beyond nonmetastatic prostate cancer in the United Kingdom: A population-based patient-reported outcome study. <i>Psycho-Oncology</i> , 2020, 29, 886-893.	1.0	26
1031	Validation of a 2-gene mRNA urine test for the detection of 5α-DHTG2 prostate cancer in an opportunistic screening population. <i>Prostate</i> , 2020, 80, 500-507.	1.2	8
1032	Active surveillance for prostate cancer: an update. <i>Trends in Urology & Men's Health</i> , 2020, 11, 8-11.	0.2	0
1033	Evaluation of erectile potency and radiation dose to the penile bulb using image guided radiotherapy in the CHHiP trial. <i>Clinical and Translational Radiation Oncology</i> , 2020, 21, 77-84.	0.9	17

#	ARTICLE	IF	CITATIONS
1034	Post-HIFU locally relapsed prostate cancer: high-dose salvage radiotherapy guided by molecular imaging. <i>Radiologia Medica</i> , 2020, 125, 491-499.	4.7	8
1035	Radical Prostatectomy or Observation for Clinically Localized Prostate Cancer: Extended Follow-up of the Prostate Cancer Intervention Versus Observation Trial (PIVOT). <i>European Urology</i> , 2020, 77, 713-724.	0.9	108
1036	Development and Internal Validation of a Web-based Tool to Predict Sexual, Urinary, and Bowel Function Longitudinally After Radiation Therapy, Surgery, or Observation. <i>European Urology</i> , 2020, 78, 248-255.	0.9	12
1037	All change in the prostate cancer diagnostic pathway. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 372-381.	12.5	64
1038	Clinical Outcomes of Dose-escalated Radiotherapy for Localised Prostate Cancer: A Single-institution Experience. <i>In Vivo</i> , 2020, 34, 757-765.	0.6	4
1040	Prostate MRI: staging and decision-making. <i>Abdominal Radiology</i> , 2020, 45, 2143-2153.	1.0	8
1041	Focal therapy for localized prostate cancer in the era of routine multi-parametric MRI. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 232-243.	2.0	20
1042	Fast contour propagation for MR-guided prostate radiotherapy using convolutional neural networks. <i>Medical Physics</i> , 2020, 47, 1238-1248.	1.6	34
1043	Long-term oncological and functional follow-up in low-dose-rate brachytherapy for prostate cancer: results from the prospective nationwide Swiss registry. <i>BJU International</i> , 2020, 125, 827-835.	1.3	7
1044	The long-term outcomes of Gleason grade groups 2 and 3 prostate cancer managed by active surveillance: Results from a large population-based cohort. <i>Canadian Urological Association Journal</i> , 2020, 14, 174-181.	0.3	13
1045	Clinical outcome comparison of Grade Group 1 and Grade Group 2 prostate cancer with and without cribriform architecture at the time of radical prostatectomy. <i>Histopathology</i> , 2020, 76, 755-762.	1.6	18
1046	The Emerging Role of Local Therapy in Metastatic Prostate Cancer. <i>Current Oncology Reports</i> , 2020, 22, 2.	1.8	7
1047	Effect of a Behavioral Intervention to Increase Vegetable Consumption on Cancer Progression Among Men With Early-Stage Prostate Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 140.	3.8	36
1048	Patient-Reported Outcomes Through 5 Years for Active Surveillance, Surgery, Brachytherapy, or External Beam Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 149.	3.8	172
1049	Preoperative %p2PSA and Prostate Health Index Predict Pathological Outcomes in Patients with Prostate Cancer Undergoing Radical Prostatectomy. <i>Scientific Reports</i> , 2020, 10, 776.	1.6	4
1050	Comparing Radiotherapy to Prostatectomy for High-Risk Prostate Cancer. <i>Cancer Journal (Sudbury, Tj ETQq1 1 0.784314 rgBT /Overl</i>	1.0	2
1051	<p></p>Subcellular Performance of Nanoparticles in Cancer Therapy</p>. <i>International Journal of Nanomedicine</i> , 2020, Volume 15, 675-704.	3.3	99
1052	Early Mortality of Prostatectomy vs. Radiotherapy as a Primary Treatment for Prostate Cancer: A Population-Based Study From the United States and East Germany. <i>Frontiers in Oncology</i> , 2019, 9, 1451.	1.3	0

#	ARTICLE	IF	CITATIONS
1053	The Development and Validation of Prostate Cancer-specific Physician-Hospital Networks. <i>Urology</i> , 2020, 138, 37-44.	0.5	0
1054	Development of a patient decision aid for the management of superficial basal cell carcinoma (BCC) in adults with a limited life expectancy. <i>BMC Medical Informatics and Decision Making</i> , 2020, 20, 81.	1.5	8
1055	Urologic Robotic Surgery. <i>Surgical Clinics of North America</i> , 2020, 100, 361-378.	0.5	35
1056	First statement on preparation for the COVID-19 pandemic in large German Speaking University-based radiation oncology departments. <i>Radiation Oncology</i> , 2020, 15, 74.	1.2	50
1057	Influence of sociodemographic factors on treatmentâ€™s choice for localized prostate cancer in Portugal. <i>Archivio Italiano Di Urologia Andrologia</i> , 2020, 92, 45-49.	0.4	3
1058	Secondary bladder and rectal cancer risk estimates following standard fractionated and moderately hypofractionated VMAT for prostate carcinoma. <i>Medical Physics</i> , 2020, 47, 2805-2813.	1.6	8
1060	Prostate cancer upgrading with serial prostate magnetic resonance imaging and repeat biopsy in men on active surveillance: are confirmatory biopsies still necessary?. <i>BJU International</i> , 2020, 126, 124-132.	1.3	30
1061	Clinical-genomic Characterization Unveils More Aggressive Disease Features in Elderly Prostate Cancer Patients with Low-grade Disease. <i>European Urology Focus</i> , 2020, 7, 797-806.	1.6	1
1062	Ultrahypofractionated versus hypofractionated and conventionally fractionated radiation therapy for localized prostate cancer: A systematic review and meta-analysis of phase III randomized trials. <i>Radiotherapy and Oncology</i> , 2020, 148, 235-242.	0.3	33
1063	Further evidence that surgery after focal therapy for prostate cancer is safe. <i>BJU International</i> , 2020, 125, 481-482.	1.3	0
1064	Impact of prebiopsy magnetic resonance imaging on biopsy and radical prostatectomy grade concordance. <i>Cancer</i> , 2020, 126, 2986-2990.	2.0	20
1065	Association of Age With Risk of Adverse Pathological Findings at Radical Prostatectomy in Men With Gleason Score 6 Prostate Cancer. <i>JAMA Network Open</i> , 2020, 3, e202041.	2.8	6
1066	Comparative Healthcare Research Outcomes of Novel Surgery in prostate cancer (IP4-CHRONOS): A prospective, multi-centre therapeutic phase II parallel Randomised Control Trial. <i>Contemporary Clinical Trials</i> , 2020, 93, 105999.	0.8	20
1067	Intermediate-risk Prostate Cancer: Stratification and Management. <i>European Urology Oncology</i> , 2020, 3, 270-280.	2.6	51
1068	Reconsidering Prostate Cancer Mortality â€™ The Future of PSA Screening. <i>New England Journal of Medicine</i> , 2020, 382, 1557-1563.	13.9	120
1069	High-intensity focused ultrasound for prostate cancer. <i>Expert Review of Medical Devices</i> , 2020, 17, 427-433.	1.4	34
1070	Profiling of Circulating microRNAs in Prostate Cancer Reveals Diagnostic Biomarker Potential. <i>Diagnostics</i> , 2020, 10, 188.	1.3	22
1071	Exploring Patient Views and Acceptance of Multiparametric Magnetic Resonance Imaging for the Investigation of Suspected Prostate Cancer (the PACT Study): A Mixed-Methods Study Protocol. <i>Methods and Protocols</i> , 2020, 3, 26.	0.9	4

#	ARTICLE	IF	CITATIONS
1072	Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19. <i>Advances in Radiation Oncology</i> , 2020, 5, 659-665.	0.6	149
1073	²³ Na-MRI as a Noninvasive Biomarker for Cancer Diagnosis and Prognosis. <i>Journal of Magnetic Resonance Imaging</i> , 2021, 53, 995-1014.	1.9	13
1074	Termination rates and histological reclassification of active surveillance patients with low- and early intermediate-risk prostate cancer: results of the PREFERE trial. <i>World Journal of Urology</i> , 2021, 39, 65-72.	1.2	2
1075	Comparing confirmatory biopsy outcomes between MRI-targeted biopsy and standard systematic biopsy among men being enrolled in prostate cancer active surveillance. <i>BJU International</i> , 2021, 127, 340-348.	1.3	12
1076	Oncological and functional outcomes in patients over 70 years of age treated with robotic radical prostatectomy: a propensity-matched analysis. <i>World Journal of Urology</i> , 2021, 39, 1131-1140.	1.2	16
1077	Treatment decision satisfaction and regret after focal HIFU for localized prostate cancer. <i>World Journal of Urology</i> , 2021, 39, 1121-1129.	1.2	13
1078	Accuracy of MRI-guided Versus Systematic Prostate Biopsy in Patients Under Active Surveillance: A Systematic Review and Meta-analysis. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 3-11.e1.	0.9	4
1079	Serial Molecular Profiling of Low-grade Prostate Cancer to Assess Tumor Upgrading: A Longitudinal Cohort Study. <i>European Urology</i> , 2021, 79, 456-465.	0.9	8
1080	A discussion on controversies and ethical dilemmas in prostate cancer screening. <i>Journal of Medical Ethics</i> , 2021, 47, 152-158.	1.0	11
1081	Treatment of low-risk prostate cancer: a retrospective study with 477 patients comparing external beam radiotherapy and I-125 seeds brachytherapy in terms of biochemical control and late side effects. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 118-123.	1.0	10
1082	Age-related urologic problems in the complex urologic patient. <i>World Journal of Urology</i> , 2021, 39, 1037-1044.	1.2	6
1083	Prostate Bed Delineation Guidelines for Postoperative Radiation Therapy: On Behalf Of The Francophone Group of Urological Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 1243-1253.	0.4	35
1084	The Value of a New Diagnostic Test for Prostate Cancer: A Cost-Utility Analysis in Early Stage of Development. <i>PharmacoEconomics - Open</i> , 2021, 5, 77-88.	0.9	3
1085	Mental distress and need for psychosocial support in prostate cancer patients: An observational cross-sectional study. <i>International Journal of Psychiatry in Medicine</i> , 2021, 56, 51-63.	0.8	8
1086	Long-term ureteroscopic management of upper tract urothelial carcinoma: 28-year single-centre experience. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 130-137.	0.6	4
1087	Gain-loss framing and patients' decisions: a linguistic examination of information framing in physician-patient conversations. <i>Journal of Behavioral Medicine</i> , 2021, 44, 38-52.	1.1	5
1089	Real-world dosimetric comparison between CyberKnife SBRT and HDR brachytherapy for the treatment of prostate cancer. <i>Brachytherapy</i> , 2021, 20, 44-49.	0.2	11
1090	Early Results of Unilateral Prostatic Artery Embolization as a Focal Therapy in Patients with Prostate Cancer under Active Surveillance: Cancer Prostate Embolisation, a Pilot Study. <i>Journal of Vascular and Interventional Radiology</i> , 2021, 32, 247-255.	0.2	15

#	ARTICLE	IF	CITATIONS
1091	Current and emerging therapies for localized high-risk prostate cancer. Expert Review of Anticancer Therapy, 2021, 21, 267-282.	1.1	3
1092	Genetic ablation of <i>FASN</i> attenuates the invasive potential of prostate cancer driven by <i>Pten</i> loss. Journal of Pathology, 2021, 253, 292-303.	2.1	13
1093	Influence of Geography on Prostate Cancer Treatment. International Journal of Radiation Oncology Biology Physics, 2021, 109, 1286-1295.	0.4	19
1094	Current evidence for focal therapy and partial gland ablation for organ-confined prostate cancer: systematic review of literature published in the last 2 years. Current Opinion in Urology, 2021, 31, 49-57.	0.9	7
1095	Radical Cystectomy Against Intravesical BCG for High-Risk High-Grade Nonmuscle Invasive Bladder Cancer: Results From the Randomized Controlled BRAVO-Feasibility Study. Journal of Clinical Oncology, 2021, 39, 202-214.	0.8	53
1096	Neglected side effects to curative prostate cancer treatments. International Journal of Impotence Research, 2021, 33, 428-438.	1.0	18
1097	Differences in Use of Aggressive Therapy for Localized Prostate Cancer in New York City. Clinical Genitourinary Cancer, 2021, 19, e55-e62.	0.9	1
1098	Photodynamic therapy for prostate cancer – A narrative review. Photodiagnosis and Photodynamic Therapy, 2021, 33, 102158.	1.3	34
1099	Prognostic capabilities and clinical utility of cell cycle progression testing, prostate imaging reporting and data system, version 2, and clinicopathologic data in management of localized prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 366.e19-366.e28.	0.8	1
1100	“More men die with prostate cancer than because of it”- an old adage that still holds true in the 21st century.. Cancer Treatment and Research Communications, 2021, 26, 100225.	0.7	11
1101	Performance of Ga-68 PSMA PET/CT for diagnosis and grading of local prostate cancer. Prostate International, 2021, 9, 107-112.	1.2	21
1102	Funding of prostate magnetic resonance imaging leads to fewer biopsies and potential savings to health systems in the management of prostate cancer. BJU International, 2021, 127, 6-12.	1.3	5
1103	A novel tool to predict functional outcomes after robot-assisted radical prostatectomy and the value of additional surgery for incontinence. BJU International, 2021, 127, 575-584.	1.3	13
1104	Rectal spacer hydrogel in 1.5T MR-guided and daily adapted SBRT for prostate cancer: dosimetric analysis and preliminary patient-reported outcomes. British Journal of Radiology, 2021, 94, 20200848.	1.0	28
1105	Do radiation oncologists and urologists endorse decision aids for active surveillance of low-risk prostate cancer: Results from a national survey. European Journal of Cancer Care, 2021, 30, e13301.	0.7	0
1106	Oncological outcomes of pathologically organ-confined, lymph node-positive prostate cancer after radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 234.e1-234.e7.	0.8	3
1107	The Prepare for Kidney Care Study: prepare for renal dialysis versus responsive management in advanced chronic kidney disease. Nephrology Dialysis Transplantation, 2021, 36, 975-982.	0.4	16
1108	Incorporating Magnetic Resonance Imaging and Biomarkers in Active Surveillance Protocols - Results From the Prospective Stockholm3 Active Surveillance Trial (STHLM3AS). Journal of the National Cancer Institute, 2021, 113, 632-640.	3.0	9

#	ARTICLE	IF	CITATIONS
1109	Pretransplant solid organ malignancy and organ transplant candidacy: A consensus expert opinion statement. <i>American Journal of Transplantation</i> , 2021, 21, 460-474.	2.6	67
1110	Results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial). <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 235-242.	1.2	9
1111	Adherence to Active Surveillance Protocols: Well Meant but Overconcerned?. <i>European Urology Oncology</i> , 2021, 4, 202-203.	2.6	0
1112	Defining and Measuring Adherence in Observational Studies Assessing Outcomes of Real-world Active Surveillance for Prostate Cancer: A Systematic Review. <i>European Urology Oncology</i> , 2021, 4, 192-201.	2.6	6
1113	Prostatectomy Versus Observation for Localized Prostate Cancer: A Meta-Analysis. <i>Scandinavian Journal of Surgery</i> , 2021, 110, 78-85.	1.3	1
1114	How to implement the requirements of a quality assurance system for prostate cancer. <i>World Journal of Urology</i> , 2021, 39, 41-47.	1.2	1
1115	Actualizaci3n y optimizaci3n de la vigilancia activa en c3ncer de pr3stata en 2021. <i>Actas Urol3gicas Espa3olas</i> , 2021, 45, 1-7.	0.3	9
1116	Grade group 2 (10%â€‰â‰¥â€‰GP4) patients have very similar malignant potential with grade group 1 patients, given the risk of intraductal carcinoma of the prostate. <i>International Journal of Clinical Oncology</i> , 2021, 26, 764-769.	1.0	5
1117	Role of MRI for the detection of prostate cancer. <i>World Journal of Urology</i> , 2021, 39, 637-649.	1.2	6
1118	Robotic Salvage Prostatectomy: a Contemporary Review. <i>SN Comprehensive Clinical Medicine</i> , 2021, 3, 233-241.	0.3	0
1119	Impact of PSMA PET on management of biochemical recurrent prostate cancer: a systematic review and meta-analysis of prospective studies. <i>Clinical and Translational Imaging</i> , 2021, 9, 95-108.	1.1	4
1120	Cause-specific mortality of low and selective intermediate-risk prostate cancer patients with active surveillance or watchful waiting. <i>Translational Andrology and Urology</i> , 2021, 10, 154-163.	0.6	4
1121	Oncological Long-term Outcome After Whole-gland High-intensity Focused Ultrasound for Prostate Cancerâ€”21-yr Follow-up. <i>European Urology Focus</i> , 2022, 8, 134-140.	1.6	10
1122	Is there a nonnegligible effect of maximum standardized uptake value in the staging and management of prostate cancer with 68Ga-prostate-specific membrane antigen positron emission tomography/computerized tomography imaging? A single-center experience. <i>Journal of Cancer Research and Therapeutics</i> , 2021, 17, 1351.	0.3	0
1123	Long Noncoding RNAs as Innovative Urinary Diagnostic Biomarkers. <i>Methods in Molecular Biology</i> , 2021, 2292, 73-94.	0.4	4
1124	Focal therapy compared to radical prostatectomy for non-metastatic prostate cancer: a propensity score-matched study. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 567-574.	2.0	28
1125	External beam radiotherapy for prostate cancer: What are the current research trends and hotspots?. <i>Cancer Medicine</i> , 2021, 10, 772-782.	1.3	3
1126	Five-year quality of life in patients with high-risk localized prostate cancer treated with external beam radiotherapy alone versus external beam radiotherapy with high-dose-rate brachytherapy boost: a prospective multicenter study. <i>Journal of Contemporary Brachytherapy</i> , 2021, 13, 1-11.	0.4	2

#	ARTICLE	IF	CITATIONS
1127	An injectable double-crosslinking iodinated composite hydrogel as a potential radioprotective spacer with durable imaging function. <i>Journal of Materials Chemistry B</i> , 2021, 9, 3346-3356.	2.9	6
1128	Phase I Trial of Encapsulated Rapamycin in Patients with Prostate Cancer Under Active Surveillance to Prevent Progression. <i>Cancer Prevention Research</i> , 2021, 14, 551-562.	0.7	6
1129	Association between incidental dose outside the prostate and tumor control after modern image-guided radiotherapy. <i>Physics and Imaging in Radiation Oncology</i> , 2021, 17, 25-31.	1.2	6
1130	Active Surveillance for Incidental (cT1a/b) Prostate Cancer: Long-Term Outcomes of the Prospective Noninterventonal HAROW Study. <i>Urologia Internationalis</i> , 2021, 105, 428-435.	0.6	11
1131	Generating comprehensive comparative evidence on various interventions for penile rehabilitation in patients with erectile dysfunction after radical prostatectomy: a systematic review and network meta-analysis. <i>Translational Andrology and Urology</i> , 2021, 10, 109-124.	0.6	4
1132	Long-term outcomes of a prospective randomized trial of 131Cs/125I permanent prostate brachytherapy. <i>Brachytherapy</i> , 2021, 20, 38-43.	0.2	3
1133	Focal therapy for primary and salvage prostate cancer treatment: a narrative review. <i>Translational Andrology and Urology</i> , 2021, 10, 3144-3154.	0.6	0
1134	Dynamic Changes of Generic Quality of Life after Different Treatments for Localized Prostate Cancer. <i>Journal of Clinical Medicine</i> , 2021, 10, 158.	1.0	4
1135	The Management of Prostate Cancer. <i>Practical Guides in Radiation Oncology</i> , 2021, , 3-23.	0.0	0
1136	The cost of metastatic prostate cancer using time-driven activity-based costing. <i>International Journal of Technology Assessment in Health Care</i> , 2021, 37, e60.	0.2	1
1137	Cancer nanomedicine. , 2021, , 537-566.		0
1138	The Role of Radiation Therapy in the Older Patient. <i>Current Oncology Reports</i> , 2021, 23, 11.	1.8	7
1139	Long-term follow-up comparing salvage radiation therapy and androgen-deprivation therapy for biochemical recurrence after radical prostatectomy. <i>International Journal of Clinical Oncology</i> , 2021, 26, 744-752.	1.0	0
1140	A comparison of the survival outcomes of robotic-assisted radical prostatectomy and radiation therapy in patients over 75 years old with non-metastatic prostate cancer: A Korean multicenter study. <i>Investigative and Clinical Urology</i> , 2021, 62, 535.	1.0	3
1141	Prospective trial of regional (hockey-stick) prostate cryoablation: oncologic and quality of life outcomes. <i>World Journal of Urology</i> , 2021, 39, 3259-3264.	1.2	5
1142	Identification of a Prognostic Signature Model with Tumor Microenvironment for predicting Disease-free Survival after Radical Prostatectomy. <i>Journal of Cancer</i> , 2021, 12, 2371-2384.	1.2	7
1143	Development and Challenges of the Discovery of HER2 Inhibitors. <i>Mini-Reviews in Medicinal Chemistry</i> , 2021, 20, 2123-2134.	1.1	2
1144	Differences in Implementation Outcomes of a Shared Decision-Making Program for Men with Prostate Cancer between an Academic Medical Center and County Health Care System. <i>Medical Decision Making</i> , 2021, 41, 120-132.	1.2	2

#	ARTICLE	IF	CITATIONS
1145	Active surveillance in males with low- to intermediate-risk localized prostate cancer: A modern prospective cohort study. <i>Investigative and Clinical Urology</i> , 2021, 62, 416.	1.0	3
1146	The comparison of survival between active surveillance or watchful waiting and focal therapy for low-risk prostate cancer: a real-world study from the SEER database. <i>Asian Journal of Andrology</i> , 2021, .	0.8	0
1147	Updating Perspectives on Meta-Analyses in the Field of Radiation Oncology. <i>Medicina (Lithuania)</i> , 2021, 57, 117.	0.8	15
1148	An Assessment of Comparative Marginal Costs to Non-Robotic Surgery for Radical Prostatectomy amongst Public Patients. <i>Journal of Service Science and Management</i> , 2021, 14, 399-411.	0.4	0
1149	Psychological aspects of active surveillance. <i>World Journal of Urology</i> , 2022, 40, 9-13.	1.2	6
1150	A review on the role of tissue-based molecular biomarkers for active surveillance. <i>World Journal of Urology</i> , 2022, 40, 27-34.	1.2	5
1151	Polygenic hazard score is associated with prostate cancer in multi-ethnic populations. <i>Nature Communications</i> , 2021, 12, 1236.	5.8	40
1152	Câncer de prÃ³stata. <i>Medicine</i> , 2021, 13, 1454-1466.	0.0	0
1153	Developing Tumor Radiosensitivity Signatures Using LncRNAs. <i>Radiation Research</i> , 2021, 195, 324-333.	0.7	10
1154	Coronavirus disease 2019 and the cancellation of face-to-face prostate cancer active surveillance clinic reviews: Does the omission of digital rectal examination alone put patients at risk of missed detection of disease progression?. <i>Journal of Clinical Urology</i> , 2022, 15, 103-108.	0.1	2
1155	â€œPaediatric surgical research in the UK â€œ Challenges and opportunitiesâ€™. <i>Seminars in Pediatric Surgery</i> , 2021, 30, 151019.	0.5	0
1156	Impact of anatomical changes on radiation absorbed dose of prostate and bladder in a potential scenario of magnetic resonance imaging (MRI)-guided carbon-ion radiotherapy (MRgCT) of prostate cancer. <i>Measurement: Journal of the International Measurement Confederation</i> , 2021, 171, 108772.	2.5	0
1157	Patient Reported vs Claims Based Measures of Health for Modeling Life Expectancy in Men with Prostate Cancer. <i>Journal of Urology</i> , 2021, 205, 434-440.	0.2	9
1158	Retrospective cohort study evaluating clinical, biochemical and pharmacological prognostic factors for prostate cancer progression using primary care data. <i>BMJ Open</i> , 2021, 11, e044420.	0.8	8
1159	Liquid biomarkers in active surveillance. <i>World Journal of Urology</i> , 2022, 40, 21-26.	1.2	6
1160	A modified Delphi study to develop a practical guide for selecting patients with prostate cancer for active surveillance. <i>BMC Urology</i> , 2021, 21, 18.	0.6	3
1161	Liproca Depot: A New Antiandrogen Treatment for Active Surveillance Patients. <i>European Urology Focus</i> , 2021, , .	1.6	3
1162	Assessment of PSIM (Prostatic Systemic Inflammatory Markers) Score in Predicting Pathologic Features at Robotic Radical Prostatectomy in Patients with Low-Risk Prostate Cancer Who Met the Inclusion Criteria for Active Surveillance. <i>Diagnostics</i> , 2021, 11, 355.	1.3	12

#	ARTICLE	IF	CITATIONS
1163	Magnetic Resonance Imaging Based Radiomic Models of Prostate Cancer: A Narrative Review. <i>Cancers</i> , 2021, 13, 552.	1.7	21
1164	Morbidity and All-Cause Mortality Following Radical Prostatectomy Compared with Observation for Localized Prostate Cancer in Chinese Men: A Non-Randomized Retrospective Study. <i>Medical Science Monitor</i> , 2021, 27, e928596.	0.5	0
1165	Emerging role of multiparametric magnetic resonance imaging in identifying clinically relevant localized prostate cancer. <i>Current Opinion in Oncology</i> , 2021, 33, 244-251.	1.1	4
1166	GPS Assay Association With Long-Term Cancer Outcomes: Twenty-Year Risk of Distant Metastasis and Prostate Cancer-Specific Mortality. <i>JCO Precision Oncology</i> , 2021, 5, 442-449.	1.5	10
1167	Patient Satisfaction and Regret After Robot-assisted Radical Prostatectomy: A Decision Regret Analysis. <i>Urology</i> , 2021, 149, 122-128.	0.5	17
1168	Benefit, Harm, and Cost-effectiveness Associated With Magnetic Resonance Imaging Before Biopsy in Age-based and Risk-stratified Screening for Prostate Cancer. <i>JAMA Network Open</i> , 2021, 4, e2037657.	2.8	34
1169	Using CT-guided stereotactic prostate radiation therapy (CT-SPRT) to assess sustained murine prostate ablation. <i>Scientific Reports</i> , 2021, 11, 6571.	1.6	0
1170	BCG versus Cystectomy for High Risk, High Grade Non Muscle Invasive Bladder Cancer. <i>Bladder Cancer</i> , 2021, 7, 107-108.	0.2	0
1171	Salvage lymph node dissection for prostate-specific membrane antigen (PSMA) positron emission tomography (PET)-identified oligometastatic disease. <i>Canadian Urological Association Journal</i> , 2021, 15, E545-E552.	0.3	3
1172	Dosimetric feasibility of neurovascular bundle-sparing stereotactic body radiotherapy with periprostatic hydrogel spacer for localized prostate cancer to preserve erectile function. <i>British Journal of Radiology</i> , 2021, 94, 20200433.	1.0	13
1173	Evaluation of Patient- and Surgeon-Specific Variations in Patient-Reported Urinary Outcomes 3 Months After Radical Prostatectomy From a Statewide Improvement Collaborative. <i>JAMA Surgery</i> , 2021, 156, e206359.	2.2	13
1174	A Deep Learning Approach to Diagnostic Classification of Prostate Cancer Using Pathology-Radiology Fusion. <i>Journal of Magnetic Resonance Imaging</i> , 2021, 54, 462-471.	1.9	41
1175	Oncologic Outcomes of Radical Prostatectomy and High-Dose Intensity-Modulated Radiotherapy with Androgen-Deprivation Therapy for Relatively Young Patients with Unfavorable Intermediate-Risk Prostate Adenocarcinoma. <i>Cancers</i> , 2021, 13, 1517.	1.7	7
1176	TRPM8 protein expression in hormone naïve local and lymph node metastatic prostate cancer. <i>Pathologica</i> , 2021, 113, 95-101.	1.3	11
1177	Is prostate cancer radiotherapy using implantable rectum spacers safe and effective in inflammatory bowel disease patients?. <i>Clinical and Translational Radiation Oncology</i> , 2021, 27, 121-125.	0.9	6
1178	Patient-Reported Financial Toxicity Associated with Contemporary Treatment for Localized Prostate Cancer. <i>Journal of Urology</i> , 2021, 205, 761-768.	0.2	21
1179	High-dose vitamin D supplementation to prevent prostate cancer progression in localised cases with low-to-intermediate risk of progression on active surveillance (ProsD): protocol of a phase II randomised controlled trial. <i>BMJ Open</i> , 2021, 11, e044055.	0.8	3
1180	99mTc-labelled PSMA ligand for radio-guided surgery in nodal metastatic prostate cancer: proof of principle. <i>EJNMMI Research</i> , 2021, 11, 22.	1.1	12

#	ARTICLE	IF	CITATIONS
1181	Localized and Locally Advanced Prostate Cancer: Treatment Options. <i>Oncology</i> , 2021, 99, 1-9.	0.9	12
1182	Patterns of care for men with prostate cancer: the 45 and Up Study. <i>Medical Journal of Australia</i> , 2021, 214, 271-278.	0.8	17
1183	Active surveillance for prostate cancer: selection criteria, guidelines, and outcomes. <i>World Journal of Urology</i> , 2022, 40, 35-42.	1.2	13
1184	Intermediate clinical endpoints in localised prostate cancer. <i>Lancet Oncology</i> , The, 2021, 22, 294-296.	5.1	2
1186	Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy. <i>European Urology</i> , 2021, 80, 746-757.	0.9	50
1187	Application of a novel machine learning framework for predicting non-metastatic prostate cancer-specific mortality in men using the Surveillance, Epidemiology, and End Results (SEER) database. <i>The Lancet Digital Health</i> , 2021, 3, e158-e165.	5.9	56
1188	Prevalence of Prostate Cancer at Different Clinical Stages in Italy: Estimated Burden of Disease Based on a Modelling Study. <i>Biology</i> , 2021, 10, 210.	1.3	4
1189	Utilization of focal therapy for patients discontinuing active surveillance of prostate cancer: Recommendations of an international Delphi consensus. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 781.e17-781.e24.	0.8	10
1190	Evaluation of PSA and PSA Density in a Multiparametric Magnetic Resonance Imaging-Directed Diagnostic Pathway for Suspected Prostate Cancer: The INNOVATE Trial. <i>Cancers</i> , 2021, 13, 1985.	1.7	10
1191	Mapping expanded prostate cancer index composite to EQ5D utilities to inform economic evaluations in prostate cancer: Secondary analysis of NRG/RTOG 0415. <i>PLoS ONE</i> , 2021, 16, e0249123.	1.1	4
1192	Personalized Radiation Attenuating Materials for Gastrointestinal Mucosal Protection. <i>Advanced Science</i> , 2021, 8, 2100510.	5.6	3
1193	Evaluation of two-dimensional electronic portal imaging device using integrated images during volumetric modulated arc therapy for prostate cancer. <i>Reports of Practical Oncology and Radiotherapy</i> , 2021, 26, 281-290.	0.3	3
1194	Long-term Clinical Outcomes of Repeat Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: A Case Series. <i>European Urology Focus</i> , 2021, , .	1.6	3
1195	Understanding Active Surveillance for Prostate Cancer. <i>JCO Oncology Practice</i> , 2021, 17, OP.20.00929.	1.4	0
1198	Brachytherapy Boost in Prostate Cancer: What Does Observational Data Add to the Debate?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 1230-1231.	0.4	0
1199	Preoperative exercise interventions to optimize continence outcomes following radical prostatectomy. <i>Nature Reviews Urology</i> , 2021, 18, 259-281.	1.9	29
1200	Long-term Outcomes of Focal Cryotherapy for Low- to Intermediate-risk Prostate Cancer: Results and Matched Pair Analysis with Active Surveillance. <i>European Urology Focus</i> , 2022, 8, 701-709.	1.6	14
1201	Evidence for Focal Grade Group Progression in Low-risk Prostate Cancer. <i>European Urology</i> , 2021, 79, 466-467.	0.9	0

#	ARTICLE	IF	CITATIONS
1202	Radical prostatectomy versus external beam radiation therapy for high-grade, clinically localized prostate cancer: Emulation of a target clinical trial. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 785.e1-785.e10.	0.8	4
1203	Therapies for Clinically Localized Prostate Cancer: A Comparative Effectiveness Review. <i>Journal of Urology</i> , 2021, 205, 967-976.	0.2	35
1204	Options for Curative Treatment of Localized Prostate Cancer. <i>Deutsches A&#x0308;rzteblatt International</i> , 2021, 118, .	0.6	7
1205	Screening of chronic radiation proctitis and colorectal cancer using periodic total colonoscopy after external beam radiation therapy for prostate cancer. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 1298-1302.	0.6	2
1206	What is the effect of MRI with targeted biopsies on the rate of patients discontinuing active surveillance? A reflection of the use of MRI in the PRIAS study. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 1048-1054.	2.0	10
1207	Developing 1/4SpherePlatform Using a Commercial Hairbrush: An Agarose 3D Culture Platform for Deep-Tissue Imaging of Prostate Cancer. <i>ACS Applied Bio Materials</i> , 2021, 4, 4254-4270.	2.3	3
1208	MR-Guided Hypofractionated Radiotherapy: Current Emerging Data and Promising Perspectives for Localized Prostate Cancer. <i>Cancers</i> , 2021, 13, 1791.	1.7	21
1209	Individual risk prediction of urinary incontinence after prostatectomy and impact on treatment choice in patients with localized prostate cancer. <i>Neurourology and Urodynamics</i> , 2021, 40, 1550-1558.	0.8	7
1210	Immunotherapy Combined With Radiation Therapy for Genitourinary Malignancies. <i>Frontiers in Oncology</i> , 2021, 11, 663852.	1.3	19
1211	Prostate-specific Antigen Screening Using the Traditional Cut Point of 3 ng/ml: Con. <i>European Urology Focus</i> , 2021, 7, 501-502.	1.6	2
1213	Magnetic Resonance Imaging-Targeted and Systematic Biopsy for Detection of Grade Progression in Patients on Active Surveillance for Prostate Cancer. <i>Journal of Urology</i> , 2021, 205, 1352-1360.	0.2	3
1214	Comparative effectiveness of robotic and open radical prostatectomy. <i>Translational Andrology and Urology</i> , 2021, 10, 2158-2170.	0.6	3
1215	Management of Lower Urinary Tract Symptoms after Prostate Radiation. <i>Current Urology Reports</i> , 2021, 22, 37.	1.0	4
1216	Time pressure predicts decisional regret in men with localized prostate cancer: data from a longitudinal multicenter study. <i>World Journal of Urology</i> , 2021, 39, 3755-3761.	1.2	5
1217	Change of preoperative symptoms of the late-onset hypogonadism syndrome after robot-assisted radical prostatectomy. <i>Current Urology</i> , 2021, 15, 85-90.	0.4	0
1218	Modeling-Based Decision Support System for Radical Prostatectomy Versus External Beam Radiotherapy for Prostate Cancer Incorporating an In Silico Clinical Trial and a Cost“Utility Study. <i>Cancers</i> , 2021, 13, 2687.	1.7	1
1219	18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial. <i>Lancet, The</i> , 2021, 397, 1895-1904.	6.3	107
1220	Identification of a serum biomarker signature associated with metastatic prostate cancer. <i>Proteomics - Clinical Applications</i> , 2021, 15, 2000025.	0.8	3

#	ARTICLE	IF	CITATIONS
1221	Head to head randomized trial of two decision aids for prostate cancer. BMC Medical Informatics and Decision Making, 2021, 21, 154.	1.5	4
1222	Variation in Prostate-Specific Antigen Testing Rates and Prostate Cancer Treatments and Outcomes in a National 20-Year Cohort. JAMA Network Open, 2021, 4, e219444.	2.8	5
1223	External beam radiation therapy carries lower risk of sexual dysfunction as compared to radical prostatectomy in treatment of patients with localized prostate cancer. Clinical Research in Practice the Journal of Team Hippocrates, 2021, 7, .	0.0	0
1224	Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: study protocol. BMC Cancer, 2021, 21, 512.	1.1	14
1225	Decision Making in Older Adults With Cancer. Journal of Clinical Oncology, 2021, 39, 2164-2174.	0.8	51
1226	Conventional radical versus focal treatment for localised prostate cancer: a propensity score weighted comparison of 6-year tumour control. Prostate Cancer and Prostatic Diseases, 2021, 24, 1120-1128.	2.0	10
1227	Oncological and functional outcome after partial prostate HIFU ablation with Focal-One®: a prospective single-center study. Prostate Cancer and Prostatic Diseases, 2021, 24, 1189-1197.	2.0	13
1228	Differences in treatment choices for localised prostate cancer diagnosed in private and public health services. Medical Journal of Australia, 2021, 214, 485.	0.8	0
1229	Announcing the Lancet Commission on Prostate Cancer. Lancet, The, 2021, 397, 1865-1866.	6.3	5
1230	Improved COVID-19 ICU admission and mortality outcomes following treatment with statins: a systematic review and meta-analysis. Archives of Medical Science, 2021, 17, 579-595.	0.4	61
1231	Combination Treatment Options for Castration-Resistant Prostate Cancer. , 0, , 59-80.		5
1232	Head-to-head Comparison of Conventional, and Image- and Biomarker-based Prostate Cancer Risk Calculators. European Urology Focus, 2021, 7, 546-553.	1.6	16
1234	A polymorphism in the promoter of FRAS1 is a candidate SNP associated with metastatic prostate cancer. Prostate, 2021, 81, 683-693.	1.2	5
1235	Optimizing External Beam Radiotherapy as per the Risk Group of Localized Prostate Cancer: A Nationwide Multi-Institutional Study (KROG 18-15). Cancers, 2021, 13, 2732.	1.7	1
1236	Predictive Factors of De Novo Overactive Bladder After Radical Prostatectomy in Patients With Clinically Localized Prostate Cancer: A Prospective Observational Study. The Korean Journal of Urological Oncology, 2021, 19, 109-116.	0.1	1
1237	Patient-reported outcomes following neoadjuvant endocrine therapy, external beam radiation, and adjuvant continuous/intermittent endocrine therapy for locally advanced prostate cancer: A randomized phase III trial. Cancer Medicine, 2021, 10, 3240-3248.	1.3	3
1238	MicroRNAs as Epigenetic Determinants of Treatment Response and Potential Therapeutic Targets in Prostate Cancer. Cancers, 2021, 13, 2380.	1.7	12
1239	Biorepositories and Databanks for the Development of Novel Biomarkers for Genitourinary Cancer Prevention and Management. European Urology Focus, 2021, 7, 513-521.	1.6	0

#	ARTICLE	IF	CITATIONS
1240	Active surveillance in prostate cancer management: where do we stand now?. Archives of Medical Science, 2021, 17, 805-811.	0.4	1
1241	Computer extracted gland features from H&E predicts prostate cancer recurrence comparably to a genomic companion diagnostic test: a large multi-site study. Npj Precision Oncology, 2021, 5, 35.	2.3	13
1242	Difference in Incontinence Pad Use between Patients after Radical Prostatectomy and Cancer-Free Population with Subgroup Analysis for Open vs. Minimally Invasive Radical Prostatectomy: A Descriptive Analysis of Insurance Claims-Based Data. International Journal of Environmental Research and Public Health, 2021, 18, 6891.	1.2	1
1243	Evaluation of Oncological Outcomes and Data Quality in Studies Assessing Nerve-sparing Versus Non-nerve-sparing Radical Prostatectomy in Nonmetastatic Prostate Cancer: A Systematic Review. European Urology Focus, 2022, 8, 690-700.	1.6	10
1244	Prognostic comparison between radical prostatectomy and radiotherapy in prostate cancer patients at different stages and ages. Aging, 2021, 13, 16773-16785.	1.4	0
1245	Can high b-value 3.0T biparametric MRI with the Simplified Prostate Image Reporting and Data System (S-PI-RADS) be used in biopsy-naïve men?. Clinical Imaging, 2021, , .	0.8	6
1246	Barriers and facilitators to mobile health and active surveillance use among older adults with skin disease. Health Expectations, 2021, 24, 1582-1592.	1.1	7
1247	Development and Validation of an Interpretable Artificial Intelligence Model to Predict 10-Year Prostate Cancer Mortality. Cancers, 2021, 13, 3064.	1.7	8
1248	The Risk of Prostate Cancer Progression in Active Surveillance Patients with Bilateral Disease Detected by Combined Magnetic Resonance Imaging-Fusion and Systematic Biopsy. Journal of Urology, 2021, 206, 1157-1165.	0.2	10
1249	Negative impact of neoadjuvant hormonal therapy on detecting biochemical recurrence after radical prostatectomy. International Journal of Clinical Oncology, 2021, 26, 1722-1728.	1.0	0
1250	Vigilancia activa del c�ncer de pr�stata. EMC - Urolog�a, 2021, 53, 1-8.	0.0	0
1251	68 Ga-prostate-specific membrane antigen (PSMA) PET/CT as a clinical decision-making tool in biochemically recurrent prostate cancer. Asia-Pacific Journal of Clinical Oncology, 2021, , .	0.7	0
1252	Antecedentes de neoplasias urol�gicas previos al trasplante renal. Resultados oncol�gicos a largo plazo. Actas Urol�gicas Espa�olas, 2021, 45, 623-634.	0.3	0
1253	Radical prostatectomy for localized prostate cancer: 20-year oncological outcomes from a German high-volume center. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 830.e17-830.e26.	0.8	17
1254	Temporal changes in cause-specific death in men with localised prostate cancer treated with radical prostatectomy: a population-based, nationwide study. Journal of Surgical Oncology, 2021, 124, 867-875.	0.8	1
1255	Active surveillance for prostate cancer. Translational Andrology and Urology, 2021, 10, 2809-2819.	0.6	16
1256	Data-driven Focal Therapy for Localized Prostate Cancer: A Wake-up Call. European Urology Oncology, 2021, 4, 424-425.	2.6	1
1257	Trends and practices for managing low-risk prostate cancer: a SEER-Medicare study. Prostate Cancer and Prostatic Diseases, 2022, 25, 100-108.	2.0	11

#	ARTICLE	IF	CITATIONS
1258	Focal therapy for localized cancer: a patent review. <i>Expert Review of Medical Devices</i> , 2021, 18, 751-769.	1.4	1
1259	Measuring Quality of Life Following Robot-Assisted Radical Prostatectomy. <i>Patient Preference and Adherence</i> , 2021, Volume 15, 1373-1382.	0.8	3
1260	Prostate Cancer Screening in Brazil: a single center experience in the public health system. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2021, 47, 558-565.	0.7	6
1261	A narrative review of the management of benign prostatic hyperplasia in patients undergoing penile prosthesis surgery. <i>Translational Andrology and Urology</i> , 2021, 10, 2695-2704.	0.6	3
1262	A disease by any other name: Effects of cancer grading nomenclature on perception of prostate cancer risk. <i>Cancer</i> , 2021, 127, 3290-3293.	2.0	0
1264	Effects of Delayed Radical Prostatectomy and Active Surveillance on Localised Prostate Cancer—A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2021, 13, 3274.	1.7	8
1265	Multiparametric magnetic resonance imaging of the prostate underestimates tumour volume of small visible lesions. <i>BJU International</i> , 2022, 129, 201-207.	1.3	11
1266	Imaging of prostate cancer: optimizing affinity to prostate specific membrane antigen by spacer modifications in a tumor spheroid model. <i>Journal of Biomolecular Structure and Dynamics</i> , 2021, 1-22.	2.0	4
1267	Long-term outcomes of androgen deprivation therapy in prostate cancer among Japanese men over 80 years old. <i>Cancer Science</i> , 2021, 112, 3074-3082.	1.7	6
1268	Long-term overall survival of radical prostatectomy patients is often superior to the general population: A comparison using life-table data. <i>Prostate</i> , 2021, 81, 785-793.	1.2	6
1269	Receipt of Guideline-Recommended Surveillance in a Population-Based Cohort of Prostate Cancer Patients Undergoing Active Surveillance. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 712-715.	0.4	2
1270	Non-Adaptive MR-Guided Radiotherapy for Prostate SBRT: Less Time, Equal Results. <i>Journal of Clinical Medicine</i> , 2021, 10, 3396.	1.0	11
1271	Evaluation of clinical and mpMRI findings of irreversible electroporation therapy for the treatment of localized prostate cancer: Preliminary results. , 2021, 47, 299-304.		1
1273	Acute side effects after definitive stereotactic body radiation therapy (SBRT) for patients with clinically localized or locally advanced prostate cancer: a single institution prospective study. <i>Radiology and Oncology</i> , 2021, 55, 474-481.	0.6	1
1274	Automated treatment planning of prostate stereotactic body radiotherapy with focal boosting on a fast-rotating O-ring linac: Plan quality comparison with C-arm linacs. <i>Journal of Applied Clinical Medical Physics</i> , 2021, 22, 59-72.	0.8	5
1275	Impact of Decipher Biopsy testing on clinical outcomes in localized prostate cancer in a prospective statewide collaborative. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 677-683.	2.0	15
1276	Can patients with low-risk prostate cancer really benefit from radical treatment?: A systematic review and network meta-analysis. <i>Andrologia</i> , 2021, 53, e14122.	1.0	1
1277	Comparison of Oncological Outcomes Between Radical Prostatectomy and Radiotherapy by Type of Radiotherapy in Elderly Prostate Cancer Patients. <i>Frontiers in Oncology</i> , 2021, 11, 708373.	1.3	5

#	ARTICLE	IF	CITATIONS
1278	Intermediate-risk Prostate Cancer – A Sheep in Wolf’s Clothing?. <i>European Urology Oncology</i> , 2021, , .	2.6	0
1279	Management Recommendations for Prostate Cancer during the COVID-19 pandemic: A Systematic Review. <i>Soci�t� Internationale D’urologie Journal</i> , 2021, 2, 240-254.	0.2	1
1280	Indication for Active Surveillance in the Era of MRI-Targeted Prostate Biopsies. <i>Urologia Internationalis</i> , 2022, 106, 83-89.	0.6	2
1281	Hydrogel Spacer Rectal Wall Infiltration Associated With Severe Rectal Injury and Related Complications After Dose Intensified Prostate Cancer Stereotactic Ablative Radiation Therapy. <i>Advances in Radiation Oncology</i> , 2021, 6, 100713.	0.6	14
1282	Comparative Effectiveness Research in Localized Prostate Cancer: A 10-Year Follow-up Cohort Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 718-726.	0.4	7
1283	Protons Versus Photons for Prostate Cancer: An Answer That Is Long Overdue and Coming. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 1098-1100.	0.4	3
1284	A comparative analysis between low-dose-rate brachytherapy and external beam radiation therapy for low- and intermediate-risk prostate cancer in Asian men. <i>Acta Oncol�gica</i> , 2021, 60, 1291-1295.	0.8	3
1286	Photons, Protons, SBRT, Brachytherapy – What Is Leading the Charge for the Management of Prostate Cancer? A Perspective From the GU Editorial Team. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 1114-1121.	0.4	4
1287	Factors Affecting Satisfaction with the Decision-Making Process and Decision Regret for Men with a New Diagnosis of Prostate Cancer. <i>American Journal of Men's Health</i> , 2021, 15, 155798832110268.	0.7	12
1288	Patient and Public Involvement in research: A journey to co-production. <i>Patient Education and Counseling</i> , 2022, 105, 1041-1047.	1.0	28
1289	Progression on active surveillance for prostate cancer in Black men: a systematic review and meta-analysis. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 165-173.	2.0	4
1290	Salvage stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate cancer radiotherapy: An ESTRO ACROP Delphi consensus. <i>Cancer Treatment Reviews</i> , 2021, 98, 102206.	3.4	30
1291	The Evolving Role of 18F-FDG PET/CT in Diagnosis and Prognosis Prediction in Progressive Prostate Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 683793.	1.3	28
1292	The prognostic value of digital rectal exam for the existence of advanced pathologic features after prostatectomy. <i>Prostate</i> , 2021, 81, 1064-1070.	1.2	3
1293	Medium-term oncological and functional outcomes of hemi-gland brachytherapy using iodine-125 seeds for intermediate-risk unilateral prostate cancer. <i>Brachytherapy</i> , 2021, 20, 842-848.	0.2	5
1294	Biomarker in Active Surveillance for Prostate Cancer: A Systematic Review. <i>Cancers</i> , 2021, 13, 4251.	1.7	17
1295	First results of active observation of patients with prostate cancer and low oncological risk. <i>Andrologia Genital'naa Chirurgia</i> , 2021, 22, 78-83.	0.1	2
1296	PROState Pathway Embedded Comparative Trial: The IP3-PROSPECT study. <i>Contemporary Clinical Trials</i> , 2021, 107, 106485.	0.8	2

#	ARTICLE	IF	CITATIONS
1297	Quantifying the impact of SpaceOAR hydrogel on intermediate-risk fractional rectal and bladder dose during 0.35ÂT MRI-guided prostate adaptive radiotherapy. <i>Journal of Applied Clinical Medical Physics</i> , 2021, 22, 49-58.	0.8	4
1298	Factors Associated with Time to Conversion from Active Surveillance to Treatment for Prostate Cancer in a Multi-Institutional Cohort. <i>Journal of Urology</i> , 2021, 206, 1147-1156.	0.2	14
1299	Practical considerations for prostate hypofractionation in the developing world. <i>Nature Reviews Urology</i> , 2021, 18, 669-685.	1.9	20
1300	What men want: Results from a national survey on decision making for prostate cancer treatment and research participation. <i>Clinical and Translational Science</i> , 2021, 14, 2314-2326.	1.5	4
1301	Yttrium-90 Radioembolization to the Prostate Gland: Proof of Concept in a Canine Model and Clinical Translation. <i>Journal of Vascular and Interventional Radiology</i> , 2021, 32, 1103-1112.e12.	0.2	11
1303	Strategies toward Discovery of Potent and Orally Bioavailable Proteolysis Targeting Chimera Degradable of Androgen Receptor for the Treatment of Prostate Cancer. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 12831-12854.	2.9	69
1304	Effects of Exercise on Cardiorespiratory Fitness and Biochemical Progression in Men With Localized Prostate Cancer Under Active Surveillance. <i>JAMA Oncology</i> , 2021, 7, 1487.	3.4	42
1306	Active surveillance for intermediate-risk prostate cancer in African American and non-Hispanic White men. <i>Cancer</i> , 2021, 127, 4403-4412.	2.0	3
1308	Radiation treatment in prostate cancer: covering the waterfront. <i>BJU International</i> , 2021, 128, 398-407.	1.3	3
1309	A machine learning approach to predict progression on active surveillance for prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 161.e1-161.e7.	0.8	11
1310	Active surveillance in favorable intermediate-risk prostate cancer patients: Predictors of deferred intervention and treatment choice. <i>Canadian Urological Association Journal</i> , 2021, 16, .	0.3	5
1311	Novel bone microenvironment model of castration-resistant prostate cancer with chitosan fiber matrix and osteoblasts. <i>Oncology Letters</i> , 2021, 22, 689.	0.8	3
1312	Comparison of EBRT and I-125 seed brachytherapy concerning outcome in intermediate-risk prostate cancer. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 986-992.	1.0	4
1313	Early health economic analysis of 1.5ÂT MRI-guided radiotherapy for localized prostate cancer: Decision analytic modelling. <i>Radiotherapy and Oncology</i> , 2021, 161, 74-82.	0.3	21
1315	Validation of the cell cycle progression score to differentiate indolent from aggressive prostate cancer in men diagnosed through transurethral resection of the prostate biopsy. <i>Cancer Reports</i> , 2021, , e1535.	0.6	2
1316	Examining the Racial Disparities in Prostate Cancer. <i>Urology</i> , 2022, 163, 107-111.	0.5	17
1317	Impact of Hypofractionated Radiotherapy on Patient-reported Outcomes in Prostate Cancer: Results up to 5Âyr in the CHHiP trial (CRUK/06/016). <i>European Urology Oncology</i> , 2021, 4, 980-992.	2.6	14
1319	Multi-criteria optimization for planning volumetric-modulated arc therapy for prostate cancer. <i>PLoS ONE</i> , 2021, 16, e0257216.	1.1	2

#	ARTICLE	IF	CITATIONS
1321	Comparison of radical prostatectomy and external beam radiotherapy in high-risk prostate cancer. <i>Radiation Oncology Journal</i> , 2021, 39, 231-238.	0.7	6
1322	Tune the channel: TRPM8 targeting in prostate cancer. <i>Oncoscience</i> , 2021, 8, 97-100.	0.9	5
1323	Re: Radical Cystectomy Against Intravesical BCG for High-risk High-grade Nonmuscle Invasive Bladder Cancer: Results from the Randomized Controlled BRAVO-feasibility Study. <i>European Urology</i> , 2021, 80, 386-387.	0.9	0
1324	Focal Therapy Is a Viable Treatment for Low-Risk Prostate Cancer. <i>Journal of Endourology</i> , 2021, 35, 1281-1283.	1.1	3
1325	Proton therapy for prostate cancer: current state and future perspectives. <i>British Journal of Radiology</i> , 2022, 95, 20210670.	1.0	5
1326	Evaluation of Benefits and Harms of Surgical Treatments for Post-radical Prostatectomy Urinary Incontinence: A Systematic Review and Meta-analysis. <i>European Urology Focus</i> , 2022, 8, 1042-1052.	1.6	8
1327	Providing a Framework for Meaningful Patient Involvement in Clinical Practice Guideline Development and Implementation. <i>European Urology Focus</i> , 2021, 7, 947-950.	1.6	8
1328	SILAC-based quantitative MS approach reveals Withaferin A regulated proteins in prostate cancer. <i>Journal of Proteomics</i> , 2021, 247, 104334.	1.2	10
1329	Clinical Outcomes from Dose-Reduced Radiotherapy to the Prostate in Elderly Patients with Localized Prostate Cancer. <i>Current Oncology</i> , 2021, 28, 3729-3737.	0.9	2
1330	EDITORIAL COMMENT. <i>Urology</i> , 2021, 155, 90.	0.5	0
1331	Mapping the Patient-Oriented Prostate Utility Scale From the Expanded Prostate Cancer Index Composite and the Short-Form Health Surveys. <i>Value in Health</i> , 2021, 24, 1676-1685.	0.1	0
1332	In Reply. <i>Deutsches Arzteblatt International</i> , 2021, 118, 616-617.	0.6	0
1333	Illness representations, coping and anxiety among men with localized prostate cancer over an 18-months period: A parallel vs. level-contrast mediation approach. <i>Psycho-Oncology</i> , 2021, , .	1.0	1
1334	Short Androgen Suppression and Radiation Dose Escalation in Prostate Cancer: 12-Year Results of EORTC Trial 22991 in Patients With Localized Intermediate-Risk Disease. <i>Journal of Clinical Oncology</i> , 2021, 39, 3022-3033.	0.8	24
1335	Treatment planning comparison between dynamic wave arc and volumetric modulated arc therapies for prostate-cancer treatment. <i>Medical Dosimetry</i> , 2021, , .	0.4	0
1336	Focal Therapy for Low-Risk Prostate Cancer Opinion: No. <i>Journal of Endourology</i> , 2021, 35, 1284-1287.	1.1	1
1337	PSA testing, cancer treatment, and prostate cancer mortality reduction: What is the mechanism?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2023, 41, 78-81.	0.8	8
1338	Association of Age With Risk of Adverse Pathological Findings in Men Undergoing Delayed Radical Prostatectomy Following Active Surveillance. <i>Urology</i> , 2021, 155, 91-95.	0.5	6

#	ARTICLE	IF	CITATIONS
1339	Influence of Sociodemographic Factors on Definitive Intervention Among Low-risk Active Surveillance Patients. <i>Urology</i> , 2021, 155, 117-123.	0.5	7
1340	Functional and Oncological Outcomes After Open Versus Robot-assisted Laparoscopic Radical Prostatectomy for Localised Prostate Cancer: 8-Year Follow-up. <i>European Urology</i> , 2021, 80, 650-660.	0.9	46
1341	Active Surveillance Strategies for Low-Grade Prostate Cancer: Comparative Benefits and Cost-effectiveness. <i>Radiology</i> , 2021, 300, 594-604.	3.6	8
1342	An Updated Systematic Review on Focal Therapy in Localized Prostate Cancer: What Has Changed over the Past 5 Years?. <i>European Urology</i> , 2022, 81, 5-33.	0.9	66
1343	Prostate cancer. <i>Lancet, The</i> , 2021, 398, 1075-1090.	6.3	240
1344	Effects on annual income changes after radical radiotherapy versus after prostatectomy in patients with localized prostate cancer with a specific employment status: A web-based pilot study. <i>PLoS ONE</i> , 2021, 16, e0258116.	1.1	1
1345	Out-of-pocket costs for commercially insured patients with localized prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 797-805.	0.8	4
1346	Oncologic and patient-reported outcomes after robot-assisted radical prostatectomy in men aged ≥75 years. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 729.e17-729.e25.	0.8	6
1347	Letter to the Editor, Re: Reitblat et al. 2021. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 740-741.	0.8	0
1348	Long-term functional outcomes after robot-assisted prostatectomy compared to laparoscopic prostatectomy: Results from a national retrospective cluster study. <i>European Journal of Surgical Oncology</i> , 2021, 47, 2658-2666.	0.5	7
1349	Risk of adverse pathology at prostatectomy in the era of MRI and targeted biopsies; rethinking active surveillance for intermediate risk prostate cancer patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 729.e1-729.e6.	0.8	6
1350	Role of radiotherapy for high risk localized prostate cancers. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2021, 25, 660-662.	0.6	1
1351	A phase II study of docetaxel plus lycopene in metastatic castrate resistant prostate cancer. <i>Biomedicine and Pharmacotherapy</i> , 2021, 143, 112226.	2.5	12
1352	Patient Reported Quality of Life Outcomes After Definitive Radiation Therapy With Absorbable Spacer Hydrogel for Prostate Cancer. <i>Advances in Radiation Oncology</i> , 2021, 6, 100755.	0.6	1
1353	Cost-Effectiveness Analysis of Prostate Cancer Screening in Brazil. <i>Value in Health Regional Issues</i> , 2021, 26, 89-97.	0.5	1
1355	Cryopreserved placental tissue allograft accelerates time to continence following robot-assisted radical prostatectomy. <i>Journal of Robotic Surgery</i> , 2021, 15, 877-883.	1.0	3
1356	Conventional and Moderately Hypofractionated Radiation Therapy for Prostate Cancer. <i>Practical Guides in Radiation Oncology</i> , 2021, , 91-104.	0.0	0
1357	Navigate: a study protocol for a randomised controlled trial of an online treatment decision aid for men with low-risk prostate cancer and their partners. <i>Trials</i> , 2021, 22, 49.	0.7	6

#	ARTICLE	IF	CITATIONS
1358	Dosimetric Effects Due to Inter-Observer Variability of Organ Contouring When Utilizing a Knowledge-Based Planning System for Prostate Cancer. <i>International Journal of Medical Physics, Clinical Engineering and Radiation Oncology</i> , 2021, 10, 47-58.	0.3	1
1359	Sexual function and rehabilitation after radiation therapy for prostate cancer: a review. <i>International Journal of Impotence Research</i> , 2021, 33, 410-417.	1.0	7
1360	Insights into Urological Cancer. <i>Cancers</i> , 2021, 13, 204.	1.7	4
1361	When metal-organic framework mediated smart drug delivery meets gastrointestinal cancers. <i>Journal of Materials Chemistry B</i> , 2021, 9, 3967-3982.	2.9	22
1362	Has the COVID-19 outbreak changed the way we are treating prostate cancer? An EAU YAU Prostate Cancer Working Group multi-institutional study. <i>Central European Journal of Urology</i> , 2021, 74, 362-365.	0.2	3
1363	High Dose Rate Prostate Brachytherapy. <i>Practical Guides in Radiation Oncology</i> , 2021, , 127-151.	0.0	0
1365	Adherence to the Mediterranean diet and grade group progression in localized prostate cancer: An active surveillance cohort. <i>Cancer</i> , 2021, 127, 720-728.	2.0	7
1366	Management of prostate cancer radiotherapy during the COVID-19 pandemic: A necessary paradigm change. <i>Cancer Treatment and Research Communications</i> , 2021, 27, 100331.	0.7	9
1367	Update and optimization of active surveillance in prostate cancer in 2021. <i>Actas Urológicas Españolas (English Edition)</i> , 2021, 45, 1-7.	0.2	1
1368	Distribution analysis of hydrogel spacer and evaluation of rectal dose reduction in Japanese prostate cancer patients undergoing stereotactic body radiation therapy. <i>International Journal of Clinical Oncology</i> , 2021, 26, 736-743.	1.0	4
1369	Men's experiences of radiotherapy treatment for localized prostate cancer and its long-term treatment side effects: a longitudinal qualitative study. <i>Cancer Causes and Control</i> , 2021, 32, 261-269.	0.8	8
1370	Making a case for focal therapy of the prostate in intermediate risk prostate cancer: current perspective and ongoing trials. <i>World Journal of Urology</i> , 2021, 39, 729-739.	1.2	7
1371	Understanding temporal trends in medical costs associated with progression to metastatic prostate cancer. <i>Cancer</i> , 2017, 123, 3447-3449.	2.0	2
1372	Surgical Reconstruction of Posterior Urethral Complications Following Prostate Cancer Treatments. , 2020, , 303-317.		2
1373	Resolution of Cellular Heterogeneity in Human Prostate Cancers: Implications for Diagnosis and Treatment. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1164, 207-224.	0.8	7
1374	Management of Localized and Locally Advanced Prostate Cancer. , 2020, , 579-590.		1
1375	Tissue Preservation: Active Surveillance and Focal Therapy as Complimentary Strategies. <i>Current Clinical Urology</i> , 2018, , 217-227.	0.0	1
1376	Pain, fatigue and depression symptom cluster in survivors of prostate cancer. <i>Supportive Care in Cancer</i> , 2020, 28, 4813-4824.	1.0	36

#	ARTICLE	IF	CITATIONS
1377	Crioablaci3n total o hemiglandular para el c3ncer de pr3stata primario localizado: resultados oncol3gicos y funcionales a corto y medio plazo. Actas Urol3gicas Espa3olas, 2020, 44, 172-178.	0.3	6
1380	Quality of Life After Radiation Therapy for Prostate Cancer With a Hydrogel Spacer: 5-Year Results. International Journal of Radiation Oncology Biology Physics, 2017, 99, 374-377.	0.4	34
1381	Coffee, Caffeine Metabolism Genotype and Disease Progression in Patients with Localized Prostate Cancer Managed with Active Surveillance. Journal of Urology, 2019, 201, 308-314.	0.2	10
1382	Tumor-targeted dose escalation for localized prostate cancer using MR-guided HDR brachytherapy (HDR) or integrated VMAT (IB-VMAT) boost: Dosimetry, toxicity and health related quality of life. Radiotherapy and Oncology, 2020, 149, 240-245.	0.3	10
1383	Role of Multiparametric Magnetic Resonance Imaging Prostate Specific Antigen Density and PI-RADS4 Score in Predicting Up Staging in Men on Active Surveillance. Urology Practice, 2019, 6, 117-122.	0.2	2
1385	Clinical Staging in Psychiatry. , 2019, , .		31
1386	Quantifying treatment selection bias effect on survival in comparative effectiveness research: findings from low-risk prostate cancer patients. Prostate Cancer and Prostatic Diseases, 2021, 24, 414-422.	2.0	9
1387	Therapeutic Ultrasound and Prostate Cancer. Seminars in Interventional Radiology, 2017, 34, 187-200.	0.3	16
1388	Impact of the Primary Information Source Used for Decision Making on Treatment Perceptions and Regret in Prostate Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 898-904.	0.6	10
1389	Interpretation of Domain Scores on the EPIC5 How Does the Domain Score Translate into Functional Outcomes?. Journal of Urology, 2019, 202, 1150-1158.	0.2	11
1390	Long-Term Outcomes of Active Surveillance for Prostate Cancer: The Memorial Sloan Kettering Cancer Center Experience. Journal of Urology, 2020, 203, 1122-1127.	0.2	58
1391	Magnetic Resonance Imaging for the Detection of High Grade Cancer in the Canary Prostate Active Surveillance Study. Journal of Urology, 2020, 204, 701-706.	0.2	19
1392	The Long-Term Risks of Metastases in Men on Active Surveillance for Early Stage Prostate Cancer. Journal of Urology, 2020, 204, 1222-1228.	0.2	30
1393	Identification and evaluation of clinically significant prostate cancer. Current Opinion in Urology, 2017, 27, 217-224.	0.9	8
1394	Ki67 in Gleason Pattern 3 as a Marker of the Presence of Higher-Grade Prostate Cancer. Applied Immunohistochemistry and Molecular Morphology, 2021, 29, 112-117.	0.6	11
1396	Evaluation of benefits and harms of surgical treatments for post-radical prostatectomy urinary incontinence: a systematic review and meta-analysis protocol. F1000Research, 2019, 8, 1155.	0.8	3
1397	The impact of combining human and online supportive resources for prostate cancer patients. Journal of Community and Supportive Oncology, 2017, 15, e321-e329.	0.1	8
1398	Association of polymorphisms of PTEN, AKT1, PI3K, AR, and AMACR genes in patients with prostate cancer. Genetics and Molecular Biology, 2020, 43, e20180329.	0.6	11

#	ARTICLE	IF	CITATIONS
1399	Impact of the COVID-19 Pandemic on the Urologist's clinical practice in Brazil: a management guideline proposal for low- and middle-income countries during the crisis period. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2020, 46, 501-510.	0.7	59
1400	Clinical and surgical assistance in prostate cancer during the COVID-19 Pandemic: implementation of assistance protocols. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2020, 46, 50-61.	0.7	10
1401	New US Preventive Service Task Force recommendations for prostate cancer screening: a needed update, but not enough. <i>Einstein (Sao Paulo, Brazil)</i> , 2017, 15, 7-10.	0.3	3
1402	Radiation-induced erectile dysfunction in patients with prostate cancer: current methods of radiotherapy. <i>Onkourologiya</i> , 2020, 16, 143-152.	0.1	2
1403	Comparison on efficacy of radical prostatectomy versus external beam radiotherapy for the treatment of localized prostate cancer. <i>Oncotarget</i> , 2017, 8, 79854-79863.	0.8	20
1404	Comparisons of health-related quality of life among surgery and radiotherapy for localized prostate cancer: a systematic review and meta-analysis. <i>Oncotarget</i> , 2017, 8, 99057-99065.	0.8	11
1405	Long-term prediction of prostate cancer diagnosis and death using PSA and obesity related anthropometrics at early middle age: data from the malmö preventive project. <i>Oncotarget</i> , 2018, 9, 5778-5785.	0.8	1
1406	Patient centered care for prostate cancer—how can artificial intelligence and machine learning help make the right decision for the right patient?. <i>Annals of Translational Medicine</i> , 2019, 7, S1-S1.	0.7	8
1407	Can active surveillance really reduce the harms of overdiagnosing prostate cancer? A reflection of real life clinical practice in the PRIAS study. <i>Translational Andrology and Urology</i> , 2018, 7, 98-105.	0.6	24
1408	Nanoparticle Therapy for Prostate Cancer: Overview and Perspectives. <i>Current Topics in Medicinal Chemistry</i> , 2019, 19, 57-73.	1.0	33
1409	Investigation of the Effect of Level of Family Needs Coverage that Nursing Care Given to Family with Disabled Children. <i>Turkish Journal of Family Medicine & Primary Care</i> , 0, , 10-10.	0.2	1
1410	p2PSA for predicting biochemical recurrence of prostate cancer earlier than total prostate-specific antigen after radical prostatectomy: an observational prospective cohort study. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2019, 71, 273-279.	3.9	4
1411	Overview of potential determinants of radical prostatectomy versus radiation therapy in management of clinically localized prostate cancer: results from an Italian, prospective, observational study (the Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50). <i>Urology</i> , 2020, 72, 595-604.	3.9	10
1412	Conservative management of urinary incontinence following robot-assisted radical prostatectomy. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2020, 72, 555-562.	3.9	15
1413	Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study. <i>Health Technology Assessment</i> , 2018, 22, 1-176.	1.3	70
1414	Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT. <i>Health Technology Assessment</i> , 2020, 24, 1-176.	1.3	22
1415	The Predictive Role of Prostate-Specific Antigen Changes Following Transurethral Resection of the Prostate for Patients with Localized Prostate Cancer. <i>Cancers</i> , 2021, 13, 74.	1.7	2
1416	THE EFFECTIVENESS OF SCREENING FOR CANCER. <i>Voprosy Onkologii</i> , 2017, 63, 557-567.	0.1	2

#	ARTICLE	IF	CITATIONS
1417	Cancer-related fatigue during combined treatment of androgen deprivation therapy and radiotherapy is associated with mitochondrial dysfunction. <i>International Journal of Molecular Medicine</i> , 2020, 45, 485-496.	1.8	14
1418	Men's health 2018: BPH, prostate cancer, erectile dysfunction, supplements. <i>Cleveland Clinic Journal of Medicine</i> , 2018, 85, 871-880.	0.6	5
1419	Focal therapy for localized prostate cancer: is there a "middle ground" between active surveillance and definitive treatment?. <i>Asian Journal of Andrology</i> , 2019, 21, 37.	0.8	8
1420	Neoadjuvant therapy in high-risk prostate cancer. <i>Indian Journal of Urology</i> , 2020, 36, 251.	0.2	6
1421	Saudi Oncology Society and Saudi Urology Association combined clinical management guidelines for prostate cancer 2017. <i>Urology Annals</i> , 2018, 10, 138.	0.3	12
1422	A structured framework for optimizing high-intensity focused ultrasound ablative treatment in localized prostate cancer. <i>Investigative and Clinical Urology</i> , 2019, 60, 312.	1.0	4
1423	Prediction of pathologic upgrading in Gleason score 3+4 prostate cancer: Who is a candidate for active surveillance?. <i>Investigative and Clinical Urology</i> , 2020, 61, 405.	1.0	9
1424	PSA Testing Use and Prostate Cancer Diagnostic Stage After the 2012 U.S. Preventive Services Task Force Guideline Changes. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 795-803.	2.3	17
1425	Prostate Cancer Grade and Stage Misclassification in Active Surveillance Candidates: Black Versus White Patients. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1492-1499.	2.3	8
1426	Prostate Cancer: Locoregional Disease. <i>UNIPA Springer Series</i> , 2021, , 791-803.	0.1	0
1427	Prostate Magnetic Resonance Imaging Analyses, Clinical Parameters, and Preoperative Nomograms in the Prediction of Extraprostatic Extension. <i>Clinics and Practice</i> , 2021, 11, 763-775.	0.6	2
1428	Devastated Bladder Outlet in Pelvic Cancer Survivors: Issues on Surgical Reconstruction and Quality of Life. <i>Journal of Clinical Medicine</i> , 2021, 10, 4920.	1.0	8
1429	Characterization of an Iodinated Rectal Spacer for Prostate Photon and Proton Radiation Therapy. <i>Practical Radiation Oncology</i> , 2022, 12, 135-144.	1.1	7
1430	Impact of prostate biopsy secondary pathology review on radiotherapy management. <i>Prostate</i> , 2022, 82, 210-215.	1.2	3
1431	Traitement "focal" de l'adénocarcinome prostatique par HIFU. <i>Progrès En Urologie - FMC</i> , 2021, 31, F107-F107.	0.2	0
1433	Long-term Clinical Outcomes in Favorable Risk Prostate Cancer Patients Receiving Proton Beam Therapy. <i>International Journal of Particle Therapy</i> , 2022, 8, 14-24.	0.9	3
1434	Acute toxicity and patient-reported symptom score after conventional versus moderately hypofractionated proton therapy for prostate cancer. <i>Journal of Medical Radiation Sciences</i> , 2022, 69, 198-207.	0.8	3
1435	Treatment Regret, Mental and Physical Health Indicators of Psychosocial Well-Being among Prostate Cancer Survivors. <i>Current Oncology</i> , 2021, 28, 3900-3917.	0.9	6

#	ARTICLE	IF	CITATIONS
1436	Dose-Based Radiomic Analysis (Dosiomics) for Intensity Modulated Radiation Therapy in Patients With Prostate Cancer: Correlation Between Planned Dose Distribution and Biochemical Failure. International Journal of Radiation Oncology Biology Physics, 2022, 112, 247-259.	0.4	21
1437	The Psychosocial Consequences of Prostate Cancer Treatments on Body Image, Sexuality, and Relationships. Frontiers in Psychology, 2021, 12, 765315.	1.1	4
1438	Prostate cancer in multiethnic Asian men: Real-world experience in the Malaysia Prostate Cancer (MaCaP) Study. Cancer Medicine, 2021, 10, 8020-8028.	1.3	2
1441	Natural History of Untreated Localized Prostate Cancer: Rational for Active Surveillance. , 2017, , 1-11.		0
1443	Re: Behandling eller aktiv monitorering ved prostatakraft?. Tidsskrift for Den Norske Laegeforening, 2017, 137, 259-260.	0.2	0
1444	Patient Recruitment and Retention in Procedural Trials. , 2017, , 259-267.		0
1445	Most of patients with localized prostate cancer will be treated in the future? Opinion: No. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2017, 43, 584-587.	0.7	1
1446	Most of patients with localized prostate cancer will be treated in the future? Opinion: Yes. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2017, 43, 579-583.	0.7	0
1447	Tissue-Based Markers for Risk Prediction. Current Clinical Urology, 2018, , 121-133.	0.0	0
1448	Risk-Based Selection for Active Surveillance. Current Clinical Urology, 2018, , 53-64.	0.0	0
1450	Can MRI Replace Biopsy in Men on Surveillance?. Current Clinical Urology, 2018, , 111-119.	0.0	0
1451	Ethical and Legal Considerations in Active Surveillance for Prostate Cancer. Current Clinical Urology, 2018, , 31-39.	0.0	0
1452	Outcomes of Active Surveillance in Localized Prostate Cancer. The Korean Journal of Urological Oncology, 2017, 15, 93-102.	0.1	0
1454	The Nonsurgical Management of Ductal Carcinoma In Situ (DCIS). , 2018, , 159-170.		0
1455	Prostatakarzinom. , 2018, , 305-368.		0
1456	Prostate Cancer: Management in Elderly Men Population in 2017. , 2018, , 1-16.		0
1457	Why "watch and wait"™ is still a valuable option for low grade lymphomas. Cancer Nursing Practice, 2018, 17, 20-24.	0.2	0
1458	CLINICAL EXPERIENCE OF USING BRACHYTHERAPY WITH HIGH DOSE RATE SOURCES FOR MONOTHERAPY IN PROSTATE CANCER PATIENTS. Voprosy Onkologii, 2018, 64, 366-373.	0.1	1

#	ARTICLE	IF	CITATIONS
1459	Combination of nuclear NF-kB/p65 localization and gland morphological features from surgical specimens appears to be predictive of early biochemical recurrence in prostate cancer patients. , 2018, , .		0
1460	Outcomes Following Various Treatment Options for Clinically Localized Prostate Cancer. The Korean Journal of Urological Oncology, 2018, 16, 7-14.	0.1	0
1461	Risk-adapted approach to prostate cancer screening. Onkourologiya, 2018, 14, 109-121.	0.1	3
1462	Overview of Toxicity Outcomes with Prostate SBRT and Comparison to Other Treatment Interventions (Urinary, Rectal and Sexual Outcomes). , 2019, , 111-127.		0
1463	Radiotherapy for Localized and Locally Advanced Prostate Cancer. , 2019, , 1-16.		0
1464	Does seminal vesicle-sparing robotic radical prostatectomy influence postoperative prostate-specific antigen measured with an ultrasensitive immunoassay?. Swiss Medical Weekly, 2018, 148, w14685.	0.8	2
1465	Multiparametrische Prostata-MRT: VorzÄ¼age und Grenzen. Deutsches Ärzteblatt International, 0, , .	0.6	0
1466	Initial Experience of Transperineal Biopsy After Multiparametric Magnetic Resonance Imaging in Korea; Comparison With Transrectal Biopsy. The Korean Journal of Urological Oncology, 2018, 16, 110-118.	0.1	0
1467	Prostatakrebs â€œ PrÄ¼valenz, Bedeutung und Implikationen fÄ¼r die PrÄ¼vention und GesundheitsfÄ¼rderung. The Springer Reference Pfliegerapie, Gesundheit, 2019, , 1-6.	0.2	0
1468	Literatur zu Giordano/Wenz: Strahlentherapie kompakt, 3. Auflage. , 2019, , e.1-e.39.		0
1469	ClasificaciÃ³n de los desenlaces en los ensayos clÃ©nicos. Medicina UPB, 2019, 38, 147-157.	0.1	2
1470	Optimization for Non-Markovian Disease Models: An Application to Active Surveillance for Prostate Cancer. SSRN Electronic Journal, 0, , .	0.4	0
1471	Management of Nonmetastatic Failure Following Local Prostate Cancer Therapy. , 2019, , 227-240.		0
1472	Landmark Trials in Selected Genitourinary Malignancies. , 2019, , 75-121.		0
1473	Natural History of Untreated Localized Prostate Cancer: Rational for Active Surveillance. , 2019, , 179-190.		0
1474	Genitourinary Cancers. , 2019, , 313-359.		0
1475	Prostatakarzinom. , 2019, , 137-159.		0
1476	Radiotherapy for Localized and Locally Advanced Prostate Cancer. , 2019, , 211-226.		0

#	ARTICLE	IF	CITATIONS
1477	Urological neoplasia. , 2019, , 252-406.		1
1478	The Treatments for Low-Risk Prostate Cancer. The Korean Journal of Urological Oncology, 2019, 17, 7-21.	0.1	0
1480	Super active surveillance for low-risk prostate cancer Opinion: No. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2019, 45, 215-219.	0.7	0
1481	Psychological effects of choosing active surveillance on men with prostate cancer. Cancer Nursing Practice, 2019, 18, 35-41.	0.2	0
1484	Practice Patterns and Outcomes Among Patients With NOMO Prostate Cancer and a Very High Prostate-Specific Antigen Level. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 941-948.	2.3	0
1485	Natural History, Role of Biopsy, and Active Surveillance of Renal Masses. , 2020, , 133-157.		0
1487	Prostate Cancer: Management in Elderly Men Population in 2017. , 2020, , 655-670.		0
1488	First Russian experience of the stereotactic radiotherapy on the prostate bed. Urologicheskie Vedomosti, 2020, 10, 133-142.	0.4	0
1489	Comparative effectiveness of surgery and radiotherapy for survival of patients with clinically localized prostate cancer: A populationâ€based coarsened exact matching retrospective cohort study. Oncology Letters, 2020, 20, 1-1.	0.8	2
1491	Comparison of Gleason scoring and the new Grade-Group System in prostate cancers: a 15-year retrospective study. Journal of Health Sciences and Medicine, 0, , .	0.0	0
1492	Proposal for Establishing a New Radiotherapy Facility. , 2022, , 41-55.		0
1493	Does Protocol Make a Difference? Comparison of Two Prostate Cancer Active Surveillance Cohorts: A Nonâ€protocol-based Follow-up and a Protocol-based Contemporary Follow-up. European Urology Open Science, 2021, 34, 33-40.	0.2	1
1494	Multiparametric MRI in the management of prostate cancer: an updateâ€a narrative review. Gland Surgery, 2020, 9, 2321-2330.	0.5	6
1495	PI-RADSÂ® Category as a Predictor of Progression to Unfavorable Risk Prostate Cancer in Men on Active Surveillance. Journal of Urology, 2020, 204, 1229-1235.	0.2	5
1496	Open retropubic radical prostatectomy. Translational Andrology and Urology, 2020, 9, 3025-3035.	0.6	3
1497	Prostate cancer screening and the role of PSA: A UK perspective. Cleveland Clinic Journal of Medicine, 2021, 88, 14-16.	0.6	3
1498	Prostatakarzinom beim geriatrischen Patienten. , 2020, , 141-172.		0
1499	Whole-gland ablation therapy versus active surveillance for low-risk prostate cancer: a prospective study. Central European Journal of Urology, 2020, 73, 127-133.	0.2	0

#	ARTICLE	IF	CITATIONS
1500	A Primer on Prostate MRI for the Practicing Urologist: Update on the Current Literature. , 2020, , 89-96.		0
1502	Urologic Surgery in the Elderly. , 2020, , 339-361.		0
1503	Malignant diseases of the urinary tract. , 2020, , 5136-5149.		0
1505	HIGH DOSE RATE BRACHYTHERAPY AS MONOTHERAPY FOR PROSTATE CANCER: FIVE YEAR RESULTS. Voprosy Onkologii, 2020, 66, 404-412.	0.1	1
1506	Contamination in control group led to no effect of PSA-based screening on prostate cancer mortality at 9 years follow-up: Results of the French section of European Randomized Study of Screening for Prostate Cancer (ERSPC). Progres En Urologie, 2020, 30, 252-260.	0.3	2
1507	Evidence-based Urology: Subgroup Analysis in Randomized Controlled Trials. European Urology Focus, 2021, 7, 1237-1239.	1.6	6
1509	The Effects of Ionising and Non-Ionising Electromagnetic Radiation on Extracellular Matrix Proteins. Cells, 2021, 10, 3041.	1.8	20
1510	Outcome of 5-year follow-up in men with negative findings on initial biparametric MRI. Heliyon, 2021, 7, e08325.	1.4	4
1511	History of urological malignancies before kidney transplantation, oncological outcome on the long term. Actas Urológicas Españolas (English Edition), 2021, 45, 623-634.	0.2	0
1512	Melanoma Screening – Time for a Reset?. JAMA Dermatology, 2021, 157, 1409.	2.0	2
1513	American Society of Clinical Oncology 2021 Annual Meeting Highlights for Radiation Oncologists. Advances in Radiation Oncology, 2022, 7, 100779.	0.6	1
1516	Management of erectile dysfunction following robot-assisted radical prostatectomy: a systematic review. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2020, 72, 543-554.	3.9	11
1518	Roundup. Indian Journal of Urology, 2017, 33, 2-3.	0.2	0
1519	Prostate biopsy characteristics: A comparison between pre- and post- United States Preventive Service Task Force Prostate Cancer Screening Guidelines of 2012. Reviews in Urology, 2017, 19, 25-31.	0.9	8
1520	Active surveillance of prostate cancer: Current state of practice and utility of multiparametric magnetic resonance imaging. Reviews in Urology, 2017, 19, 77-88.	0.9	8
1521	Active Surveillance Use Among a Low-risk Prostate Cancer Population in a Large US Payer System: 17-Gene Genomic Prostate Score Versus Other Risk Stratification Methods. Reviews in Urology, 2017, 19, 203-212.	0.9	8
1522	A Multi-scale U-Net for Semantic Segmentation of Histological Images from Radical Prostatectomies. AMIA ... Annual Symposium proceedings, 2017, 2017, 1140-1148.	0.2	16
1523	Radiation Therapy for Prostate Cancer. Missouri Medicine, 2018, 115, 146-150.	0.3	7

#	ARTICLE	IF	CITATIONS
1524	Surgical Management for Prostate Cancer. Missouri Medicine, 2018, 115, 142-145.	0.3	4
1525	Prostate Cancer Surveillance After Radiation Therapy in a National Delivery System. Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS, 2019, 36, S16-S21.	0.6	0
1526	Perceived levels of collaboration between cancer patients and their providers during radiation therapy. Canadian Oncology Nursing Journal = Revue Canadienne De Nursing Oncologique, 2019, 29, 110-115.	0.1	1
1527	DegrÃ©s de collaboration perÃ©us entre les patients atteints de cancer et leurs prestataires de soins pendant la radiothÃ©rapie. Canadian Oncology Nursing Journal = Revue Canadienne De Nursing Oncologique, 2019, 29, 116-122.	0.1	0
1528	Prostate Cancer Screening and Management in Solid Organ Transplant Candidates and Recipients. Reviews in Urology, 2019, 21, 85-92.	0.9	3
1529	Trends in treatments for prostate cancer in the United States, 2010-2015. American Journal of Cancer Research, 2021, 11, 2351-2368.	1.4	3
1530	Prostatakarzinom. , 2022, , 314-327.		0
1531	Genetic factors associated with prostate cancer conversion from active surveillance to treatment. Human Genetics and Genomics Advances, 2022, 3, 100070.	1.0	10
1532	The Uro-Oncology Multi-disciplinary team (MDT) Clinic â€“ Clinical and Patient-Reported Outcomes From Implementing a New Model of Care. Proceedings of Singapore Healthcare, 0, , 201010582110552.	0.2	0
1534	A Review of High-Intensity Focused Ultrasound in Urology. Cancers, 2021, 13, 5696.	1.7	8
1535	Analysis of Complications Development Predictors after Radical Prostatectomy. Open Access Macedonian Journal of Medical Sciences, 2020, 9, 1575-1579.	0.1	0
1536	Correlation of Urine Loss after Catheter Removal and Early Continence in Men Undergoing Radical Prostatectomy. Current Oncology, 2021, 28, 4738-4747.	0.9	10
1537	Prostate-Specific Antigen Testing for Prostate Cancer Screeningâ€”Is the Message Getting Through?. JAMA Oncology, 2022, 8, 47.	3.4	3
1538	Association of Treatment Modality, Functional Outcomes, and Baseline Characteristics With Treatment-Related Regret Among Men With Localized Prostate Cancer. JAMA Oncology, 2022, 8, 50.	3.4	45
1539	Magnetic resonance linear accelerator technology and adaptive radiation therapy: An overview for clinicians. Ca-A Cancer Journal for Clinicians, 2022, 72, 34-56.	157.7	45
1540	Separation Effect and Development of Implantation Technique of Hydrogel Spacer for Prostate Cancers. Practical Radiation Oncology, 2022, 12, 226-235.	1.1	5
1541	Emergency Department Visits for Radiation Cystitis Among Patients with a Prostate Cancer History. BJU International, 2021, , .	1.3	1
1542	Validating the association of adverse pathology with distant metastasis and prostate cancer mortality 20-years after radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 104.e1-104.e7.	0.8	4

#	ARTICLE	IF	CITATIONS
1543	Health-Related Quality of Life following Cytoreductive Radical Prostatectomy in Patients with De-Novo Oligometastatic Prostate Cancer. <i>Cancers</i> , 2021, 13, 5636.	1.7	9
1544	An Adaptation, Extension and Pre-Testing of an Interactive Decision Aid for Men Diagnosed with Localized Prostate Cancer in Iceland: A Mixed-Method Study. <i>Behavioral Medicine</i> , 2023, 49, 137-150.	1.0	0
1545	A nationwide trend away from radical prostatectomy for Gleason grade group 1 prostate cancer. <i>BJU International</i> , 2021, , .	1.3	1
1547	Description of Surgical Technique and Oncologic and Functional Outcomes of the Precision Prostatectomy Procedure (IDEAL Stage 1â€²b Study). <i>European Urology</i> , 2022, 81, 396-406.	0.9	11
1548	Evaluating the Outcomes of Active Surveillance in Grade Group 2 Prostate Cancer: Prospective Results from the Canary PASS Cohort. <i>Journal of Urology</i> , 2022, 207, 805-813.	0.2	3
1549	The utility of prostate MRI within active surveillance: description of the evidence. <i>World Journal of Urology</i> , 2022, 40, 71-77.	1.2	6
1550	Dual-tracer PET/CT-targeted, mpMRI-targeted, systematic biopsy, and combined biopsy for the diagnosis of prostate cancer: a pilot study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 2821-2832.	3.3	15
1551	Incorporating artificial intelligence in urology: Supervised machine learning algorithms demonstrate comparative advantage over nomograms in predicting biochemical recurrence after prostatectomy. <i>Prostate</i> , 2022, 82, 298-305.	1.2	10
1552	Prostate Cancer Risk Stratification via Nondestructive 3D Pathology with Deep Learningâ€“Assisted Gland Analysis. <i>Cancer Research</i> , 2022, 82, 334-345.	0.4	42
1553	Association between Treatment for Localized Prostate Cancer and Mental Health Outcomes. <i>Journal of Urology</i> , 2022, 207, 1029-1037.	0.2	9
1554	The association of statin use and biochemical recurrence after curative treatment for prostate cancer. <i>Medicine (United States)</i> , 2022, 101, e28513.	0.4	7
1555	The Impact of PSMA PET/CT Imaging in Prostate Cancer Radiation Treatment. <i>Seminars in Nuclear Medicine</i> , 2022, 52, 255-262.	2.5	8
1556	Hospital readmissions for patients with prostate cancer are higher after radiotherapy than after prostatectomy. <i>Investigative and Clinical Urology</i> , 2022, 63, 34.	1.0	1
1557	Re: Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-specific Mortality Results from the International Staging Collaboration for Cancer of the Prostate. <i>European Urology</i> , 2022, , .	0.9	0
1558	Patient Decision-Making Factors in Aggressive Treatment of Low-Risk Prostate Cancer. <i>JNCI Cancer Spectrum</i> , 2022, 6, .	1.4	1
1559	The prostate cancer landscape in Europe: Current challenges, future opportunities. <i>Cancer Letters</i> , 2022, 526, 304-310.	3.2	16
1560	Prostatakarzinom: Strahlentherapie als kurative Option. , 0, , .		0
1561	Metastatic progression following multimodal therapy for unfavorable-risk prostate cancer. <i>Canadian Urological Association Journal</i> , 2021, 16, .	0.3	0

#	ARTICLE	IF	CITATIONS
1562	Follow-up care over 12 months of patients with prostate cancer in Spain. <i>Medicine (United States)</i> , 2021, 100, e27801.	0.4	2
1563	Two Decades of Active Surveillance for Prostate Cancer in a Single-Center Cohort: Favorable Outcomes after Transurethral Resection of the Prostate. <i>Cancers</i> , 2022, 14, 368.	1.7	9
1566	Prostate radiotherapy and the risk of secondary rectal cancer—a meta-analysis. <i>International Journal of Colorectal Disease</i> , 2022, 37, 437-447.	1.0	5
1567	A “real-world” standard for radical prostatectomy: Analysis of the British Association of Urological Surgeons Complex Operations Reports, 2016–2018. <i>Journal of Clinical Urology</i> , 0, , 205141582110639.	0.1	0
1568	Trpm8 Expression in Human and Mouse Castration Resistant Prostate Adenocarcinoma Paves the Way for the Preclinical Development of TRPM8-Based Targeted Therapies. <i>Biomolecules</i> , 2022, 12, 193.	1.8	12
1569	STAT3-regulated LncRNA LINC00160 mediates cell proliferation and cell metabolism of prostate cancer cells by repressing RCAN1 expression. <i>Molecular and Cellular Biochemistry</i> , 2022, 477, 865-875.	1.4	4
1570	Ductal Carcinoma in Situ: State-of-the-Art Review. <i>Radiology</i> , 2022, 302, 246-255.	3.6	30
1571	Two-year quality of life after robot-assisted radical prostatectomy according to pentafecta criteria and cancer of the prostate risk assessment (CAPRA-S). <i>Scientific Reports</i> , 2022, 12, 244.	1.6	5
1572	Clinical management of low-risk papillary thyroid microcarcinoma. <i>Minerva Endocrinology</i> , 2022, 46, .	0.6	1
1573	NEAR trial: A single-arm phase II trial of neoadjuvant apalutamide monotherapy and radical prostatectomy in intermediate- and high-risk prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, , .	2.0	6
1574	Prediction of recurrence from metabolites and expression of TOP2A and EZH2 in prostate cancer patients treated with radiotherapy. <i>NMR in Biomedicine</i> , 2023, 36, e4694.	1.6	4
1575	Impact of multiparametric MRI and PSA density on the initial indication or the maintaining in active surveillance during follow-up in low-risk prostate cancer. <i>Clinical Genitourinary Cancer</i> , 2022, , .	0.9	4
1576	A randomized trial of risk-adapted screening for prostate cancer in young men—Results of the first screening round of the <sc>PROBASE</sc> trial. <i>International Journal of Cancer</i> , 2022, 150, 1861-1869.	2.3	23
1578	Stereotactic Radiotherapy after Radical Prostatectomy in Patients with Prostate Cancer in the Adjuvant or Salvage Setting: A Systematic Review. <i>Cancers</i> , 2022, 14, 696.	1.7	14
1579	Primary Tumor Treatment in Oligometastatic Prostate Cancer: Radiotherapy Versus Radical Prostatectomy. <i>European Urology Open Science</i> , 2022, 35, 68-69.	0.2	2
1580	Primary Tumour Treatment in Oligometastatic Prostate Cancer: Radiotherapy Versus Radical Prostatectomy. <i>European Urology Open Science</i> , 2022, 35, 72-73.	0.2	0
1581	The transcriptional landscape and biomarker potential of circular RNAs in prostate cancer. <i>Genome Medicine</i> , 2022, 14, 8.	3.6	19
1582	The Effects of Statins on Prostate Cancer Patients Receiving Androgen Deprivation Therapy or Definitive Therapy: A Systematic Review and Meta-Analysis. <i>Pharmaceuticals</i> , 2022, 15, 131.	1.7	5

#	ARTICLE	IF	CITATIONS
1583	Personalized Medicine for Prostate Cancer: Is Targeting Metabolism a Reality?. <i>Frontiers in Oncology</i> , 2021, 11, 778761.	1.3	8
1586	Active surveillance for intermediate-risk prostate cancer. <i>World Journal of Urology</i> , 2022, 40, 79-86.	1.2	4
1587	Patient participation in treatment decision-making of prostate cancer: a qualitative study. <i>Supportive Care in Cancer</i> , 2022, 30, 4189-4200.	1.0	4
1588	Cancer Control Outcomes Following Focal Therapy Using High-intensity Focused Ultrasound in 1379 Men with Nonmetastatic Prostate Cancer: A Multi-institute 15-year Experience. <i>European Urology</i> , 2022, 81, 407-413.	0.9	41
1589	Lipophagy-Related Protein Perilipin-3 and Resistance of Prostate Cancer to Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 401-414.	0.4	8
1590	Treatment Patterns and Overall Survival Outcomes Among Patients Aged 80 yr or Older with High-risk Prostate Cancer. <i>European Urology Open Science</i> , 2022, 37, 80-89.	0.2	2
1591	Risk Factors of Patients with Prostate Cancer Upgrading for International Society of Urological Pathology Grade Group I After Radical Prostatectomy. <i>Åæroonkoloji BÅ¼lteni</i> , 2022, 21, 10-13.	0.1	0
1592	Nomograms for predicting the risk of biochemical recurrence in patients with prostate cancer after surgery. <i>Onkourologiya</i> , 2022, 17, 100-110.	0.1	1
1594	Implications and effects of COVID-19 on diagnosis and management of prostate cancer. <i>Current Opinion in Urology</i> , 2022, 32, 311-317.	0.9	2
1595	Bias Reduction through Analysis of Competing Events (BRACE) Correction to Address Cancer Treatment Selection Bias in Observational Data. <i>Clinical Cancer Research</i> , 2022, 28, 1832-1840.	3.2	7
1596	Metastasis and Mortality in Men With Low- and Intermediate-Risk Prostate Cancer on Active Surveillance. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 151-159.	2.3	11
1597	May outcomes of RALP performed after an initial surveillance strategy differ from those from immediate surgery? A propensity score matched analysis on 362 patients undergoing surgery at a referral center.. <i>Journal of Endourology</i> , 2022, , .	1.1	0
1598	External radiotherapy for prostatic cancers. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2022, 26, 329-343.	0.6	7
1599	Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 755-761.	2.0	14
1600	Association Between a 22-feature Genomic Classifier and Biopsy Gleason Upgrade During Active Surveillance for Prostate Cancer. <i>European Urology Open Science</i> , 2022, 37, 113-119.	0.2	10
1601	Creation of a protective space between the rectum and prostate prior to prostate radiotherapy using a hydrogel spacer. <i>Clinical Radiology</i> , 2022, 77, e195-e200.	0.5	2
1602	There Is No Longer a Role for Systematic Biopsies in Prostate Cancer Diagnosis. <i>European Urology Open Science</i> , 2022, 38, 12-13.	0.2	8
1603	Identification and Characterization of Key Differentially Expressed Genes Associated With Metronomic Dosing of Topotecan in Human Prostate Cancer. <i>Frontiers in Pharmacology</i> , 2021, 12, 736951.	1.6	8

#	ARTICLE	IF	CITATIONS
1604	Application of Machine Learning Algorithms in Breast Cancer Diagnosis and Classification. International Journal of Science Academic Research, 2021, 2, 3081-3086.	0.0	0
1605	Predicting toxicity caused by high-dose-rate brachytherapy single boost for prostate cancer. Journal of Contemporary Brachytherapy, 2022, 14, 7-14.	0.4	0
1607	New TRPM8 Blockers Exert Anticancer Activity Over Castration-Resistant Prostate Cancer Models. SSRN Electronic Journal, 0, , .	0.4	0
1608	The provision of prostate cancer patient information leaflets on an electronic tablet: A further step to paperless health-care provision. Urology Annals, 2022, 14, 156.	0.3	1
1611	Compliance with recommended cancer patient pathway timeframes and choice of treatment differed by cancer type and place of residence among cancer patients in Norway in 2015-2016. BMC Cancer, 2022, 22, 220.	1.1	4
1612	Focal therapy: definition and rationale. Current Opinion in Urology, 2022, 32, 218-223.	0.9	0
1613	Retzius-sparing technique independently predicts early recovery of urinary continence after robot-assisted radical prostatectomy. Journal of Robotic Surgery, 2022, 16, 1419-1426.	1.0	4
1614	Prediction of Postradical Prostatectomy Urinary Incontinence Through the Combination of the Urethral Pressure Profile With Electromyography of the Urethral Sphincter. International Neurourology Journal, 2022, 26, S68-75.	0.5	2
1615	Self-reported functional assessment after treatment for prostate cancer: 5-year results of the prospective cohort VICAN. Future Oncology, 2022, , .	1.1	0
1616	Management of prostate cancer in older patients. Japanese Journal of Clinical Oncology, 2022, 52, 513-525.	0.6	5
1617	Localized prostate cancer: An analysis of the CDC Breast and Prostate Cancer Data Quality and Patterns of Care study (CDC PoC-BP). Canadian Urological Association Journal, 2022, 16, .	0.3	0
1618	Uncovering interpretable potential confounders in electronic medical records. Nature Communications, 2022, 13, 1014.	5.8	14
1619	Updating and Integrating Core Outcome Sets for Localised, Locally Advanced, Metastatic, and Nonmetastatic Castration-resistant Prostate Cancer: An Update from the PIONEER Consortium. European Urology, 2022, 81, 503-514.	0.9	13
1620	Características clínicas-patológicas y supervivencia de pacientes con cáncer de mama de riesgo muy bajo. Medicina Clínica, 2022, 159, 351-358.	0.3	0
1621	Tomotherapy-based moderate hypofractionation for localized prostate cancer: a mono-institutional analysis. Reports of Practical Oncology and Radiotherapy, 2022, 27, 142-151.	0.3	2
1622	Implementation of patient-reported outcome measures into health care for men with localized prostate cancer. Nature Reviews Urology, 2022, 19, 263-279.	1.9	5
1623	Experience Measures after Radical Prostatectomy: A Register-Based Study Evaluating the Association between Patient-Reported Symptoms and Quality of Information. Healthcare (Switzerland), 2022, 10, 519.	1.0	1
1624	Nomogram Predicting Adverse Pathology Outcome on Radical Prostatectomy in Low-Risk Prostate Cancer Men. Urology, 2022, 166, 189-195.	0.5	6

#	ARTICLE	IF	CITATIONS
1625	Active surveillance protocol in prostate cancer in Portugal. <i>Actas Urológicas Españolas (English)</i> 2022, 10, 100-102.	0.2	1
1626	Trends in Incidence of Metastatic Prostate Cancer in the US. <i>JAMA Network Open</i> , 2022, 5, e222246.	2.8	83
1627	Contribution of the Cluster randomised trial of PSA testing for Prostate cancer (CAP) to the ongoing debate on the value of prostate cancer screening. <i>BJU International</i> , 2022, 129, 269-270.	1.3	1
1628	Health-related quality of life 24 months after prostate cancer diagnosis: an update from the Pros-IT CNR prospective observational study. <i>Minerva Urology and Nephrology</i> , 2022, 74, .	1.3	5
1629	UPDATE â€“ 2022 Canadian Urological Association recommendations on prostate cancer screening and early diagnosis: Endorsement of the 2021 Cancer Care Ontario guidelines on prostate multiparametric magnetic resonance imaging. <i>Canadian Urological Association Journal</i> , 2021, 16, E184-96.	0.3	12
1630	Long term erectile function results of radical perineal prostatectomy. <i>Revista Internacional De Andrología</i> , 2022, , .	0.1	1
1631	Safety and efficacy of salvage high-dose rate brachytherapy for prostate-bed recurrences following radical prostatectomy and external beam radiotherapy. <i>International Urology and Nephrology</i> , 2022, 54, 1031.	0.6	1
1632	Biomarkers Accurately Inform Treatment Decisions in Localised Prostate Cancer. <i>European Urology Focus</i> , 2022, , .	1.6	3
1633	Salvage robot-assisted radical prostatectomy following focal ablation with irreversible electroporation: feasibility, oncological and functional outcomes. <i>BMC Urology</i> , 2022, 22, 28.	0.6	7
1634	Neoadjuvant Systemic Therapy Prior to Radical Prostatectomy for Clinically Localized High-Risk Prostate Cancer. <i>Frontiers in Urology</i> , 2022, 2, .	0.2	2
1636	Active surveillance in favorable intermediate risk prostate cancer. <i>Current Opinion in Oncology</i> , 2022, Publish Ahead of Print, .	1.1	2
1637	Rationale for Utilization of Hydrogel Rectal Spacers in Dose Escalated SBRT for the Treatment of Unfavorable Risk Prostate Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 860848.	1.3	3
1639	Targeting Oncoproteins for Degradation by Small Molecule-Based Proteolysis-Targeting Chimeras (PROTACs) in Sex Hormone-Dependent Cancers. <i>Frontiers in Endocrinology</i> , 2022, 13, 839857.	1.5	3
1640	Disparities in radiation therapy utilization for cancer patients in Victoria. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2022, 66, 830-839.	0.9	2
1641	The waiting time for prostate cancer treatment in Italy: analysis from the PROS-IT CNR Study. <i>Minerva Urology and Nephrology</i> , 2022, 74, .	1.3	1
1643	Machine learning-based prediction of upgrading on magnetic resonance imaging targeted biopsy in patients eligible for active surveillance. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 191.e15-191.e20.	0.8	3
1644	Development of a new adapted QuinteT Recruitment Intervention (QRI-Two) for rapid application to RCTs underway with enrolment shortfallsâ€”to identify previously hidden barriers and improve recruitment. <i>Trials</i> , 2022, 23, 258.	0.7	10
1645	Long-term outcomes of whole gland high-intensity focused ultrasound for localized prostate cancer. <i>International Urology and Nephrology</i> , 2022, 54, 1233-1238.	0.6	2

#	ARTICLE	IF	CITATIONS
1646	Functional and quality of life outcomes of localised prostate cancer treatments (Prostate Testing) Tj ETQq0 0 0 rgBT /Overlock,10 Tf 50	1.3	23
1647	Editorial: Sequelae of Prostate Cancer Therapy: Avoidance Strategies and Management Options. <i>Frontiers in Surgery</i> , 2022, 9, 849669.	0.6	0
1648	Real-Time MRI-Guided Prostate Interventions. <i>Cancers</i> , 2022, 14, 1860.	1.7	6
1649	Safety and Feasibility of Soractelite Transperineal Focal Laser Ablation for Prostate Cancer and Short-term Quality of Life Analysis from a Multicenter Pilot Study. <i>European Urology Open Science</i> , 2022, 39, 48-54.	0.2	5
1650	Recent advances in radiation therapy and photodynamic therapy. <i>Applied Physics Reviews</i> , 2021, 8, .	5.5	29
1651	Epigenetic loss of heterogeneity from low to high grade localized prostate tumours. <i>Nature Communications</i> , 2021, 12, 7292.	5.8	15
1652	Stability of health-related quality of life and morbidity burden from 18 months after diagnosis of prostate cancer: results of a UK-wide population-based outcome cohort. <i>Supportive Care in Cancer</i> , 2022, 30, 3151-3164.	1.0	1
1653	Practice-changing Clinical Studies in Prostate Cancer: an Update for the Medical Oncologist. <i>Journal of Medical & Radiation Oncology</i> , 2021, 1, 27-34.	0.0	0
1654	Current androgen receptor antagonists under investigation for resistant prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 191-202.	1.1	5
1655	A personalized decision aid for prostate cancer shared decision making. <i>BMC Medical Informatics and Decision Making</i> , 2021, 21, 374.	1.5	4
1656	Shared decision-making in urology and female pelvic floor medicine and reconstructive surgery. <i>Nature Reviews Urology</i> , 2022, 19, 161-170.	1.9	2
1657	Low-risk prostate cancer: evaluation of quality of life after surgical treatment and during active observation. <i>Andrologia Genital'naa Chirurgia</i> , 2021, 22, 60-67.	0.1	0
1658	Active surveillance inclusion criteria under scrutiny in magnetic resonance imaging-guided prostate biopsy: a multicenter cohort study. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 109-116.	2.0	6
1659	Prospective Randomized Phase II Study of Stereotactic Body Radiotherapy (SBRT) vs. Conventional Fractionated Radiotherapy (CFRT) for Chinese Patients with Early-Stage Localized Prostate Cancer. <i>Current Oncology</i> , 2022, 29, 27-37.	0.9	1
1660	Outcomes of active surveillance for clinically localized prostate cancer in a middle eastern tertiary care center. <i>Archivio Italiano Di Urologia Andrologia</i> , 2021, 93, 385-388.	0.4	0
1661	Psychological predictors of delayed active treatment following active surveillance for low-risk prostate cancer: The Patient REported outcomes for Prostate cARE prospective cohort study. <i>BJUI Compass</i> , 2022, 3, 226-237.	0.7	4
1662	Stereotactic Radiotherapy and Androgen Deprivation Therapy for Localized Prostate Cancer: A Retrospective Mono-institutional Experience. <i>In Vivo</i> , 2022, 36, 306-313.	0.6	1
1663	Efficacy, toxicity, and quality of life outcomes of ultrahypofractionated radiotherapy in patients with localized prostate cancer: A single-arm phase 2 trial from Asia. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2022, 18, .	0.7	4

#	ARTICLE	IF	CITATIONS
1664	Delayed radical prostatectomy after a period of active surveillance is not associated with the use of secondary treatments compared with immediate prostatectomy. <i>Prostate</i> , 2022, 82, 323-329.	1.2	1
1667	Anal cancer in older adults: A Young International Society of Geriatric Oncology review paper. <i>Journal of Geriatric Oncology</i> , 2022, 13, 914-923.	0.5	2
1668	Optimization of Biomarker-Based Prostate Cancer Screening Policies. , 2022, , 141-158.		0
1670	INCREASING STRESS RESISTANCE BY TRANSCRANIAL ELECTRICAL STIMULATION IN PATIENTS AFTER PROSTATE CANCER SURGERY. <i>Ulyanovsk Medico-biological Journal</i> , 2022, , 75-86.	0.0	0
1671	Effect of Clinical Parameters on Risk of Death from Cancer after Radical Prostatectomy in Men with Localized and Locally Advanced Prostate Cancer. <i>Cancers</i> , 2022, 14, 2032.	1.7	1
1672	Early experience in avoiding biopsies for biopsy-naïve men with clinical suspicion of prostate cancer but non-suspicious biparametric magnetic resonance imaging results and prostate-specific antigen density 0.15 ng/mL^2: A 2-year follow-up study. <i>Acta Radiologica Open</i> , 2022, 11, 205846012210948.	0.3	2
1673	Low-Grade Prostate Cancer: Time to Stop Calling It Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 3110-3114.	0.8	41
1674	Radical Prostatectomy for Prostate Cancer – Hong Kong Status in the Era of $SOMIP$. <i>Surgical Practice</i> , 0, , .	0.1	0
1685	Association of Race With Receipt of Proton Beam Therapy for Patients With Newly Diagnosed Cancer in the US, 2004-2018. <i>JAMA Network Open</i> , 2022, 5, e228970.	2.8	6
1686	Full functional-length urethral sphincter- and neurovascular bundle preservation improves long-term continence rates after robotic-assisted radical prostatectomy. <i>Journal of Robotic Surgery</i> , 2022, , 1.	1.0	2
1687	No significant difference in intermediate key outcomes in men with low- and intermediate-risk prostate cancer managed by active surveillance. <i>Scientific Reports</i> , 2022, 12, 6743.	1.6	4
1688	Decisional Conflict is Associated with Treatment Modality and not Disease Knowledge in South African Men with Prostate Cancer: Baseline Results from a Longitudinal Prospective Observational Study. <i>Cancer Control</i> , 2022, 29, 107327482210827.	0.7	1
1693	Perceived levels of collaboration between cancer patients and their providers during radiation therapy. <i>Canadian Oncology Nursing Journal = Revue Canadienne De Nursing Oncologique</i> , 2019, 29, 110-115.	0.1	1
1696	Focal therapy for prostate cancer with irreversible electroporation: Oncological and functional results of a single institution study. <i>Investigative and Clinical Urology</i> , 2022, 63, 285.	1.0	9
1697	Paradigm Shift in Prostate Cancer Diagnosis: Pre-Biopsy Prostate Magnetic Resonance Imaging and Targeted Biopsy. <i>Korean Journal of Radiology</i> , 2022, 23, 625.	1.5	6
1698	Stereotactic Radiation Therapy versus Brachytherapy: Relative Strengths of Two Highly Efficient Options for the Treatment of Localized Prostate Cancer. <i>Cancers</i> , 2022, 14, 2226.	1.7	4
1699	Local Control after Locally Ablative, Image-Guided Radiotherapy of Oligometastases Identified by Gallium-68-PSMA-Positron Emission Tomography in Castration-Sensitive Prostate Cancer Patients (OLI-P). <i>Cancers</i> , 2022, 14, 2073.	1.7	7
1700	New TRPM8 blockers exert anticancer activity over castration-resistant prostate cancer models. <i>European Journal of Medicinal Chemistry</i> , 2022, 238, 114435.	2.6	8

#	ARTICLE	IF	CITATIONS
1702	Long-Term Medical Resource Consumption of Radical Prostatectomy vs. Intensity-Modulated Radiotherapy for Old Patients With Prostate Cancer: A Nationwide Population-Based Cohort Study. <i>Frontiers in Medicine</i> , 2022, 9, 843709.	1.2	1
1703	Advancements in the radiooncological treatment of high-risk prostate cancer: a quarter century of achievements. <i>Radiology and Oncology</i> , 2022, 56, 365-370.	0.6	2
1704	Evolving Trends in the Management of Low-Risk Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 423-430.	0.9	5
1705	Communication, perception, and use of personalized side-effect risks in prostate cancer treatment-decision making: An observational and interview study. <i>Patient Education and Counseling</i> , 2022, 105, 2731-2739.	1.0	7
1706	Exploring Variation in the Receipt of Recommended Active Surveillance for Men with Favorable-Risk Prostate Cancer. <i>Journal of Urology</i> , 2022, 208, 600-608.	0.2	1
1707	Why do men with prostate cancer discontinue active surveillance for definitive treatment? A mixed methods investigation. <i>Psycho-Oncology</i> , 2022, 31, 1420-1430.	1.0	5
1708	Secondary Treatment for Men with Localized Prostate Cancer: A Pooled Analysis of PRIAS and ERSPC-Rotterdam Data within the PIONEER Data Platform. <i>Journal of Personalized Medicine</i> , 2022, 12, 751.	1.1	0
1709	Acute, Subchronic, and Chronic Complications of Radical Prostatectomy Versus Radiotherapy With Hormone Therapy in Older Adults With High-Risk Prostate Adenocarcinoma. <i>Frontiers in Oncology</i> , 2022, 12, 875036.	1.3	1
1710	Concordance between biparametric MRI, transperineal targeted plus systematic MRI-ultrasound fusion prostate biopsy, and radical prostatectomy pathology. <i>Scientific Reports</i> , 2022, 12, 6964.	1.6	2
1713	Relative Incidence of Emergency Department Visits After Treatment for Prostate Cancer with Radiation Therapy or Radical Prostatectomy. <i>Practical Radiation Oncology</i> , 2022, , .	1.1	0
1714	Neurovascular-Sparing MR-Guided Adaptive Radiotherapy in Prostate Cancer; Defining the Potential Population for Erectile Function-Sparing Treatment. <i>Journal of Sexual Medicine</i> , 2022, 19, 1196-1200.	0.3	4
1715	Patient reported outcomes and health related quality of life in localized prostate cancer: A review of current evidence. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 304-314.	0.8	3
1716	Diagnostic Age, Age at Death and Stage Migration in Men Dying with or from Prostate Cancer in Denmark. <i>Diagnostics</i> , 2022, 12, 1271.	1.3	0
1719	Direct mail from primary care and targeted recruitment strategies achieved a representative uptake of prostate cancer screening. <i>Journal of Clinical Epidemiology</i> , 2022, , .	2.4	1
1720	Risk assessment of femoral pathological fracture in prostate cancer patients by computed tomography analysis. <i>Journal of Bone and Mineral Metabolism</i> , 0, , .	1.3	1
1722	Genomic biomarkers to guide precision radiotherapy in prostate cancer. <i>Prostate</i> , 2022, 82, .	1.2	3
1723	Changes in Characteristics of Men with Lethal Prostate Cancer During the Past 25 Years: Description of Population-based Deaths. <i>European Urology Open Science</i> , 2022, 41, 81-87.	0.2	0
1724	Focal therapy for prostate cancer: what is really needed to move from investigational to valid therapeutic alternative?â€”a narrative review. <i>Annals of Translational Medicine</i> , 2022, 10, 755-755.	0.7	2

#	ARTICLE	IF	CITATIONS
1725	Artificial Intelligence and Machine Learning in Cancer Research: A Systematic and Thematic Analysis of the Top 100 Cited Articles Indexed in Scopus Database. <i>Cancer Control</i> , 2022, 29, 107327482210959.	0.7	16
1726	Adoption of the technique of laparoscopic radical prostatectomy on the example of the regional cancer center. <i>Onkologiya Zhurnal Imeni P A Gertsena</i> , 2022, 11, 31.	0.0	0
1727	Biomarkers for prostate cancer detection and risk stratification. <i>Therapeutic Advances in Urology</i> , 2022, 14, 175628722211039.	0.9	21
1728	Prostate MRI in Stereotactic Body Radiation Treatment Planning and Delivery for Localized Prostate Cancer. <i>Radiographics</i> , 0, , .	1.4	2
1729	Development and Validation of Nomograms to Predict Cancer-Specific Survival and Overall Survival in Elderly Patients With Prostate Cancer: A Population-Based Study. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	8
1730	Radiotherapy in Oligometastatic, Oligorecurrent and Oligoprogressive Prostate Cancer: A Mini-Review. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
1731	The Latest Data Specifically Focused on Long-Term Oncologic Prognostication for Very Old Adults with Acute Vulnerable Localized Prostate Cancer: A Nationwide Cohort Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 3451.	1.0	2
1732	Impact of centralization of prostate cancer services on the choice of radical treatment. <i>BJU International</i> , 2023, 131, 53-62.	1.3	4
1733	Radiation Therapy for Prostate Cancer: Challenges Facing Low-Middle Income Countries During COVID Pandemic. <i>World Journal of Oncology</i> , 2022, 13, 155-158.	0.6	0
1734	Referral to radiation oncology prior to prostatectomy: Referral rates in a New Zealand tertiary Centre. <i>Journal of Medical Imaging and Radiation Oncology</i> , 0, , .	0.9	1
1735	The Impact of a Statewide Active Surveillance Initiative: A Roadmap for Increasing Active Surveillance Utilization Nationwide. <i>European Urology</i> , 2023, 83, 307-310.	0.9	6
1736	PSA: role in screening and monitoring patients with prostate cancer. , 2022, , 131-172.		2
1738	Tailored treatment strategies for cancer patients during COVID-19 pandemic. <i>Reports of Practical Oncology and Radiotherapy</i> , 2022, 27, 318-330.	0.3	1
1739	Effects of substrate stiffness on the viscoelasticity and migration of prostate cancer cells examined by atomic force microscopy. <i>Beilstein Journal of Nanotechnology</i> , 0, 13, 560-569.	1.5	4
1740	Artificial Intelligence-Based Prognostic Model for Urologic Cancers: A SEER-Based Study. <i>Cancers</i> , 2022, 14, 3135.	1.7	3
1741	Focal High-Intensity Focused Ultrasound vs Active Surveillance for ISUP Grade 1 Prostate Cancer: Medium-Term Results of a Matched-Pair Comparison. <i>Clinical Genitourinary Cancer</i> , 2022, , .	0.9	0
1742	Does testosterone mediate the relationship between vitamin D and prostate cancer progression? A systematic review and meta-analysis. <i>Cancer Causes and Control</i> , 2022, 33, 1025-1038.	0.8	5
1743	Two Specialists, Two Recommendations: Discordance between Urologistsâ€™ & Radiation Oncologistsâ€™ Prostate Cancer Treatment Recommendations. <i>Urology</i> , 2022, , .	0.5	0

#	ARTICLE	IF	CITATIONS
1744	Renaming Gleason Score 6 Prostate to Noncancer: A Flawed Idea Scientifically and for Patient Care. <i>Journal of Clinical Oncology</i> , 2022, 40, 3106-3109.	0.8	16
1745	How MRI is changing prostate cancer management: a focus on early detection and active surveillance. <i>Progres En Urologie</i> , 2022, 32, 6S19-6S25.	0.3	2
1746	Comprehensive review of the use of hydrogel spacers prior to radiation therapy for prostate cancer. <i>BJU International</i> , 2023, 131, 280-287.	1.3	9
1747	Systematic Review of Focal and Salvage Cryotherapy for Prostate Cancer. <i>Cureus</i> , 2022, , .	0.2	1
1748	Feasibility of aspirin and/or vitamin D3 for men with prostate cancer on active surveillance with Prolaris® testing. <i>BJUI Compass</i> , 2022, 3, 458-465.	0.7	1
1749	An Update to the Malthus Model for Radiotherapy Utilisation in England. <i>Clinical Oncology</i> , 2023, 35, e1-e9.	0.6	3
1750	Adverse upgrading and/or upstaging in contemporary low-risk prostate cancer patients. <i>International Urology and Nephrology</i> , 2022, 54, 2521-2528.	0.6	3
1751	Extended Focal Ablation of Localized Prostate Cancer With High-Frequency Irreversible Electroporation. <i>JAMA Surgery</i> , 2022, 157, 693.	2.2	16
1752	A Web-Based Prediction Model for Cancer-Specific Survival of Elderly Patients Undergoing Surgery With Prostate Cancer: A Population-Based Study. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	3
1753	Optimization of active surveillance strategies for heterogeneous patients with prostate cancer. <i>Production and Operations Management</i> , 2022, 31, 4021-4037.	2.1	1
1754	New strategies for decision making in prostate cancer. The role of oncotypedx. <i>Actas Urológicas Españolas (English Edition)</i> , 2022, 46, 385-386.	0.2	1
1755	Cocultured Schwann Cells Rescue Irradiated Pelvic Neuron Outgrowth and Increase Survival. <i>Journal of Sexual Medicine</i> , 2022, 19, 1333-1342.	0.3	2
1756	Medium Term Outcomes of Focal Cryoablation for Intermediate and High Risk Prostate Cancer: MRI and PSA are Not Predictive of Residual or Recurrent Disease. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 451.e15-451.e20.	0.8	7
1757	Transperineal Targeted Microwave Ablation (TMA) of localized prostate cancer guided by MRI-Ultrasound fusion and organ-based tracking: a pilot study. <i>Prostate Cancer and Prostatic Diseases</i> , 2023, 26, 736-742.	2.0	5
1758	Impact of Statin Use on Localized Prostate Cancer Outcomes after Radiation Therapy: Long-Term Follow-Up. <i>Cancers</i> , 2022, 14, 3606.	1.7	1
1759	Delphi study to identify consensus on patient selection for hydrogel rectal spacer use during radiation therapy for prostate cancer in the UK. <i>BMJ Open</i> , 2022, 12, e060506.	0.8	0
1760	Comparative results of focal-cryoablation and stereotactic body radiotherapy in the treatment of unilateral, low-to-intermediate-risk prostate cancer. <i>International Urology and Nephrology</i> , 0, , .	0.6	0
1761	The first patient-reported outcomes from the Utrecht Prostate Cohort (UPC): the first platform facilitating "trials within cohorts" (TwICs) for the evaluation of interventions for prostate cancer. <i>World Journal of Urology</i> , 2022, 40, 2205-2212.	1.2	7

#	ARTICLE	IF	CITATIONS
1762	Expanding access to rectal spacers in the United Kingdom: an examination of current evidence and an early review of data from a single institution. <i>Journal of Radiotherapy in Practice</i> , 0, , 1-5.	0.2	0
1763	The Influence of Practice Structure on Urologistsâ€™ Treatment of Men With Low-Risk Prostate Cancer. <i>Medical Care</i> , 2022, 60, 665-672.	1.1	2
1764	The role of prophylactic prostatectomy as a primary prevention strategy in high-risk germline mutation carriers. <i>Current Opinion in Urology</i> , 0, Publish Ahead of Print, .	0.9	1
1765	Should Contemporary Western Guidelines Based on Studies Conducted in the 2000s Be Adopted for the Prostate-Specific Antigen Screening Policy for Asian Men in the 2020s?. <i>World Journal of Men's Health</i> , 2022, 40, 543.	1.7	4
1766	Assessment of Second Primary Cancer Risk Among Men Receiving Primary Radiotherapy vs Surgery for the Treatment of Prostate Cancer. <i>JAMA Network Open</i> , 2022, 5, e2223025.	2.8	15
1767	Listening to the Patient Voice Adds Value to Cancer Clinical Trials. <i>Journal of the National Cancer Institute</i> , 2022, 114, 1323-1332.	3.0	10
1768	Transperineal Ultrasound Before and After Prostatectomy. <i>Journal of Ultrasound in Medicine</i> , 0, , .	0.8	0
1770	Adverse Pathological Findings at Radical Prostatectomy following Active Surveillance: Results from the Movember GAP3 Cohort. <i>Cancers</i> , 2022, 14, 3558.	1.7	2
1771	Mortality and biochemical recurrence after surgery, brachytherapy, or external radiotherapy for localized prostate cancer: a 10-year follow-up cohort study. <i>Scientific Reports</i> , 2022, 12, .	1.6	5
1772	Assessing radiation dose for postoperative radiotherapy in prostate cancer: Real world data. <i>World Journal of Clinical Oncology</i> , 2022, 13, 652-662.	0.9	0
1773	Impact of active surveillance for prostate cancer on the risk of depression and anxiety. <i>Scientific Reports</i> , 2022, 12, .	1.6	3
1774	Ten-years outcome analysis in patients with clinically localized prostate cancer treated by radical prostatectomy or external beam radiation therapy. <i>Frontiers in Surgery</i> , 0, 9, .	0.6	0
1775	Clinical outcome in metastatic prostate cancer after primary radiotherapy. <i>Strahlentherapie Und Onkologie</i> , 2023, 199, 536-543.	1.0	2
1776	In with the old, in with the new: machine learning for time to event biomedical research. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2022, 29, 1737-1743.	2.2	1
1777	High-specificity protection against radiation-induced bone loss by a pulsed electromagnetic field. <i>Science Advances</i> , 2022, 8, .	4.7	6
1778	Five-Year Prospective Observational Study of African-American Men on Active Surveillance for Prostate Cancer Demonstrates Race Is Not Predictive of Oncologic Outcomes. <i>Oncologist</i> , 2023, 28, 149-156.	1.9	1
1779	Multiparametric MRI for Staging of Prostate Cancer: A Multicentric Analysis of Predictive Factors to Improve Identification of Extracapsular Extension before Radical Prostatectomy. <i>Cancers</i> , 2022, 14, 3966.	1.7	6
1780	Association Between Receipt of Definitive Treatment for Localized Prostate Cancer and Adverse Health Outcomes: A Claims-Based Approach. <i>Value in Health</i> , 2022, , .	0.1	0

#	ARTICLE	IF	CITATIONS
1781	Improving multiparametric ¹³C-pyruvate metabolic imaging: A technical development study. Magnetic Resonance in Medicine, 2022, 88, 2609-2620.	1.9	4
1782	Active surveillance versus nonradical treatment for low-risk men with prostate cancer: a review. Prostate International, 2022, 10, 117-122.	1.2	3
1783	Blood Prostate-specific Antigen by Volume of Benign, Gleason Pattern 3 and 4 Prostate Tissue. Urology, 2022, 170, 154-160.	0.5	3
1784	Effect of the COVID-19 Pandemic on Radical Prostatectomy: A Turkish Multicenter Study. , 2022, 48, 339-345.		1
1785	An Magnetic Resonance Imagingâ€‘directed Targeted-plus-perilesional Biopsy Approach for Prostate Cancer Diagnosis: â€œLess Is Moreâ€‘ European Urology Open Science, 2022, 43, 68-73.	0.2	4
1786	Identification of the gossypol derivatives as androgen receptor inhibitor. Bioorganic and Medicinal Chemistry Letters, 2022, 75, 128952.	1.0	0
1787	Adaptive magnetic resonance image guided radiation for intact localized prostate cancer how to optimally test a rapidly emerging technology. Frontiers in Oncology, 0, 12, .	1.3	1
1788	Cost effectiveness of treatment strategies for high risk prostate cancer. Cancer, 2022, 128, 3815-3823.	2.0	2
1789	Diagnostic Applications of Nuclear Medicine: Prostatic Cancer. , 2022, , 1-55.		0
1790	Diagnostic Applications of Nuclear Medicine: Prostatic Cancer. , 2022, , 1023-1075.		0
1791	Advances in Focal Therapy for Men with Low-Intermediate Risk Prostate Cancer. , 2022, , .		0
1793	Prostate cancer screening: Continued controversies and novel biomarker advancements. Current Urology, 2022, 16, 197-206.	0.4	2
1794	Active Surveillance in Intermediate-Risk Prostate Cancer: A Review of the Current Data. Cancers, 2022, 14, 4161.	1.7	2
1795	GSTM2 is a key molecular determinant of resistance to SG-ARIs. Oncogene, 2022, 41, 4498-4511.	2.6	1
1796	Joint models for dynamic prediction in localised prostate cancer: a literature review. BMC Medical Research Methodology, 2022, 22, .	1.4	3
1797	Social ecological influences on treatment decisionâ€‘making in men diagnosed with low risk, localised prostate cancer. European Journal of Cancer Care, 2022, 31, .	0.7	4
1799	Natural history, and impact of surgery and radiation on survival outcomes of men diagnosed with low-grade prostate cancer atâ€‘55 years of age: a 25-year follow-up ofâ€‘60,000 men. International Urology and Nephrology, 2023, 55, 295-300.	0.1	3
1800	Expanded Parameters in Active Surveillance for Low-risk Papillary Thyroid Carcinoma. JAMA Oncology, 2022, 8, 1588.	3.4	27

#	ARTICLE	IF	CITATIONS
1801	Treatment options for low-risk prostate cancer. <i>World Journal of Urology</i> , 2022, 40, 2827-2828.	1.2	1
1802	Prostate Cancer Outcomes in Patients Living with HIV/AIDS Treated with Radiation Therapy: A Systematic Review. <i>Advances in Radiation Oncology</i> , 2022, , 101074.	0.6	0
1803	Modern Active Surveillance in Prostate Cancer: A Narrative Review. <i>Clinical Genitourinary Cancer</i> , 2023, 21, 115-123.	0.9	3
1804	Impact of different unconditional monetary incentives on survey response rates in men with prostate cancer: a 2-arm randomised trial. <i>BMC Medical Research Methodology</i> , 2022, 22, .	1.4	0
1805	The evolving standards of active surveillance monitoring. <i>Prostate Cancer and Prostatic Diseases</i> , 0, , .	2.0	0
1806	Spatio-temporal analysis of prostate tumors in situ suggests pre-existence of treatment-resistant clones. <i>Nature Communications</i> , 2022, 13, .	5.8	4
1807	Impact of COVID-19 pandemic on diagnosis and surgical management of common urological conditions: results from multi-institutional database analysis from the United States. <i>World Journal of Urology</i> , 0, , .	1.2	3
1808	Cost-Effectiveness Analysis of Prostate Cancer Screening in the UK: A Decision Model Analysis Based on the CAP Trial. <i>Pharmacoeconomics</i> , 2022, 40, 1207-1220.	1.7	3
1809	Current issues in medical epistemology and statistics: a view from the frontline of medicine. <i>Synthese</i> , 2022, 200, .	0.6	1
1810	Modern paradigms for prostate cancer detection and management. <i>Medical Journal of Australia</i> , 2022, 217, 424-433.	0.8	13
1811	ASSESSMENT OF THE FUNCTIONAL STATE OF THE ORGANISM IN PROSTATE CANCER Iá€“II DEGREES BEFORE AND AFTER HIFU. , 2021, 80, 135-138.		0
1812	Ultra-Hypofractionated Stereotactic Body Radiotherapy for Localized Prostate Cancer: Clinical Outcomes, Patterns of Recurrence, Feasibility of Definitive Salvage Treatment, and Competing Oncological Risk. <i>Biomedicines</i> , 2022, 10, 2446.	1.4	3
1813	Association of nerve-sparing grading in robotic radical prostatectomy and trifecta outcome. <i>World Journal of Urology</i> , 2022, 40, 2925-2930.	1.2	1
1814	Surgical Tolerability and Frailty in Elderly Patients Undergoing Robot-Assisted Radical Prostatectomy: A Narrative Review. <i>Cancers</i> , 2022, 14, 5061.	1.7	2
1815	Population based study of morbidity and mortality rates associated to radical prostatectomy cases in Spain. <i>Actas Urológicas Españolas (English Edition)</i> , 2022, , .	0.2	0
1816	Survival analysis of localized prostate cancer with deep learning. <i>Scientific Reports</i> , 2022, 12, .	1.6	3
1818	Clinicopathological characteristics and survival results of patients with ultralow risk breast cancer. <i>Medicina Clínica (English Edition)</i> , 2022, 159, 351-358.	0.1	0
1819	Management of Localized T1c Prostate Cancer among men 75 years and older: A National Cancer Database Study. <i>Clinical Genitourinary Cancer</i> , 2022, , .	0.9	0

#	ARTICLE	IF	CITATIONS
1820	MRI/real-time ultrasound image fusion guided high-intensity focused ultrasound: a prospective comparative and functional analysis of different ablative techniques. <i>Minerva Urology and Nephrology</i> , 2023, 75, .	1.3	3
1821	Pre-Treatment Hemoglobin Concentration and Absolute Monocyte Count as Independent Prognostic Factors for Survival in Localized or Locally Advanced Prostate Cancer Patients Undergoing Radiotherapy. <i>Biomedicines</i> , 2022, 10, 2514.	1.4	2
1822	Patient-specific forecasting of postradiotherapy prostate-specific antigen kinetics enables early prediction of biochemical relapse. <i>IScience</i> , 2022, 25, 105430.	1.9	4
1823	The 17-Gene Genomic Prostate Score Test Is Prognostic for Outcomes After Primary External Beam Radiation Therapy in Men With Clinically Localized Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2023, 115, 120-131.	0.4	7
1824	Selecting interventions for a psychosocial support program for prostate cancer patients undergoing active surveillance: A modified Delphi study. <i>Psycho-Oncology</i> , 0, , .	1.0	1
1826	VMAT partial arc technique decreases dose to organs at risk in whole pelvic radiotherapy for prostate cancer when compared to full arc VMAT and IMRT. <i>Medical Dosimetry</i> , 2022, , .	0.4	1
1828	Association between body mass index and localized prostate cancer management and disease-specific quality of life. <i>BJUI Compass</i> , 2023, 4, 223-233.	0.7	1
1829	Minimal Residual Disease (MRD) and a New Immunotherapy in Locally Advanced Prostate Cancer. , 2022, , .		0
1830	Radioresistance Mechanisms in Prostate Cancer Cell Lines Surviving Ultra-Hypo-Fractionated EBRT: Implications and Possible Clinical Applications. <i>Cancers</i> , 2022, 14, 5504.	1.7	1
1831	Artificial Intelligence for Clinical Diagnosis and Treatment of Prostate Cancer. <i>Cancers</i> , 2022, 14, 5595.	1.7	13
1832	French AFU Cancer Committee Guidelines - Update 2022-2024: prostate cancer - Diagnosis and management of localised disease. <i>Progres En Urologie</i> , 2022, 32, 1275-1372.	0.3	15
1833	Distinct Profiles of DNA Repair Activity Define Favorable-risk Prostate Cancer Subtypes With Divergent Outcome. <i>Clinical Genitourinary Cancer</i> , 2023, 21, 76-83.	0.9	0
1834	Antiandrogen Treatment vs Active Surveillance for Patients With Prostate Cancer. <i>JAMA Oncology</i> , 0, , .	3.4	0
1835	Dietary Patterns and Risk of Gleason Grade Progression among Men on Active Surveillance for Prostate Cancer: Results from the Canary Prostate Active Surveillance Study. <i>Nutrition and Cancer</i> , 0, , 1-9.	0.9	4
1836	Combination of radiation and immunotherapy in the treatment of genitourinary malignancies: A systematic review and meta-analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, , .	0.8	1
1837	Cardiovascular complications of treatment for prostate cancer. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2022, 83, 1-12.	0.2	3
1838	Combination of PI-RADS score and PSAD can improve the diagnostic accuracy of prostate cancer and reduce unnecessary prostate biopsies. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
1839	Medium-term Oncological Efficacy and Patient-reported Outcomes After Focal High-intensity Focused Ultrasound: The FOXPRO Trial. <i>European Urology Focus</i> , 2023, 9, 283-290.	1.6	8

#	ARTICLE	IF	CITATIONS
1840	Screening for Prostate Cancer with Prostate-specific Antigen: The Journey Continues. <i>European Urology</i> , 2023, 83, 110-111.	0.9	1
1841	Stereotactic prostate radiotherapy with or without androgen deprivation therapy, study protocol for a phase III, multi-institutional randomized-controlled trial. <i>BJR Open</i> , 2022, 4, .	0.4	1
1842	Re: Neal D. Shore, Joseph Renzulli, Neil E. Fleshner, et al. Active Surveillance plus Enzalutamide Monotherapy vs Active Surveillance Alone in Patients with Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial. <i>JAMA Oncol</i> 2022;8:1128â€“36. <i>European Urology Open Science</i> , 2022, 46, 135-136.	0.2	0
1843	Patient preferences for treatment modalities for localised prostate cancer. <i>BJUI Compass</i> , 0, , .	0.7	0
1844	Narrative reviewâ€”focal therapy: are we ready to change the prostate cancer treatment paradigm?. <i>Annals of Translational Medicine</i> , 2023, 11, 24-24.	0.7	1
1845	Functional Recovery POST-RALP: Continence. , 2022, , 397-409.		0
1846	MR linac radiation therapy: A real-time personalized approach for prostate cancer. <i>Advances in Magnetic Resonance Technology and Applications</i> , 2023, , 341-365.	0.0	0
1847	Radical prostatectomies for treatment of prostate cancer: trends in a ten-year period in public health services in the city of SÃ£o Paulo, Brazil. <i>Einstein (Sao Paulo, Brazil)</i> , 2022, 20, .	0.3	0
1848	Therapy of prostate cancer in elderly patients. <i>Urologie Pro Praxi</i> , 2022, 23, 109-116.	0.0	0
1849	A â€œscopingâ€”review of prostate brachytherapy and immune responses. <i>Brachytherapy</i> , 2022, , .	0.2	0
1850	1.5T MR-Guided Daily-Adaptive SBRT for Prostate Cancer: Preliminary Report of Toxicity and Quality of Life of the First 100 Patients. <i>Journal of Personalized Medicine</i> , 2022, 12, 1982.	1.1	3
1851	Diagnostic activity impacts lifetime risk of prostate cancer diagnosis more strongly than life expectancy. <i>PLoS ONE</i> , 2022, 17, e0277784.	1.1	1
1852	Outcomes of Grade Group 2 and 3 Prostate Cancer on Initial Versus Confirmatory Biopsy: Implications for Active Surveillance. <i>European Urology Focus</i> , 2023, 9, 662-668.	1.6	1
1853	Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only. <i>New England Journal of Medicine</i> , 2022, 387, 2126-2137.	13.9	99
1854	Nomograms for predicting local recurrence in prostate cancer patients with a positive resection margin. <i>Onkourologiya</i> , 2022, 18, 67-75.	0.1	0
1855	Combining Molecular Subtypes with Multivariable Clinical Models has the Potential to Improve Prediction of Treatment Outcomes in Prostate Cancer at Diagnosis. <i>Current Oncology</i> , 2023, 30, 157-170.	0.9	0
1856	Treatment decision regret in longâ€”term survivors after radical prostatectomy: a longitudinal study. <i>BJU International</i> , 2023, 131, 623-630.	1.3	4
1857	Hydroxychavicol as a potential anticancer agent (Review). <i>Oncology Letters</i> , 2022, 25, .	0.8	2

#	ARTICLE	IF	CITATIONS
1858	Fact, overdiagnosis cannot be evaluated by comparing histological grading of prostate biopsy to prostatectomy specimen. <i>Prostate Cancer and Prostatic Diseases</i> , 2023, 26, 804-805.	2.0	1
1859	Partial gland ablation using high-intensity focused ultrasound versus robot-assisted radical prostatectomy: a propensity score-matched study. <i>Prostate International</i> , 2022, , .	1.2	0
1860	Two conflicting guidelines on prostate specific antigen screening in Japan. <i>Japanese Journal of Clinical Oncology</i> , 2023, 53, 280-283.	0.6	2
1861	Access of new systemic therapies for Genito-urinary cancers in low-middle income countries. <i>Frontiers in Urology</i> , 0, 2, .	0.2	0
1862	Functional outcomes after prostate cancer treatment: A comparison between single and multiple modalities. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2023, 41, 104.e1-104.e9.	0.8	1
1863	Magnetic resonance imaging-guided ultrasound ablation for prostate cancer – A contemporary review of performance. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
1864	AtualizaÃ§Ãµes sobre a prostatectomia radical para Câncer de prÃ³stata localizado. <i>Brazilian Journal of Health Review</i> , 2023, 6, 1184-1201.	0.0	0
1865	Identifying Confounders Using Bayesian Networks and Estimating Treatment Effect in Prostate Cancer With Observational Data. <i>JCO Clinical Cancer Informatics</i> , 2023, , .	1.0	4
1866	Genetic Risk Prediction for Prostate Cancer: Implications for Early Detection and Prevention. <i>European Urology</i> , 2023, 83, 241-248.	0.9	16
1867	Targeted Radiation and Immune Therapies – Advances and Opportunities for the Treatment of Prostate Cancer. <i>Pharmaceutics</i> , 2023, 15, 252.	2.0	4
1868	Examining the effectiveness and implementation of patient treatment decision-aid tools for men with localised prostate cancer: A systematic review. <i>Psycho-Oncology</i> , 2023, 32, 469-491.	1.0	4
1869	Protocol for a systematic review and meta-analysis on preoperative risk factors for failure after fixed sling implantation for post-prostatectomy stress urinary incontinence. <i>F1000Research</i> , 0, 12, 19.	0.8	0
1870	Cancer survival in Africa, central and south America, and Asia (SURVCAN-3): a population-based benchmarking study in 32 countries. <i>Lancet Oncology</i> , The, 2023, 24, 22-32.	5.1	15
1871	Advances in erectile function – preserving radiotherapy for prostate cancer. <i>Journal of Sexual Medicine</i> , 0, , .	0.3	1
1872	Machine Learning Algorithm Accuracy Using Single- versus Multi-Institutional Image Data in the Classification of Prostate MRI Lesions. <i>Applied Sciences (Switzerland)</i> , 2023, 13, 1088.	1.3	3
1873	Management of Urinary Incontinence Following Radical Prostatectomy: Challenges and Solutions. <i>Therapeutics and Clinical Risk Management</i> , 0, Volume 19, 43-56.	0.9	1
1874	A novel hydrogel orthotopic injection model in moderately hypofractionated radiation therapy for prostate cancer: Adaptive degradation and durable imaging. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
1875	Efficacy of the transvesical approach for robotic-assisted radical prostatectomy via a bladder neck and prostate combined longitudinal incision for the treatment of localized prostate cancer. <i>Frontiers in Surgery</i> , 0, 9, .	0.6	0

#	ARTICLE	IF	CITATIONS
1876	Outcomes following brachytherapy boost for intermediate- and high-risk prostate cancer: a retrospective bicenter study by the SFRO Brachytherapy Group. <i>Radiotherapy and Oncology</i> , 2023, , 109460.	0.3	0
1877	Prostate cancer risk, screening and management in patients with germline BRCA1/2 mutations. <i>Nature Reviews Urology</i> , 2023, 20, 205-216.	1.9	10
1878	Influence of vesicourethral segment reconstruction techniques in radical prostatectomy on urinary continence: evaluation of immediate and long-term outcomes. <i>Urology Herald</i> , 2023, 10, 54-69.	0.1	0
1879	Prostate Cancer in Renal Transplant Recipients: Results from a Large Contemporary Cohort. <i>Cancers</i> , 2023, 15, 189.	1.7	1
1880	Intraoperative fluorescence-based detection of positive surgical margins during radical prostatectomy: Lessons learned from a pilot ex vivo translational study. <i>Lasers in Surgery and Medicine</i> , 0, , .	1.1	0
1881	Effectiveness of robust optimization against geometric uncertainties in TomoHelical planning for prostate cancer. <i>Journal of Applied Clinical Medical Physics</i> , 2023, 24, .	0.8	5
1882	The application of S.I.S. technique improves long-term continence after robotic radical prostatectomy. <i>Neurourology and Urodynamics</i> , 0, , .	0.8	0
1883	Evolving Landscape of Practice Patterns in the Management of Localized Low-Risk Prostate Cancer: A NCDB Study. , 2023, 1, .		2
1884	Effects of gold fiducial marker implantation on tumor control and toxicity in external beam radiotherapy of prostate cancer. <i>Radiology and Oncology</i> , 2023, 57, 95-102.	0.6	2
1885	Long-Term Biochemical Control of a Prospective Cohort of Prostate Cancer Patients Treated With Interstitial Brachytherapy Versus Radical Prostatectomy. <i>Clinical Oncology</i> , 2023, , .	0.6	0
1886	Are Prostate Cancer Screenings Performed in Compliance with Cancer Guidelines?. <i>Middle Black Sea Journal of Health Science</i> , 2023, 9, 41-49.	0.2	0
1887	Epigenetics-based diagnostic and therapeutic strategies: shifting the paradigm in prostate cancer. <i>Epigenomics</i> , 2023, 15, 75-87.	1.0	0
1888	Decision Regret in Patients with Localised Prostate Cancer: A Systematic Review and Meta-analysis. <i>European Urology Oncology</i> , 2023, 6, 456-466.	2.6	2
1889	The Impact of Within-Consultation and Preconsultation Decision Aids for Localized Prostate Cancer on Patient Knowledge: Results of a Patient-Level Randomized Trial. <i>Urology</i> , 2023, 175, 90-95.	0.5	1
1890	Patient-reported Satisfaction and Regret Following Focal Therapy for Prostate Cancer: A Prospective Multicenter Evaluation. <i>European Urology Open Science</i> , 2023, 50, 10-16.	0.2	0
1891	Comparison of Outcomes of Active Surveillance in Intermediate-Risk Versus Low-Risk Localised Prostate Cancer Patients: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2023, 12, 2732.	1.0	3
1892	Risk factors for urinary incontinence in patients undergoing radical robot-assisted prostatectomy. <i>Urology Herald</i> , 2023, 11, 150-158.	0.1	1
1893	Linac-based versus MR-guided SBRT for localized prostate cancer: a comparative evaluation of acute tolerability. <i>Radiologia Medica</i> , 0, , .	4.7	0

#	ARTICLE	IF	CITATIONS
1894	The impact of life expectancy on cost-effectiveness of treatment options for clinically localized prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2023, 41, 205.e1-205.e10.	0.8	2
1895	Comparison of four-year toxicities and local control of ultra-hypofractionated vs moderate-hypofractionated image guided prostate radiation with HDR brachytherapy boost: A phase I-II single institution trial. <i>Clinical and Translational Radiation Oncology</i> , 2023, 40, 100593.	0.9	0
1896	Brachytherapy boost improves survival and decreases risk of developing distant metastases compared to external beam radiotherapy alone in intermediate and high risk group prostate cancer patients. <i>Radiotherapy and Oncology</i> , 2023, 183, 109632.	0.3	1
1897	ESTRO-ACROP recommendations for evidence-based use of androgen deprivation therapy in combination with external-beam radiotherapy in prostate cancer. <i>Radiotherapy and Oncology</i> , 2023, 183, 109544.	0.3	6
1898	The 17-Gene Genomic Prostate Score Assay Is Prognostic for Biochemical Failure in Men With Localized Prostate Cancer After Radiation Therapy at a Community Cancer Center. <i>Advances in Radiation Oncology</i> , 2023, 8, 101193.	0.6	0
1899	Prostatakarzinom: kurative Therapie. <i>Springer Reference Medizin</i> , 2022, , 1-22.	0.0	0
1900	Prostate Problems. , 2022, , 591-605.		0
1901	Upregulation of GALNT7 in prostate cancer modifies O-glycosylation and promotes tumour growth. <i>Oncogene</i> , 2023, 42, 926-937.	2.6	12
1902	Multimodality Therapies for Localized Prostate Cancer. <i>Current Oncology Reports</i> , 2023, 25, 221-229.	1.8	1
1903	Cancer Treatment Patterns and Factors Affecting Receipt of Treatment in Older Adults: Results from the ASPREE Cancer Treatment Substudy (ACTS). <i>Cancers</i> , 2023, 15, 1017.	1.7	1
1904	Robot assisted radical prostatectomy in fit older patients compared to a standard population: Clinical characteristics, surgical, oncological and functional outcomes. <i>Progres En Urologie</i> , 2023, 33, 272-278.	0.3	1
1905	Robotic stereotactic body radiotherapy for localized prostate cancer: final analysis of the German HYPOSTAT trial. <i>Strahlentherapie Und Onkologie</i> , 2023, 199, 565-573.	1.0	1
1906	First 100 cases of transvesical single-port robotic radical prostatectomy. <i>Asian Journal of Urology</i> , 2023, 10, 416-422.	0.5	6
1907	Racial inequities in the quality of surgical care among Medicare beneficiaries with localized prostate cancer. <i>Cancer</i> , 2023, 129, 1402-1410.	2.0	2
1908	<sc>The â€Rapid Access Prostate Imaging and Diagnosisâ€™ (RAPID)</sc> diagnostic pathway: what is the rush?. <i>BJU International</i> , 2023, 131, 377-379.	1.3	0
1909	Prognostic Value of the Intermediate-risk Feature in Men with Favorable Intermediate-risk Prostate Cancer: Implications for Active Surveillance. <i>European Urology Open Science</i> , 2023, 50, 61-67.	0.2	1
1910	The Association between Acute and Late Genitourinary and Gastrointestinal Toxicities: An Analysis of the PACE B Study. <i>Cancers</i> , 2023, 15, 1288.	1.7	4
1911	The role of [18F]-DCFPyL PET/MRI radiomics for pathological grade group prediction in prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2023, 50, 2167-2176.	3.3	6

#	ARTICLE	IF	CITATIONS
1912	Low-risk prostate lesions: An evidence review to inform discussion on losing the "cancer" label. <i>Prostate</i> , 2023, 83, 498-515.	1.2	1
1913	Standardized prostate cancer incidence and mortality rates following initial non-malignant biopsy result. <i>BJU International</i> , 2023, 132, 181-187.	1.3	3
1914	Retrospective Analysis of Clinical Outcomes of Stereotactic Body Radiation Therapy for Localized Prostate Cancer at an Asian Cancer Specialist Centre. <i>Asian Pacific Journal of Cancer Prevention</i> , 2023, 24, 545-550.	0.5	0
1915	Identifying Patients in Whom the Follow-Up Scheme after Robot-Assisted Radical Prostatectomy Could Be Optimized in the First Year after Surgery: Reducing Healthcare Burden. <i>Biomedicine</i> , 2023, 11, 727.	1.4	0
1916	Differences in Quality of Life between German and Dutch Patients with Prostate Cancer Treated with Robot-assisted Radical Prostatectomy: Implications for International Multicenter Randomized Controlled Trials. <i>European Urology Focus</i> , 2023, , .	1.6	1
1917	Outcomes for active surveillance are similar for men with favourable risk ISUP-2 to those with ISUP-1 prostate cancer: A pair matched cohort study. <i>Journal of Clinical Urology</i> , 0, , 205141582311547.	0.1	0
1918	DOK3 promotes proliferation and inhibits apoptosis of prostate cancer via the NF- κ B signaling pathway. <i>Chinese Medical Journal</i> , 2023, 136, 423-432.	0.9	5
1919	Metastatic prostate cancer-derived extracellular vesicles facilitate osteoclastogenesis by transferring the CDCP1 protein. <i>Journal of Extracellular Vesicles</i> , 2023, 12, .	5.5	5
1920	Health Care Costs Attributable to Prostate Cancer in British Columbia, Canada: A Population-Based Cohort Study. <i>Current Oncology</i> , 2023, 30, 3176-3188.	0.9	1
1921	Dose-escalated radiotherapy for clinically localized and locally advanced prostate cancer. <i>The Cochrane Library</i> , 2023, 2023, .	1.5	3
1922	Misclassification of Gleason grade and tumor stage in Asian-American patients with low-risk prostate cancer. <i>Precision Medical Sciences</i> , 0, , .	0.1	0
1923	Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. <i>New England Journal of Medicine</i> , 2023, 388, 1547-1558.	13.9	150
1924	Patient-Reported Outcomes 12 Years after Localized Prostate Cancer Treatment. , 2023, 2, .		18
1925	Beyond diagnosis: is there a role for radiomics in prostate cancer management?. <i>European Radiology Experimental</i> , 2023, 7, .	1.7	6
1926	Observation, Radiotherapy, or Radical Prostatectomy for Localized Prostate Cancer: Survival Analysis in the United States. <i>World Journal of Men's Health</i> , 2023, 41, 940.	1.7	1
1928	Recent Advances in Radiotherapy Modalities for Prostate Cancer. <i>Acta Clinica Croatica</i> , 2022, , .	0.1	0
1929	Extreme hypofractionated stereotactic radiotherapy for elderly prostate cancer patients: side effects preliminary analysis of a phase II trial. <i>Radiologia Medica</i> , 2023, 128, 501-508.	4.7	1
1930	Prediction of upgrade to clinically significant prostate cancer in patients under active surveillance: Performance of a fully automated AI algorithm for lesion detection and classification. <i>Prostate</i> , 2023, 83, 871-878.	1.2	5

#	ARTICLE	IF	CITATIONS
1931	Single-center, prospective phase 2 trial of high-intensity focused ultrasound (HIFU) in patients with unilateral localized prostate cancer: good functional results but oncologically not as safe as expected. <i>World Journal of Urology</i> , 2023, 41, 1293-1299.	1.2	3
1934	Virtual HDR Boost for Prostate Cancer: Rebooting a Classic Treatment Using Modern Tech. <i>Cancers</i> , 2023, 15, 2018.	1.7	1
1935	Clinical factors affecting the long-term survival of breast cancer patients. <i>Journal of International Medical Research</i> , 2023, 51, 030006052311640.	0.4	0
1936	Active Surveillance for Prostate Cancer: Past, Current, and Future Trends. <i>Journal of Personalized Medicine</i> , 2023, 13, 629.	1.1	5
1937	Stereotactic focal radiotherapy as an alternative treatment for low-risk prostate cancer: Results of a single-arm monocenter Phase-II trial. <i>Frontiers in Oncology</i> , 2023, 13, .	1.3	0
1938	A modeling study to estimate prostate cancer-specific mortality on active surveillance for men with favorable intermediate-risk prostate cancer: Results from the <sc>SEARCH</sc> cohort. <i>Cancer Medicine</i> , 2023, 12, .	1.3	1
1939	Screening for Prostate Cancer. <i>New England Journal of Medicine</i> , 2023, 388, 1405-1414.	13.9	22
1940	A comparison of machine learning models for predicting urinary incontinence in men with localized prostate cancer. <i>Frontiers in Oncology</i> , 2023, 13, .	1.3	3
1941	Treatment of intermediate-risk prostate cancer with active surveillance in the routine care—Long-term outcomes of a prospective noninterventional study (HAROW). <i>Current Urology</i> , 2023, Publish Ahead of Print, .	0.4	0
1942	Fusion-targeted biopsy significantly improves prostate cancer detection in biopsy-naïve men. <i>International Journal of Urology</i> , 2023, 30, 600-604.	0.5	3
1943	Hepatopancreatobiliary malignancies: time to treatment matters. <i>Journal of Gastrointestinal Oncology</i> , 2023, .	0.6	0
1955	Re: Fifteen-year Outcomes After Monitoring, Surgery, or Radiotherapy for Prostate Cancer. <i>European Urology</i> , 2023, .	0.9	1
1979	Considerations involving reirradiation. , 2024, , 127-140.		0
1989	Genetic and epigenetic features of neuroendocrine prostate cancer and their emerging applications. <i>International Review of Cell and Molecular Biology</i> , 2024, , 41-66.	1.6	1
1992	Progress of Porphyrin-based Nanoassemblies for Cancer Theranostics. <i>Chemical Research in Chinese Universities</i> , 2023, 39, 612-623.	1.3	2
1996	Prostatakarzinom: kurative Therapie. <i>Springer Reference Medizin</i> , 2023, , 1571-1592.	0.0	0
1999	Oncological results and cancer control definition in focal therapy for Prostate Cancer: a systematic review. <i>Prostate Cancer and Prostatic Diseases</i> , 2023, .	2.0	1
2020	Circulating Tumor Cells in Men Treated for Prostate Cancer. <i>Current Cancer Research</i> , 2023, , 565-574.	0.2	0

#	ARTICLE	IF	CITATIONS
2035	Management of Localized and Locally Advanced Prostate Cancer. , 2023, , 229-239.		0
2042	Active Surveillance of Low-Risk Differentiated Thyroid Cancer. , 2023, , 37-53.		0
2049	Cancer Screening in the Older Adult. , 2023, , 1-25.		0
2064	Prostate Cancer and Radiotherapy. , 2023, , 23-29.		0
2087	Men and Their Health. , 2024, , 1-14.		0
2089	Cancer Screening in the Older Adult. , 2024, , 801-825.		0
2100	MRI-Guided Radiation Therapy for Prostate Cancer: Less Is More When Technology and Evidence Intersect. , 2024, , 285-305.		0